



US010004558B2

(12) **United States Patent**
Long et al.(10) **Patent No.:** US 10,004,558 B2
(45) **Date of Patent:** Jun. 26, 2018(54) **ELECTRICAL ABLATION DEVICES**(71) Applicant: **Ethicon Endo-Surgery, Inc.,**
Cincinnati, OH (US)(72) Inventors: **Gary L. Long**, Cincinnati, OH (US);
Ragae M. Ghabrial, Pittsburgh, PA (US); **David N. Plescia**, Mentor, OH (US); **Omar J. Vakharia**, Cincinnati, OH (US)(73) Assignee: **Ethicon Endo-Surgery, Inc.,**
Cincinnati, OH (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 524 days.

(21) Appl. No.: 14/673,111

(22) Filed: Mar. 30, 2015

(65) **Prior Publication Data**

US 2015/0265342 A1 Sep. 24, 2015

Related U.S. Application Data(60) Continuation of application No. 13/602,742, filed on Sep. 4, 2012, now Pat. No. 9,011,431, which is a
(Continued)(51) **Int. Cl.***A61B 18/14* (2006.01)
A61B 18/12 (2006.01)
A61B 18/00 (2006.01)(52) **U.S. Cl.**CPC *A61B 18/1492* (2013.01); *A61B 18/1206* (2013.01); *A61B 18/1477* (2013.01);
(Continued)(58) **Field of Classification Search**CPC A61M 25/10; A61M 25/1043; A61M
25/1084

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

645,576 A 3/1900 Tesla
649,621 A 5/1900 Tesla
(Continued)

FOREIGN PATENT DOCUMENTS

AU 666310 B2 2/1996
DE 3008120 A1 9/1980
(Continued)


OTHER PUBLICATIONS

“Ethicon Endo-Surgery Novel Investigational Notes and SSL Devices Featured in 15 Presentations at Sages,” Apr. 22, 2009 Press Release; URL http://www.jnj.com/connect/news/all/20090422_152000; accessed Aug. 28, 2009 (3 pages).

(Continued)

Primary Examiner — Laura Bouchelle(57) **ABSTRACT**

An electrical ablation apparatus comprises first and second electrodes. Each electrode comprises a first end configured to couple an energy source and a second end configured to couple to a tissue treatment region. An energy source is coupled to the first and second electrodes. The energy source is configured to deliver a first series of electrical pulses sufficient to induce cell necrosis by irreversible electroporation and a second series of electrical pulses sufficient to induce cell necrosis by thermal heating, through at least one of the first and second electrodes. The first series of electrical pulses is characterized by a first amplitude, a first pulse length, and a first frequency. The second series of electrical pulses is characterized by a second amplitude, a second pulse length, and a second frequency.

13 Claims, 16 Drawing Sheets

US 10,004,558 B2

Page 2

Related U.S. Application Data

division of application No. 12/352,375, filed on Jan. 12, 2009, now Pat. No. 8,361,066.

(52) U.S. Cl.

CPC *A61B 2018/00214* (2013.01); *A61B 2018/00482* (2013.01); *A61B 2018/00547* (2013.01); *A61B 2018/00577* (2013.01); *A61B 2018/00613* (2013.01); *A61B 2018/00898* (2013.01); *A61B 2018/124* (2013.01); *A61B 2018/1425* (2013.01)

(56)

References Cited

U.S. PATENT DOCUMENTS

787,412 A	4/1905	Tesla	4,461,281 A	7/1984	Carson
1,039,354 A	9/1912	Bonadio	4,491,132 A	1/1985	Aikins
1,127,948 A	2/1915	Wappler	4,492,232 A	1/1985	Green
1,482,653 A	2/1924	Lilly	4,527,331 A	7/1985	Lasner et al.
1,581,706 A	4/1926	White	4,527,564 A	7/1985	Eguchi et al.
1,581,707 A	4/1926	White	4,538,594 A	9/1985	Boebel et al.
1,581,708 A	4/1926	White	D281,104 S	10/1985	Davison
1,581,709 A	4/1926	White	4,569,347 A	2/1986	Frisbie
1,581,710 A	4/1926	White	4,580,551 A	4/1986	Siegmund et al.
1,625,602 A	4/1927	Gould	4,646,722 A	3/1987	Silverstein et al.
1,916,722 A	7/1933	Ende	4,649,904 A	3/1987	Krauter et al.
2,028,635 A	1/1936	Wappler	4,653,476 A	3/1987	Bonnet
2,031,682 A	2/1936	Wappler	4,655,219 A	4/1987	Petruzzi
2,113,246 A	4/1938	Wappler	4,657,016 A	4/1987	Garito et al.
2,137,710 A	11/1938	Anderson	4,657,018 A	4/1987	Hakky
2,155,365 A	4/1939	Rankin	4,669,470 A	6/1987	Brandfield
2,191,858 A	2/1940	Moore	4,671,477 A	6/1987	Cullen
2,196,620 A	4/1940	Attarian	4,677,982 A	7/1987	Llinas et al.
2,388,137 A	10/1945	Graumlich	4,685,447 A	8/1987	Iversen et al.
2,451,077 A	10/1948	Emsig	4,711,240 A	12/1987	Goldwasser et al.
2,493,108 A	1/1950	Casey	4,712,545 A	12/1987	Honkanen
2,504,152 A	4/1950	Riker	4,721,116 A	1/1988	Schintgen et al.
2,938,382 A	5/1960	De Graaf	4,727,600 A	2/1988	Avakian
2,952,206 A	9/1960	Becksted	4,733,662 A	3/1988	DeSatnick et al.
3,044,461 A	7/1962	Murdock	D295,894 S	5/1988	Sharkany et al.
3,069,195 A	12/1962	Buck	4,742,817 A	5/1988	Kawashima et al.
3,070,088 A	12/1962	Brahos	4,753,223 A	6/1988	Bremer
3,170,471 A	2/1965	Schnitzer	4,763,669 A	8/1988	Jaeger
3,435,824 A	4/1969	Gamponia	4,770,188 A	9/1988	Chikama
3,470,876 A	10/1969	Barchilon	4,790,624 A	12/1988	Van Hoye et al.
3,481,325 A	12/1969	Glassman	4,791,707 A	12/1988	Tucker
3,595,239 A	7/1971	Petersen	4,796,627 A	1/1989	Tucker
3,669,487 A	6/1972	Roberts et al.	4,807,593 A	2/1989	Ito
3,746,881 A	7/1973	Fitch et al.	4,815,450 A	3/1989	Patel
3,799,672 A	3/1974	Vurek	4,819,620 A	4/1989	Okutsu
3,946,740 A	3/1976	Bassett	4,823,794 A	4/1989	Pierce
3,948,251 A	4/1976	Hosono	4,829,999 A	5/1989	Auth
3,961,632 A	6/1976	Moossun	4,836,188 A	6/1989	Berry
3,965,890 A	6/1976	Gauthier	4,846,573 A	7/1989	Taylor et al.
3,994,301 A	11/1976	Agris	4,867,140 A	9/1989	Hovis et al.
4,011,872 A	3/1977	Komiya	4,869,238 A	9/1989	Opie et al.
4,012,812 A	3/1977	Black	4,869,459 A	9/1989	Bourne
4,085,743 A	4/1978	Yoon	4,873,979 A	10/1989	Hanna
4,164,225 A	8/1979	Johnson et al.	4,880,015 A	11/1989	Nierman
4,170,997 A	10/1979	Pinnow et al.	4,904,048 A	2/1990	Sogawa et al.
4,174,715 A	11/1979	Hasson	4,911,148 A	3/1990	Sosnowski et al.
4,178,920 A	12/1979	Cawood, Jr. et al.	4,926,860 A	5/1990	Stice et al.
4,207,873 A	6/1980	Kruy	4,934,364 A	6/1990	Green
4,235,238 A	11/1980	Ogiu et al.	4,938,214 A	7/1990	Specht et al.
4,258,716 A	3/1981	Sutherland	4,950,273 A	8/1990	Briggs
4,269,174 A	5/1981	Adair	4,950,285 A	8/1990	Wilk
4,278,077 A	7/1981	Mizumoto	4,953,539 A	9/1990	Nakamura et al.
4,281,646 A	8/1981	Kinoshita	4,960,133 A	10/1990	Hewson
4,285,344 A	8/1981	Marshall	4,977,887 A	12/1990	Gouda
4,311,143 A	1/1982	Komiya	4,979,496 A	12/1990	Komi
4,329,980 A	5/1982	Terada	4,979,950 A	12/1990	Transue et al.
4,393,872 A	7/1983	Reznik et al.	4,984,581 A	1/1991	Stice
4,396,021 A	8/1983	Baumgartner	4,990,152 A	2/1991	Yoon
4,406,656 A	9/1983	Hattler et al.	4,991,565 A	2/1991	Takahashi et al.
4,452,246 A	6/1984	Bader et al.	4,994,079 A	2/1991	Genese et al.
			5,007,917 A	4/1991	Evans
			5,010,876 A	4/1991	Henley et al.
			5,020,514 A	6/1991	Hecke
			5,020,535 A	6/1991	Parker et al.
			5,025,778 A	6/1991	Silverstein et al.
			5,026,379 A	6/1991	Yoon
			5,033,169 A	7/1991	Bindon
			5,037,433 A	8/1991	Wilk et al.
			5,041,129 A	8/1991	Hayhurst et al.
			5,046,513 A	9/1991	Gattuma et al.
			5,050,585 A	9/1991	Takahashi
			5,052,372 A	10/1991	Shapiro
			5,065,516 A	11/1991	Dulebohn
			5,066,295 A	11/1991	Kozak et al.
			5,098,378 A	3/1992	Piontek et al.
			5,108,421 A	4/1992	Fowler
			5,123,913 A	6/1992	Wilk et al.
			5,123,914 A	6/1992	Cope
			5,133,727 A	7/1992	Bales et al.

(56)	References Cited					
U.S. PATENT DOCUMENTS						
5,147,374 A	9/1992	Fernandez	5,364,408 A	11/1994	Gordon	
5,174,300 A	12/1992	Bales et al.	5,364,410 A	11/1994	Failla et al.	
5,176,126 A	1/1993	Chikama	5,366,466 A	11/1994	Christian et al.	
5,190,050 A	3/1993	Nitzsche	5,366,467 A	11/1994	Lynch et al.	
5,190,555 A	3/1993	Wetter et al.	5,368,605 A	11/1994	Miller, Jr.	
5,192,284 A	3/1993	Pleatman	5,370,647 A	12/1994	Graber et al.	
5,192,300 A	3/1993	Fowler	5,370,679 A	12/1994	Atlee, III	
5,197,963 A	3/1993	Parins	5,374,273 A	12/1994	Nakao et al.	
5,201,752 A	4/1993	Brown et al.	5,374,275 A	12/1994	Bradley et al.	
5,201,908 A	4/1993	Jones	5,374,277 A	12/1994	Hassler	
5,203,785 A	4/1993	Slater	5,374,953 A	12/1994	Sasaki et al.	
5,203,787 A	4/1993	Noblitt et al.	5,376,077 A	12/1994	Gomringer	
5,209,747 A	5/1993	Knoepfler	5,377,695 A	1/1995	An Haack	
5,217,003 A	6/1993	Wilk	5,383,877 A	1/1995	Clarke	
5,217,453 A	6/1993	Wilk	5,383,888 A	1/1995	Zvenyatsky et al.	
5,219,357 A	6/1993	Honkanen et al.	5,386,817 A	2/1995	Jones	
5,219,358 A	6/1993	Bendel et al.	5,387,259 A	2/1995	Davidson	
5,222,362 A	6/1993	Maus et al.	5,391,174 A	2/1995	Weston	
5,222,965 A	6/1993	Haughton	5,392,789 A	2/1995	Slater et al.	
5,234,437 A	8/1993	Sepetka	5,395,386 A	3/1995	Slater	
5,234,453 A	8/1993	Smith et al.	5,397,332 A	3/1995	Kammerer et al.	
5,235,964 A	8/1993	Abenaim	5,401,248 A	3/1995	Bencini	
5,242,456 A	9/1993	Nash et al.	5,403,311 A	4/1995	Abele et al.	
5,245,460 A	9/1993	Allen et al.	5,403,328 A	4/1995	Shallman	
5,246,424 A	9/1993	Wilk	5,403,342 A	4/1995	Tovey et al.	
5,257,999 A	11/1993	Slanetz, Jr.	5,403,348 A	4/1995	Bonutti	
5,259,366 A	11/1993	Reydel et al.	5,405,073 A	4/1995	Porter	
5,263,958 A	11/1993	deGuillebon et al.	5,405,359 A	4/1995	Pierce	
5,273,524 A	12/1993	Fox et al.	5,409,478 A	4/1995	Gerry et al.	
5,275,607 A	1/1994	Lo et al.	5,417,699 A	5/1995	Klein et al.	
5,275,614 A	1/1994	Haber et al.	5,423,821 A	6/1995	Pasque	
5,275,616 A	1/1994	Fowler	5,431,635 A	7/1995	Yoon	
5,284,128 A	2/1994	Hart	5,433,721 A	7/1995	Hooven et al.	
5,284,162 A	2/1994	Wilk	5,433,735 A	7/1995	Zanakis et al.	
5,287,845 A	2/1994	Faul et al.	5,439,471 A	8/1995	Kerr	
5,287,852 A	2/1994	Arkinstall	5,439,478 A	8/1995	Palmer	
5,290,299 A	3/1994	Fain et al.	5,441,059 A	8/1995	Dannan	
5,290,302 A	3/1994	Pericic	5,441,494 A	8/1995	Ortiz	
5,295,977 A	3/1994	Cohen et al.	5,441,498 A	8/1995	Perkins	
5,297,536 A	3/1994	Wilk	5,441,499 A	8/1995	Fritzsch	
5,297,687 A	3/1994	Freed	5,443,463 A	8/1995	Stern et al.	
5,301,061 A	4/1994	Nakada et al.	5,445,638 A	8/1995	Rydell et al.	
5,312,023 A	5/1994	Green et al.	5,445,648 A	8/1995	Cook	
5,312,333 A	5/1994	Churinetz et al.	5,449,021 A	9/1995	Chikama	
5,312,351 A	5/1994	Gerrone	5,454,827 A	10/1995	Aust et al.	
5,312,416 A	5/1994	Spaeth et al.	5,456,667 A	10/1995	Ham et al.	
5,312,423 A	5/1994	Rosenbluth et al.	5,456,684 A	10/1995	Schmidt et al.	
5,318,589 A	6/1994	Lichtman	5,458,131 A	10/1995	Wilk	
5,320,636 A	6/1994	Slater	5,458,583 A	10/1995	McNeely et al.	
5,324,261 A	6/1994	Amundson et al.	5,460,168 A	10/1995	Masubuchi et al.	
5,325,845 A	7/1994	Adair	5,460,629 A	10/1995	Shlain et al.	
5,330,471 A	7/1994	Eggers	5,462,561 A	10/1995	Voda	
5,330,486 A	7/1994	Wilk	5,465,731 A	11/1995	Bell et al.	
5,330,488 A	7/1994	Goldrath	5,467,763 A	11/1995	McMahon et al.	
5,330,496 A	7/1994	Alferness	5,468,250 A	11/1995	Paraschac et al.	
5,330,502 A	7/1994	Hassler et al.	5,470,308 A	11/1995	Edwards et al.	
5,331,971 A	7/1994	Bales et al.	5,470,320 A	11/1995	Tiefenbrun et al.	
5,334,168 A	8/1994	Hemmer	5,472,441 A	12/1995	Edwards et al.	
5,334,198 A	8/1994	Hart et al.	5,478,347 A	12/1995	Aranyi	
5,336,192 A	8/1994	Palestrant	5,478,352 A	12/1995	Fowler	
5,336,222 A	8/1994	Durgin, Jr. et al.	5,480,404 A	1/1996	Kammerer et al.	
5,339,805 A	8/1994	Parker	5,482,029 A	1/1996	Sekiguchi et al.	
5,341,815 A	8/1994	Cofone et al.	5,482,054 A	1/1996	Slater et al.	
5,342,396 A	8/1994	Cook	5,484,451 A	1/1996	Akopov et al.	
5,344,428 A	9/1994	Griffiths	5,489,256 A	2/1996	Adair	
5,345,927 A	9/1994	Bonutti	5,496,347 A	3/1996	Hashiguchi et al.	
5,348,259 A	9/1994	Blanco et al.	5,499,990 A	3/1996	Schulken et al.	
5,350,391 A	9/1994	Iacovelli	5,499,992 A	3/1996	Meade et al.	
5,352,184 A	10/1994	Goldberg et al.	5,499,997 A	3/1996	Sharpe et al.	
5,352,222 A	10/1994	Rydell	5,500,012 A	3/1996	Brucker et al.	
5,354,302 A	10/1994	Ko	5,501,692 A	3/1996	Riza	
5,354,311 A	10/1994	Kambin et al.	5,503,616 A	4/1996	Jones	
5,356,381 A	10/1994	Ensminger et al.	5,505,686 A	4/1996	Willis et al.	
5,356,408 A	10/1994	Rydell	5,507,755 A	4/1996	Gresl et al.	
5,360,428 A	11/1994	Hutchinson, Jr.	5,511,564 A	4/1996	Wilk	
			5,514,157 A	5/1996	Nicholas et al.	
			5,518,501 A	5/1996	Oneda et al.	
			5,522,829 A	6/1996	Michalos	
			5,522,830 A	6/1996	Aranyi	

(56)	References Cited					
U.S. PATENT DOCUMENTS						
5,527,321 A	6/1996	Hinchliffe	5,700,275 A	12/1997	Bell et al.	
5,533,418 A	7/1996	Wu et al.	5,702,438 A	12/1997	Avitall	
5,536,234 A	7/1996	Newman	5,704,892 A	1/1998	Adair	
5,536,248 A	7/1996	Weaver et al.	5,709,708 A	1/1998	Thal	
5,538,509 A	7/1996	Dunlap et al.	5,711,921 A	1/1998	Langford	
5,540,648 A	7/1996	Yoon	5,716,326 A	2/1998	Dannan	
5,549,637 A	8/1996	Crainich	5,716,375 A	2/1998	Fowler	
5,554,151 A	9/1996	Hinchliffe	5,725,542 A	3/1998	Yoon	
5,555,883 A	9/1996	Avitall	5,728,094 A	3/1998	Edwards	
5,558,133 A	9/1996	Bortoli et al.	5,730,740 A	3/1998	Wales et al.	
5,562,693 A	10/1996	Devlin et al.	5,735,849 A	4/1998	Baden et al.	
5,569,243 A	10/1996	Kortenbach et al.	5,741,234 A	4/1998	Aboul-Hosn	
5,569,298 A	10/1996	Schnell	5,741,278 A	4/1998	Stevens	
5,571,090 A	11/1996	Sherts	5,741,285 A	4/1998	McBrayer et al.	
5,573,540 A	11/1996	Yoon	5,741,429 A	4/1998	Donadio, III et al.	
5,578,030 A	11/1996	Levin	5,743,456 A	4/1998	Jones et al.	
5,582,611 A	12/1996	Tsuruta et al.	5,746,759 A	5/1998	Meade et al.	
5,582,617 A	12/1996	Klieman et al.	5,749,826 A	5/1998	Faulkner	
5,584,845 A	12/1996	Hart	5,749,881 A	5/1998	Sackier et al.	
5,590,660 A	1/1997	MacAulay et al.	5,749,889 A	5/1998	Bacich et al.	
5,591,179 A	1/1997	Edelstein	5,762,604 A	6/1998	Kieturakis	
5,591,205 A	1/1997	Fowler	5,766,167 A	6/1998	Eggers et al.	
5,593,420 A	1/1997	Eubanks, Jr. et al.	5,766,170 A	6/1998	Eggers	
5,595,562 A	1/1997	Grier	5,766,205 A	6/1998	Zvenyatsky et al.	
5,597,378 A	1/1997	Jervis	5,769,849 A	6/1998	Eggers	
5,601,573 A	2/1997	Fogelberg et al.	5,776,188 A	7/1998	Shepherd et al.	
5,601,574 A	2/1997	Stefanchik et al.	5,779,701 A	7/1998	McBrayer et al.	
5,601,588 A	2/1997	Tonomura et al.	5,779,716 A	7/1998	Cano et al.	
5,601,602 A	2/1997	Fowler	5,779,720 A	7/1998	Walder-Utz et al.	
5,604,531 A	2/1997	Iddan et al.	5,779,727 A	7/1998	Orejola	
5,607,386 A	3/1997	Flam	5,782,859 A	7/1998	Nicholas et al.	
5,607,389 A	3/1997	Edwards et al.	5,782,861 A	7/1998	Cragg et al.	
5,607,406 A	3/1997	Hernandez et al.	5,782,866 A	7/1998	Wenstrom, Jr.	
5,607,450 A	3/1997	Zvenyatsky et al.	5,791,022 A	8/1998	Bohman	
5,609,601 A	3/1997	Kolesa et al.	5,792,113 A	8/1998	Kramer et al.	
5,613,975 A	3/1997	Christy	5,792,153 A	8/1998	Swain et al.	
5,613,977 A	3/1997	Weber et al.	5,792,165 A	8/1998	Klieman et al.	
5,614,943 A	3/1997	Nakamura et al.	5,797,835 A	8/1998	Green	
5,616,117 A	4/1997	Dinkler et al.	5,797,928 A	8/1998	Kogasaka	
5,618,303 A	4/1997	Marlow et al.	5,797,939 A	8/1998	Yoon	
5,620,415 A	4/1997	Lucey et al.	5,797,941 A	8/1998	Schulze et al.	
5,624,399 A	4/1997	Ackerman	5,797,959 A	8/1998	Castro et al.	
5,624,431 A	4/1997	Gerry et al.	5,797,960 A	8/1998	Stevens et al.	
5,626,578 A	5/1997	Tihon	5,800,449 A	9/1998	Wales	
5,626,587 A	5/1997	Bishop et al.	5,800,451 A	9/1998	Buess et al.	
5,628,732 A	5/1997	Antoon, Jr. et al.	5,803,903 A	9/1998	Athas et al.	
5,630,782 A	5/1997	Adair	5,807,395 A	9/1998	Mulier et al.	
5,630,795 A	5/1997	Kuramoto et al.	5,808,665 A	9/1998	Green	
5,643,283 A	7/1997	Younker	5,810,805 A	9/1998	Sutcu et al.	
5,643,292 A	7/1997	Hart	5,810,806 A	9/1998	Ritchart et al.	
5,643,294 A	7/1997	Tovey et al.	5,810,849 A	9/1998	Kontos	
5,644,798 A	7/1997	Shahn	5,810,865 A	9/1998	Koscher et al.	
5,645,083 A	7/1997	Essig et al.	5,810,876 A	9/1998	Kelleher	
5,645,519 A	7/1997	Lee et al.	5,810,877 A	9/1998	Roth et al.	
5,645,565 A	7/1997	Rudd et al.	5,813,976 A	9/1998	Filipi et al.	
5,649,372 A	7/1997	Souza	5,814,026 A	9/1998	Yoon	
5,653,677 A	8/1997	Okada et al.	5,814,058 A	9/1998	Carlson et al.	
5,653,690 A	8/1997	Booth et al.	5,817,061 A	10/1998	Goodwin et al.	
5,653,722 A	8/1997	Kieturakis	5,817,107 A	10/1998	Schaller	
5,657,755 A	8/1997	Desai	5,817,119 A	10/1998	Klieman et al.	
5,662,621 A	9/1997	Lafontaine	5,818,527 A	10/1998	Yamaguchi et al.	
5,662,663 A	9/1997	Shallman	5,819,736 A	10/1998	Avny et al.	
5,667,527 A	9/1997	Cook	5,823,947 A	10/1998	Yoon et al.	
5,669,875 A	9/1997	van Eerdenburg	5,824,071 A	10/1998	Nelson et al.	
5,681,276 A	10/1997	Lundquist	5,827,190 A	10/1998	Palcic et al.	
5,681,279 A	10/1997	Roper et al.	5,827,276 A	10/1998	LeVeen et al.	
5,681,324 A	10/1997	Kammerer et al.	5,827,281 A	10/1998	Levin	
5,681,330 A	10/1997	Hughett et al.	5,827,299 A	10/1998	Thomason et al.	
5,685,820 A	11/1997	Riek et al.	5,827,323 A	10/1998	Klieman et al.	
5,690,606 A	11/1997	Slotman	5,830,221 A	11/1998	Stein et al.	
5,690,656 A	11/1997	Cope et al.	5,830,231 A	11/1998	Geiges, Jr.	
5,690,660 A	11/1997	Kauker et al.	5,833,603 A	11/1998	Kovacs et al.	
5,695,448 A	12/1997	Kimura et al.	5,833,700 A	11/1998	Fogelberg et al.	
5,695,505 A	12/1997	Yoon	5,833,703 A	11/1998	Manushakian	
5,695,511 A	12/1997	Cano et al.	5,833,715 A	11/1998	Vachon et al.	

(56)	References Cited				
U.S. PATENT DOCUMENTS					
5,836,960 A	11/1998	Kolesa et al.	6,027,522 A	2/2000	Palmer
5,843,017 A	12/1998	Yoon	6,030,365 A	2/2000	Laufer
5,843,121 A	12/1998	Yoon	6,030,384 A	2/2000	Nezhat
5,849,022 A	12/1998	Sakashita et al.	6,030,634 A	2/2000	Wu et al.
5,853,374 A	12/1998	Hart et al.	6,033,399 A	3/2000	Gines
5,855,569 A	1/1999	Komi	6,033,401 A	3/2000	Edwards et al.
5,855,585 A	1/1999	Kontos	6,036,640 A	3/2000	Corace et al.
5,860,913 A	1/1999	Yamaya et al.	6,036,685 A	3/2000	Mueller
5,860,995 A	1/1999	Berkelaar	6,050,992 A	4/2000	Nichols
5,868,762 A	2/1999	Cragg et al.	6,053,927 A	4/2000	Hamas
5,873,849 A	2/1999	Bernard	6,053,937 A	4/2000	Edwards et al.
5,876,411 A	3/1999	Kontos	6,059,719 A	5/2000	Yamamoto et al.
5,882,331 A	3/1999	Sasaki	6,066,160 A	5/2000	Colvin et al.
5,882,344 A	3/1999	Stouder, Jr.	6,068,603 A	5/2000	Suzuki
5,893,846 A	4/1999	Bales et al.	6,068,629 A	5/2000	Haissaguerre et al.
5,893,874 A	4/1999	Bourque et al.	6,071,233 A	6/2000	Ishikawa et al.
5,893,875 A	4/1999	O'Connor et al.	6,074,408 A	6/2000	Freeman
5,897,487 A	4/1999	Ouchi	6,086,530 A	7/2000	Mack
5,899,919 A	5/1999	Eubanks, Jr. et al.	6,090,105 A	7/2000	Lepeda et al.
5,902,238 A	5/1999	Golden et al.	6,090,108 A	7/2000	McBrayer et al.
5,902,254 A	5/1999	Magram	6,090,129 A	7/2000	Ouchi
5,904,702 A	5/1999	Ek et al.	6,096,046 A	8/2000	Weiss
5,906,625 A	5/1999	Bito et al.	6,102,909 A	8/2000	Chen et al.
5,908,420 A	6/1999	Parins et al.	6,102,926 A	8/2000	Tartaglia et al.
5,908,429 A	6/1999	Yoon	6,106,473 A	8/2000	Violante et al.
5,911,737 A	6/1999	Lee et al.	6,106,521 A	8/2000	Blewett et al.
5,916,146 A	6/1999	Allotta et al.	6,109,852 A	8/2000	Shahinpoor et al.
5,916,147 A	6/1999	Boury	6,110,154 A	8/2000	Shimomura et al.
5,921,892 A	7/1999	Easton	6,110,183 A	8/2000	Cope
5,921,993 A	7/1999	Yoon	6,113,593 A	9/2000	Tu et al.
5,921,997 A	7/1999	Fogelberg et al.	6,117,144 A	9/2000	Nobles et al.
5,922,008 A	7/1999	Gimpelson	6,117,158 A	9/2000	Measamer et al.
5,925,052 A	7/1999	Simmons	6,123,718 A *	9/2000	Tu A61B 18/1492
5,928,255 A	7/1999	Meade et al.			606/41
5,928,266 A	7/1999	Kontos	6,131,790 A	10/2000	Piraka
5,936,536 A	8/1999	Morris	6,139,555 A	10/2000	Hart et al.
5,938,661 A	8/1999	Hahnen	6,141,037 A	10/2000	Upton et al.
5,941,815 A	8/1999	Chang	6,146,391 A	11/2000	Cigaina
5,944,718 A	8/1999	Austin et al.	6,148,222 A	11/2000	Ramsey, III
5,951,547 A	9/1999	Gough et al.	6,149,653 A	11/2000	Deslauriers
5,951,549 A	9/1999	Richardson et al.	6,149,662 A	11/2000	Pugliesi et al.
5,954,720 A	9/1999	Wilson et al.	6,152,871 A	11/2000	Foley et al.
5,954,731 A	9/1999	Yoon	6,152,920 A	11/2000	Thompson et al.
5,957,936 A	9/1999	Yoon et al.	6,156,006 A	12/2000	Brosens et al.
5,957,943 A	9/1999	Vaitekunas	6,159,200 A	12/2000	Verdura et al.
5,957,953 A	9/1999	DiPoto et al.	6,165,175 A	12/2000	Wampler et al.
5,964,782 A	10/1999	Lafontaine et al.	6,165,184 A	12/2000	Verdura et al.
5,970,581 A	10/1999	Chadwick et al.	6,168,570 B1	1/2001	Ferrera
5,971,995 A	10/1999	Rousseau	6,168,605 B1	1/2001	Measamer et al.
5,972,002 A	10/1999	Bark et al.	6,169,269 B1	1/2001	Maynard
5,976,074 A	11/1999	Moriyama	6,170,130 B1	1/2001	Hamilton et al.
5,976,075 A	11/1999	Beane et al.	6,173,872 B1	1/2001	Cohen
5,976,130 A	11/1999	McBrayer et al.	6,179,776 B1	1/2001	Adams et al.
5,976,131 A	11/1999	Guglielmi et al.	6,179,832 B1	1/2001	Jones et al.
5,980,539 A	11/1999	Kontos	6,179,837 B1	1/2001	Hooven
5,980,556 A	11/1999	Giordano et al.	6,183,420 B1	2/2001	Douk et al.
5,984,938 A	11/1999	Yoon	6,190,353 B1	2/2001	Makower et al.
5,984,939 A	11/1999	Yoon	6,190,383 B1	2/2001	Schmaltz et al.
5,984,950 A	11/1999	Cragg et al.	6,190,384 B1	2/2001	Ouchi
5,989,182 A	11/1999	Hori et al.	6,190,399 B1	2/2001	Palmer et al.
5,993,447 A	11/1999	Blewett et al.	6,203,533 B1	3/2001	Ouchi
5,993,474 A	11/1999	Ouchi	6,206,872 B1	3/2001	Lafond et al.
5,995,875 A	11/1999	Blewett et al.	6,206,877 B1	3/2001	Kese et al.
5,997,555 A	12/1999	Kontos	6,206,904 B1	3/2001	Ouchi
6,001,120 A	12/1999	Levin	6,210,409 B1	4/2001	Ellman et al.
6,004,269 A	12/1999	Crowley et al.	6,214,007 B1	4/2001	Anderson
6,004,330 A	12/1999	Middleman et al.	6,214,028 B1	4/2001	Yoon et al.
6,007,566 A	12/1999	Wenstrom, Jr.	6,216,043 B1	4/2001	Swanson et al.
6,010,515 A	1/2000	Swain et al.	6,228,096 B1	5/2001	Marchand
6,012,494 A	1/2000	Balazs	6,231,506 B1	5/2001	Hu et al.
6,016,452 A	1/2000	Kasevich	6,234,958 B1	5/2001	Snoke et al.
6,017,356 A	1/2000	Frederick et al.	6,240,312 B1	5/2001	Alfano et al.
6,019,770 A	2/2000	Christoudias	6,245,079 B1	6/2001	Nobles et al.
6,024,708 A	2/2000	Bales et al.	6,246,914 B1	6/2001	de la Rama et al.
6,024,747 A	2/2000	Kontos	6,258,064 B1	7/2001	Smith et al.
			6,261,242 B1	7/2001	Roberts et al.
			6,264,664 B1	7/2001	Avellanet
			6,270,497 B1	8/2001	Sekino et al.
			6,270,505 B1	8/2001	Yoshida et al.

(56)	References Cited				
U.S. PATENT DOCUMENTS					
6,277,136 B1	8/2001 Bonutti	6,554,823 B2	4/2003 Palmer et al.		
6,283,963 B1	9/2001 Regula	6,554,829 B2	4/2003 Schulze et al.		
6,287,304 B1	9/2001 Eggers et al.	6,558,384 B2	5/2003 Mayenberger		
6,293,909 B1	9/2001 Chu et al.	6,562,034 B2	5/2003 Edwards et al.		
6,293,952 B1	9/2001 Brosens et al.	6,562,035 B1	5/2003 Levin		
6,296,630 B1	10/2001 Altman et al.	6,562,052 B2	5/2003 Nobles et al.		
6,314,963 B1	11/2001 Vaska et al.	6,569,085 B2	5/2003 Kortenbach et al.		
6,322,578 B1	11/2001 Houle et al.	6,569,091 B2	5/2003 Dickno et al.		
6,325,534 B1	12/2001 Hawley et al.	6,569,120 B1	5/2003 Green et al.		
6,326,177 B1	12/2001 Schoenbach et al.	6,569,159 B1	5/2003 Edwards et al.		
6,328,730 B1	12/2001 Harkrider, Jr.	6,572,629 B2	6/2003 Kalloo et al.		
6,350,267 B1	2/2002 Stefanchik	6,572,635 B1	6/2003 Bonutti		
6,350,278 B1	2/2002 Lenker et al.	6,575,988 B2	6/2003 Rousseau		
6,352,503 B1	3/2002 Matsui et al.	6,579,311 B1	6/2003 Makower		
6,352,541 B1	3/2002 Kienzle et al.	6,581,889 B2	6/2003 Carpenter et al.		
6,352,543 B1	3/2002 Cole	6,585,642 B2	7/2003 Christopher		
6,355,013 B1	3/2002 van Muiden	6,585,717 B1	7/2003 Wittenberger et al.		
6,355,035 B1	3/2002 Manushakian	6,587,750 B2	7/2003 Gerbi et al.		
6,361,534 B1	3/2002 Chen et al.	6,592,559 B1	7/2003 Pakter et al.		
6,364,879 B1	4/2002 Chen et al.	6,592,603 B2	7/2003 Lasner		
6,368,340 B2	4/2002 Malecki et al.	6,594,971 B1	7/2003 Addy et al.		
6,371,956 B1	4/2002 Wilson et al.	6,602,262 B2	8/2003 Griego et al.		
6,379,366 B1	4/2002 Fleischman et al.	6,605,105 B1	8/2003 Cuschieri et al.		
6,383,195 B1	5/2002 Richard	6,610,072 B1	8/2003 Christy et al.		
6,383,197 B1	5/2002 Conlon et al.	6,610,074 B2	8/2003 Santilli		
6,387,671 B1	5/2002 Rubinsky et al.	6,613,038 B2	9/2003 Bonutti et al.		
6,391,029 B1	5/2002 Hooven et al.	6,613,068 B2	9/2003 Ouchi		
6,398,708 B1	6/2002 Hastings et al.	6,616,632 B2	9/2003 Sharp et al.		
6,402,735 B1	6/2002 Langevin	6,620,193 B1	9/2003 Lau et al.		
6,402,746 B1	6/2002 Whayne et al.	6,623,448 B2	9/2003 Slater		
6,406,440 B1	6/2002 Stefanchik	6,626,919 B1	9/2003 Swanstrom		
6,409,727 B1	6/2002 Bales et al.	6,632,171 B2	10/2003 Iddan et al.		
6,409,733 B1	6/2002 Conlon et al.	6,632,229 B1	10/2003 Yamanouchi		
6,419,639 B2	7/2002 Walther et al.	6,632,234 B2	10/2003 Kieturakis et al.		
6,419,641 B1	7/2002 Mark et al.	6,638,275 B1	10/2003 McGaffigan et al.		
6,427,089 B1	7/2002 Knowlton	6,638,286 B1	10/2003 Burbank et al.		
6,431,500 B1	8/2002 Jacobs et al.	6,645,225 B1	11/2003 Atkinson		
6,436,107 B1	8/2002 Wang et al.	6,652,518 B2	11/2003 Wellman et al.		
6,443,970 B1	9/2002 Schulze et al.	6,652,521 B2	11/2003 Schulze		
6,443,988 B2	9/2002 Felt et al.	6,652,545 B2	11/2003 Shipp et al.		
6,447,444 B1	9/2002 Avni et al.	6,652,551 B1	11/2003 Heiss		
6,447,511 B1	9/2002 Slater	6,656,194 B1	12/2003 Gannoe et al.		
6,447,523 B1	9/2002 Middleman et al.	6,663,641 B1	12/2003 Kovac et al.		
6,454,783 B1	9/2002 Piskun	6,663,655 B2	12/2003 Ginn et al.		
6,454,785 B2	9/2002 De Hoyos Garza	6,666,854 B1	12/2003 Lange		
6,458,074 B1	10/2002 Matsui et al.	6,672,338 B1	1/2004 Esashi et al.		
6,458,076 B1	10/2002 Pruitt	6,673,058 B2	1/2004 Snow		
6,464,701 B1	10/2002 Hooven et al.	6,673,070 B2	1/2004 Edwards et al.		
6,464,702 B2	10/2002 Schulze et al.	6,673,087 B1	1/2004 Chang et al.		
6,470,218 B1	10/2002 Behl	6,673,092 B1	1/2004 Bacher		
6,475,104 B1	11/2002 Lutz et al.	6,676,685 B2	1/2004 Pedros et al.		
6,485,411 B1	11/2002 Konstorum et al.	6,679,882 B1	1/2004 Kornerup		
6,489,745 B1	12/2002 Koreis	6,685,628 B2	2/2004 Vu		
6,491,626 B1	12/2002 Stone et al.	6,685,724 B1	2/2004 Haluck		
6,491,627 B1	12/2002 Komi	6,692,445 B2	2/2004 Roberts et al.		
6,491,691 B1	12/2002 Morley et al.	6,692,462 B2	2/2004 Mackenzie et al.		
6,493,590 B1	12/2002 Wessman et al.	6,692,493 B2	2/2004 McGovern et al.		
6,494,893 B2	12/2002 Dubrul et al.	6,699,180 B2	3/2004 Kobayashi		
6,500,176 B1	12/2002 Truckai et al.	6,699,256 B1	3/2004 Logan et al.		
6,503,192 B1	1/2003 Ouchi	6,699,263 B2	3/2004 Cope		
6,506,190 B1	1/2003 Walshe	6,706,018 B2	3/2004 Westlund et al.		
6,508,827 B1	1/2003 Manhes	6,708,066 B2	3/2004 Herbst et al.		
6,514,239 B2	2/2003 Shimmura et al.	6,709,188 B2	3/2004 Ushimaru		
6,517,534 B1	2/2003 McGovern et al.	6,709,445 B2	3/2004 Boebel et al.		
6,520,954 B2	2/2003 Ouchi	6,716,226 B2	4/2004 Sixto, Jr. et al.		
6,526,320 B2	2/2003 Mitchell	6,731,875 B1	5/2004 Kartalopoulos		
6,527,782 B2	3/2003 Hogg et al.	6,736,822 B2	5/2004 McClellan et al.		
6,530,880 B2	3/2003 Pagliuca	6,740,030 B2	5/2004 Martone et al.		
6,530,922 B2	3/2003 Cosman et al.	6,740,082 B2	5/2004 Shadduck		
6,535,764 B2	3/2003 Imran et al.	6,743,166 B2	6/2004 Berci et al.		
6,537,200 B2	3/2003 Leysieffer et al.	6,743,226 B2	6/2004 Cosman et al.		
6,543,456 B1	4/2003 Freeman	6,743,239 B1	6/2004 Kuehn et al.		
6,551,270 B1	4/2003 Bimbo et al.	6,743,240 B2	6/2004 Smith et al.		
6,551,356 B2	4/2003 Rousseau	6,749,560 B1	6/2004 Konstorum et al.		
6,554,766 B2	4/2003 Maeda et al.	6,749,609 B1	6/2004 Lunsford et al.		
		6,752,768 B2	6/2004 Burdorff et al.		
		6,752,811 B2	6/2004 Chu et al.		
		6,752,822 B2	6/2004 Jespersen		
		6,758,857 B2	7/2004 Cioanta et al.		

(56)

References Cited**U.S. PATENT DOCUMENTS**

6,761,685 B2	7/2004	Adams et al.	6,960,163 B2	11/2005	Ewers et al.
6,761,718 B2	7/2004	Madsen	6,960,183 B2	11/2005	Nicolette
6,761,722 B2	7/2004	Cole et al.	6,962,587 B2	11/2005	Johnson et al.
6,767,356 B2	7/2004	Kanner et al.	6,964,662 B2	11/2005	Kidooka
6,773,434 B2	8/2004	Ciarrocca	6,966,909 B2	11/2005	Marshall et al.
6,776,165 B2	8/2004	Jin	6,966,919 B2	11/2005	Sixto, Jr. et al.
6,776,787 B2	8/2004	Phung et al.	6,967,462 B1	11/2005	Landis
6,780,151 B2	8/2004	Grabover et al.	6,971,988 B2	12/2005	Orban, III
6,780,352 B2	8/2004	Jacobson	6,972,017 B2	12/2005	Smith et al.
6,783,491 B2	8/2004	Saadat et al.	6,974,411 B2	12/2005	Belson
6,786,382 B1	9/2004	Hoffman	6,976,992 B2	12/2005	Sachatello et al.
6,786,864 B2	9/2004	Matsuura et al.	6,980,858 B2	12/2005	Fuimaono et al.
6,786,905 B2	9/2004	Swanson et al.	6,984,203 B2	1/2006	Tartaglia et al.
6,788,977 B2	9/2004	Fenn et al.	6,984,205 B2	1/2006	Gazdzinski
6,790,173 B2	9/2004	Saadat et al.	6,986,738 B2	1/2006	Glukhovsky et al.
6,790,217 B2	9/2004	Schulze et al.	6,986,774 B2	1/2006	Middleman et al.
6,795,728 B2	9/2004	Chornenky et al.	6,988,987 B2	1/2006	Ishikawa et al.
6,800,056 B2	10/2004	Tartaglia et al.	6,989,028 B2	1/2006	Lashinski et al.
6,808,491 B2	10/2004	Kortenbach et al.	6,991,602 B2	1/2006	Nakazawa et al.
6,814,697 B2	11/2004	Ouchi	6,991,627 B2	1/2006	Madhani et al.
6,817,974 B2	11/2004	Cooper et al.	6,991,631 B2	1/2006	Woloszko et al.
6,818,007 B1	11/2004	Dampney et al.	6,994,706 B2	2/2006	Chornenky et al.
6,824,548 B2	11/2004	Smith et al.	6,994,708 B2	2/2006	Manzo
6,830,545 B2	12/2004	Bendall	6,997,870 B2	2/2006	Couvillon, Jr.
6,836,688 B2	12/2004	Ingle et al.	6,997,931 B2	2/2006	Sauer et al.
6,837,847 B2	1/2005	Ewers et al.	7,000,818 B2	2/2006	Shelton, IV et al.
6,840,246 B2	1/2005	Downing	7,001,329 B2	2/2006	Kobayashi et al.
6,840,938 B1	1/2005	Morley et al.	7,001,341 B2	2/2006	Gellman et al.
6,843,794 B2	1/2005	Sixto, Jr. et al.	7,008,375 B2	3/2006	Weisel
6,852,078 B2	2/2005	Ouchi	7,008,419 B2	3/2006	Shadduck
6,861,250 B1	3/2005	Cole et al.	7,009,634 B2	3/2006	Iddan et al.
6,866,627 B2	3/2005	Nozue	7,010,340 B2	3/2006	Scarantino et al.
6,866,628 B2	3/2005	Goodman et al.	7,011,669 B2	3/2006	Kimblad
6,869,394 B2	3/2005	Ishibiki	7,018,373 B2	3/2006	Suzuki
6,869,395 B2	3/2005	Page et al.	7,020,531 B1	3/2006	Colliou et al.
6,869,398 B2	3/2005	Obenchain et al.	7,025,580 B2	4/2006	Heagy et al.
6,878,106 B1	4/2005	Herrmann	7,025,721 B2	4/2006	Cohen et al.
6,878,110 B2	4/2005	Yang et al.	7,029,435 B2	4/2006	Nakao
6,881,213 B2	4/2005	Ryan et al.	7,029,438 B2	4/2006	Morin et al.
6,881,216 B2	4/2005	Di Caprio et al.	7,029,450 B2	4/2006	Gellman
6,884,213 B2	4/2005	Raz et al.	7,032,600 B2	4/2006	Fukuda et al.
6,887,255 B2	5/2005	Shimm	7,035,680 B2	4/2006	Partridge et al.
6,889,089 B2	5/2005	Behl et al.	7,037,290 B2	5/2006	Gardeski et al.
6,890,295 B2	5/2005	Michels et al.	7,041,052 B2	5/2006	Saadat et al.
6,896,683 B1	5/2005	Gadberry et al.	7,052,454 B2	5/2006	Taylor
6,896,692 B2	5/2005	Ginn et al.	7,052,489 B2	5/2006	Griego et al.
6,899,710 B2	5/2005	Hooven	7,056,330 B2	6/2006	Gayton
6,908,427 B2	6/2005	Fleener et al.	7,060,024 B2	6/2006	Long et al.
6,908,476 B2	6/2005	Jud et al.	7,060,025 B2	6/2006	Long et al.
6,911,019 B2	6/2005	Mulier et al.	7,063,697 B2	6/2006	Slater
6,913,613 B2	7/2005	Schwarz et al.	7,063,715 B2	6/2006	Onuki et al.
6,916,284 B2	7/2005	Moriyama	7,066,879 B2	6/2006	Fowler et al.
6,918,871 B2	7/2005	Schulze	7,066,936 B2	6/2006	Ryan
6,918,906 B2	7/2005	Long	7,070,559 B2	7/2006	Adams et al.
6,918,908 B2	7/2005	Bonner et al.	7,070,602 B2	7/2006	Smith et al.
6,926,723 B1	8/2005	Mulhauser et al.	7,076,305 B2	7/2006	Imran et al.
6,926,725 B2	8/2005	Cooke et al.	7,083,618 B2	8/2006	Couture et al.
6,932,810 B2	8/2005	Ryan	7,083,620 B2	8/2006	Jahns et al.
6,932,824 B1	8/2005	Roop et al.	7,083,629 B2	8/2006	Weller et al.
6,932,827 B2	8/2005	Cole	7,083,635 B2	8/2006	Ginn
6,932,834 B2	8/2005	Lizardi et al.	7,087,010 B2	8/2006	Ootawara et al.
6,936,003 B2	8/2005	Iddan	7,087,071 B2	8/2006	Nicholas et al.
6,939,290 B2	9/2005	Iddan	7,088,923 B2	8/2006	Haruyama
6,939,292 B2	9/2005	Mizuno	7,090,673 B2	8/2006	Dycus et al.
6,939,327 B2	9/2005	Hall et al.	7,090,683 B2	8/2006	Brock et al.
6,939,347 B2	9/2005	Thompson	7,090,685 B2	8/2006	Kortenbach et al.
6,942,613 B2	9/2005	Ewers et al.	7,093,518 B2	8/2006	Gmeilbauer
6,944,490 B1	9/2005	Chow	7,101,371 B2	9/2006	Dycus et al.
6,945,472 B2	9/2005	Wuttke et al.	7,101,372 B2	9/2006	Dycus et al.
6,945,479 B2	9/2005	Kortenbach et al.	7,101,373 B2	9/2006	Dycus et al.
6,949,096 B2	9/2005	Davison et al.	7,105,000 B2	9/2006	McBrayer
6,955,641 B2	10/2005	Lubbock	7,105,005 B2	9/2006	Blake
6,955,683 B2	10/2005	Bonutti	7,108,696 B2	9/2006	Daniel et al.
6,958,035 B2	10/2005	Friedman et al.	7,108,703 B2	9/2006	Danitz et al.
6,960,162 B2	11/2005	Saadat et al.	7,112,208 B2	9/2006	Morris et al.
			7,115,092 B2	10/2006	Park et al.
			7,115,124 B1	10/2006	Xiao
			7,117,703 B2	10/2006	Kato et al.
			7,118,531 B2	10/2006	Krill

(56)

References Cited**U.S. PATENT DOCUMENTS**

7,118,578 B2	10/2006	West, Jr. et al.	7,381,216 B2	6/2008	Buzzard et al.
7,118,587 B2	10/2006	Dycus et al.	7,390,324 B2	6/2008	Whalen et al.
7,128,708 B2	10/2006	Saadat et al.	7,393,322 B2	7/2008	Wenchell
7,130,697 B2	10/2006	Chornenky et al.	7,402,162 B2	7/2008	Ouchi
RE39,415 E	11/2006	Bales et al.	7,404,791 B2	7/2008	Linares et al.
7,131,978 B2	11/2006	Sancoff et al.	7,410,483 B2	8/2008	Danitz et al.
7,131,979 B2	11/2006	DiCarlo et al.	7,413,563 B2	8/2008	Corcoran et al.
7,131,980 B1	11/2006	Field et al.	7,416,554 B2	8/2008	Lam et al.
7,137,980 B2	11/2006	Buyssse et al.	7,422,590 B2	9/2008	Kupferschmid et al.
7,137,981 B2	11/2006	Long	7,431,694 B2	10/2008	Stefanchik et al.
7,146,984 B2	12/2006	Stack et al.	7,435,229 B2	10/2008	Wolf
7,147,650 B2	12/2006	Lee	7,435,257 B2	10/2008	Lashinski et al.
7,150,097 B2	12/2006	Sremcich et al.	7,441,507 B2	10/2008	Teraura et al.
7,150,655 B2	12/2006	Mastrototaro et al.	7,442,166 B2	10/2008	Huang et al.
7,150,750 B2	12/2006	Damarati	7,452,327 B2	11/2008	Durgin et al.
7,152,488 B2	12/2006	Hedrich et al.	7,455,208 B2	11/2008	Wales et al.
7,153,321 B2	12/2006	Andrews	7,455,675 B2	11/2008	Schur et al.
7,156,845 B2	1/2007	Mulier et al.	7,468,066 B2	12/2008	Vargas et al.
7,160,296 B2	1/2007	Pearson et al.	7,476,237 B2	1/2009	Taniguchi et al.
7,163,525 B2	1/2007	Franer	7,479,104 B2	1/2009	Lau et al.
7,169,104 B2	1/2007	Ueda et al.	7,485,093 B2	2/2009	Glukhovsky
7,169,115 B2	1/2007	Nobis et al.	7,488,295 B2	2/2009	Burbank et al.
7,172,714 B2	2/2007	Jacobson	7,494,499 B2	2/2009	Nagase et al.
7,175,591 B2	2/2007	Kaladelfos	7,497,867 B2	3/2009	Lasner et al.
7,179,254 B2	2/2007	Pendekanti et al.	7,498,950 B1	3/2009	Ertas et al.
7,186,265 B2	3/2007	Sharkawy et al.	7,507,200 B2	3/2009	Okada
7,188,627 B2	3/2007	Nelson et al.	7,507,239 B2	3/2009	Shadduck
7,189,231 B2	3/2007	Clague et al.	7,510,107 B2	3/2009	Timm et al.
7,195,612 B2	3/2007	van Sloten et al.	7,511,733 B2	3/2009	Takizawa et al.
7,195,631 B2	3/2007	Dumbauld	7,515,953 B2	4/2009	Madar et al.
7,204,804 B2	4/2007	Zirps et al.	7,520,876 B2	4/2009	Resselmann et al.
7,204,820 B2	4/2007	Akahoshi	7,520,950 B2	4/2009	Saadat et al.
7,207,997 B2	4/2007	Shipp et al.	7,524,281 B2	4/2009	Chu et al.
7,208,005 B2	4/2007	Frecker et al.	7,524,302 B2	4/2009	Tower
7,211,089 B2	5/2007	Kear et al.	7,534,228 B2	5/2009	Williams
7,211,092 B2	5/2007	Hughett	7,536,217 B2	5/2009	Minae et al.
7,220,227 B2	5/2007	Sasaki et al.	7,544,203 B2	6/2009	Chin et al.
7,223,271 B2	5/2007	Muramatsu et al.	7,547,310 B2	6/2009	Whitfield
7,223,272 B2	5/2007	Francese et al.	7,548,040 B2	6/2009	Lee et al.
7,229,438 B2	6/2007	Young	7,549,564 B2	6/2009	Boudreux
7,232,414 B2	6/2007	Gonzalez	7,549,990 B2	6/2009	Canady
7,232,445 B2	6/2007	Kortenbach et al.	7,549,991 B2	6/2009	Lu et al.
7,235,089 B1	6/2007	McGuckin, Jr.	7,549,998 B2	6/2009	Braun
7,241,290 B2	7/2007	Doyle et al.	7,553,278 B2	6/2009	Kucklick
7,241,295 B2	7/2007	Maguire et al.	7,553,298 B2	6/2009	Hunt et al.
7,244,228 B2	7/2007	Lubowski	7,559,452 B2	7/2009	Wales et al.
7,250,027 B2	7/2007	Barry	7,559,887 B2	7/2009	Dannan
7,252,660 B2	8/2007	Kunz	7,559,916 B2	7/2009	Smith et al.
7,255,675 B2	8/2007	Gertner et al.	7,560,006 B2	7/2009	Rakos et al.
7,261,725 B2	8/2007	Binmoeller	7,561,907 B2	7/2009	Fuimaono et al.
7,261,728 B2	8/2007	Long et al.	7,561,916 B2	7/2009	Hunt et al.
7,270,663 B2	9/2007	Nakao	7,565,201 B2	7/2009	Blackmore et al.
7,288,075 B2	10/2007	Parihar et al.	7,566,300 B2	7/2009	Devierre et al.
7,291,127 B2	11/2007	Eidenschink	7,566,334 B2	7/2009	Christian et al.
7,294,139 B1	11/2007	Gengler	7,575,144 B2	8/2009	Ortiz et al.
7,301,250 B2	11/2007	Cassel	7,575,548 B2	8/2009	Takemoto et al.
7,306,597 B2	12/2007	Manzo	7,578,832 B2	8/2009	Johnson et al.
7,308,828 B2	12/2007	Hashimoto	7,579,550 B2	8/2009	Dayton et al.
7,311,107 B2	12/2007	Harel et al.	7,582,096 B2	9/2009	Gellman et al.
7,318,802 B2	1/2008	Suzuki et al.	7,588,177 B2	9/2009	Racenet
7,320,695 B2	1/2008	Carroll	7,588,557 B2	9/2009	Nakao
7,322,934 B2	1/2008	Miyake et al.	7,591,781 B2	9/2009	Hirata
7,323,006 B2	1/2008	Andreas et al.	7,591,783 B2	9/2009	Boulais et al.
7,329,256 B2	2/2008	Johnson et al.	7,597,229 B2	10/2009	Boudreux et al.
7,329,257 B2	2/2008	Kanehira et al.	7,604,150 B2	10/2009	Boudreux
7,329,383 B2	2/2008	Stinson	7,608,083 B2	10/2009	Lee et al.
7,331,968 B2	2/2008	Arp et al.	7,611,479 B2	11/2009	Cragg et al.
7,335,220 B2	2/2008	Khosravi et al.	7,615,002 B2	11/2009	Rothweiler et al.
7,341,554 B2	3/2008	Sekine et al.	7,615,003 B2	11/2009	Stefanchik et al.
7,344,536 B1	3/2008	Lunsford et al.	7,615,005 B2	11/2009	Stefanchik et al.
7,352,387 B2	4/2008	Yamamoto	7,615,058 B2	11/2009	Sixto, Jr. et al.
7,357,806 B2	4/2008	Rivera et al.	7,615,067 B2	11/2009	Lee et al.
7,364,582 B2	4/2008	Lee	7,618,398 B2	11/2009	Holman et al.
7,367,939 B2	5/2008	Smith et al.	7,618,437 B2	11/2009	Nakao
7,371,215 B2	5/2008	Colliou et al.	7,621,927 B2	11/2009	Messerly et al.
			7,621,936 B2	11/2009	Cragg et al.

(56)	References Cited				
U.S. PATENT DOCUMENTS					
7,628,792 B2	12/2009	Guerra	7,798,960 B2	9/2010	Jaeger
7,628,797 B2	12/2009	Tieu et al.	7,813,590 B2	10/2010	Horn et al.
7,632,250 B2	12/2009	Smith et al.	7,813,789 B2	10/2010	Glukhovsky
7,635,373 B2	12/2009	Ortiz	7,815,565 B2	10/2010	Stefanchik et al.
7,637,903 B2	12/2009	Lentz et al.	7,815,566 B2	10/2010	Stefanchik et al.
7,637,905 B2	12/2009	Saadat et al.	7,815,659 B2	10/2010	Conlon et al.
7,645,288 B2	1/2010	McKenna et al.	7,815,662 B2	10/2010	Spivey et al.
7,648,457 B2	1/2010	Stefanchik et al.	7,819,836 B2	10/2010	Levine et al.
7,648,519 B2	1/2010	Lee et al.	7,828,186 B2	11/2010	Wales
7,650,742 B2	1/2010	Ushijima	7,828,808 B2	11/2010	Himman et al.
7,651,483 B2	1/2010	Byrum et al.	7,833,156 B2	11/2010	Williams et al.
7,651,509 B2	1/2010	Bojarski et al.	7,833,238 B2	11/2010	Nakao
7,653,438 B2	1/2010	Deem et al.	7,837,615 B2	11/2010	Le et al.
7,654,431 B2	2/2010	Hueil et al.	7,842,028 B2	11/2010	Lee
7,655,004 B2	2/2010	Long	7,842,050 B2	11/2010	Diduch et al.
7,658,738 B2	2/2010	Nobis et al.	7,842,068 B2	11/2010	Ginn
7,662,089 B2	2/2010	Okada et al.	7,846,087 B2	12/2010	Stefanchik et al.
7,666,180 B2	2/2010	Holsten et al.	7,846,107 B2	12/2010	Hoffman et al.
7,666,203 B2	2/2010	Chanduszko et al.	7,846,171 B2	12/2010	Kullas et al.
7,670,282 B2	3/2010	Mathis	7,850,660 B2	12/2010	Uth et al.
7,670,336 B2	3/2010	Young et al.	7,850,686 B2	12/2010	Nobis et al.
7,670,346 B2	3/2010	Whitfield	7,850,712 B2	12/2010	Conlon et al.
7,674,259 B2	3/2010	Shadduck	7,857,183 B2	12/2010	Shelton, IV
7,674,275 B2	3/2010	Martin et al.	7,862,546 B2	1/2011	Conlon et al.
7,678,043 B2	3/2010	Gilad	7,862,553 B2	1/2011	Ewaschuk
7,680,543 B2	3/2010	Azure	7,862,572 B2	1/2011	Meade et al.
7,684,599 B2	3/2010	Horn et al.	7,862,582 B2	1/2011	Ortiz et al.
7,684,851 B2	3/2010	Miyake et al.	7,867,216 B2	1/2011	Wahr et al.
7,686,826 B2	3/2010	Lee et al.	7,871,371 B2	1/2011	Komiya et al.
7,691,103 B2	4/2010	Fernandez et al.	7,875,042 B2	1/2011	Martin et al.
7,697,970 B2	4/2010	Uchiyama et al.	7,879,004 B2	2/2011	Seibel et al.
7,699,835 B2	4/2010	Lee et al.	7,883,458 B2	2/2011	Hamel
7,699,864 B2	4/2010	Kick et al.	7,887,530 B2	2/2011	Zemlok et al.
7,708,756 B2	5/2010	Nobis et al.	7,887,558 B2	2/2011	Lin et al.
7,713,189 B2	5/2010	Hanke	7,892,220 B2	2/2011	Faller et al.
7,713,270 B2	5/2010	Suzuki	7,896,804 B2	3/2011	Uchimura et al.
7,721,742 B2	5/2010	Kalloo et al.	7,896,887 B2	3/2011	Rimbaugh et al.
7,727,242 B2	6/2010	Sepetka et al.	7,905,828 B2	3/2011	Brock et al.
7,727,246 B2	6/2010	Sixto, Jr. et al.	7,905,830 B2	3/2011	Stefanchik et al.
7,727,248 B2	6/2010	Smith et al.	7,909,809 B2	3/2011	Scpton et al.
7,727,249 B2	6/2010	Rahmani	7,914,513 B2	3/2011	Voorhees, Jr.
7,731,725 B2	6/2010	Gadberry et al.	7,918,783 B2	4/2011	Maseda et al.
7,736,374 B2	6/2010	Vaughan et al.	7,918,785 B2	4/2011	Okada et al.
7,744,591 B2	6/2010	Rioux et al.	7,918,844 B2	4/2011	Byrum et al.
7,744,615 B2	6/2010	Couture	7,918,845 B2	4/2011	Saadat et al.
7,749,161 B2	7/2010	Beckman et al.	7,918,848 B2	4/2011	Lau et al.
7,749,163 B2	7/2010	Mulac et al.	7,918,869 B2	4/2011	Saadat et al.
7,751,866 B2	7/2010	Aoki et al.	7,922,650 B2	4/2011	McWeeney et al.
7,751,869 B2	7/2010	Rioux et al.	7,922,717 B2	4/2011	Sugita
7,753,901 B2	7/2010	Piskun et al.	7,922,739 B2	4/2011	Downey
7,753,933 B2	7/2010	Ginn et al.	7,922,743 B2	4/2011	Heinrich et al.
7,758,577 B2	7/2010	Nobis et al.	7,927,271 B2	4/2011	Dimitriou et al.
7,758,598 B2	7/2010	Conlon et al.	7,931,624 B2	4/2011	Smith et al.
7,762,949 B2	7/2010	Nakao	7,931,661 B2	4/2011	Saadat et al.
7,762,959 B2	7/2010	Bilsbury	7,935,130 B2	5/2011	Williams
7,762,960 B2	7/2010	Timberlake et al.	7,937,143 B2	5/2011	Demarais et al.
7,762,998 B2	7/2010	Birk et al.	7,945,332 B2	5/2011	Schechter
7,763,012 B2	7/2010	Petric et al.	7,947,000 B2	5/2011	Vargas et al.
7,765,010 B2	7/2010	Chornenky et al.	7,951,073 B2	5/2011	Freed
7,766,896 B2	8/2010	Komkven Volk et al.	7,953,326 B2	5/2011	Farr et al.
7,770,584 B2	8/2010	Danek et al.	7,955,298 B2	6/2011	Carroll et al.
7,771,416 B2	8/2010	Spivey et al.	7,955,340 B2	6/2011	Michlitsch et al.
7,771,437 B2	8/2010	Hogg et al.	7,955,355 B2	6/2011	Chin
7,776,035 B2	8/2010	Rick et al.	7,959,627 B2	6/2011	Utley et al.
7,780,639 B2	8/2010	Van Lue	7,959,629 B2	6/2011	Young et al.
7,780,683 B2	8/2010	Roue et al.	7,959,642 B2	6/2011	Nobis et al.
7,780,691 B2	8/2010	Stefanchik	7,963,192 B2	6/2011	Mayenberger et al.
7,784,663 B2	8/2010	Shelton, IV	7,963,912 B2	6/2011	Zwolinski et al.
7,785,348 B2	8/2010	Kuhns et al.	7,963,975 B2	6/2011	Criscuolo
7,789,825 B2	9/2010	Nobis et al.	7,965,180 B2	6/2011	Koyama
7,794,409 B2	9/2010	Damarati	7,967,808 B2	6/2011	Fitzgerald et al.
7,794,447 B2	9/2010	Dann et al.	7,967,842 B2	6/2011	Bakos
7,794,458 B2	9/2010	McIntyre et al.	7,969,473 B2	6/2011	Kotoda
7,794,475 B2	9/2010	Hess et al.	7,972,330 B2	7/2011	Alejandro et al.
7,798,386 B2	9/2010	Schall et al.	7,972,333 B2	7/2011	Nishimura
			7,976,458 B2	7/2011	Stefanchik et al.
			7,976,552 B2	7/2011	Suzuki
			7,985,239 B2	7/2011	Suzuki
			7,988,618 B2	8/2011	Mikkaichi et al.

(56)	References Cited				
U.S. PATENT DOCUMENTS					
7,988,685 B2	8/2011 Ziae et al.	8,251,068 B2	8/2012 Schnell		
7,988,690 B2	8/2011 Chanduszko et al.	8,252,057 B2	8/2012 Fox		
7,998,132 B2	8/2011 Gregorich et al.	8,262,563 B2	9/2012 Bakos et al.		
8,007,474 B2	8/2011 Uth et al.	8,262,655 B2	9/2012 Ghabrial et al.		
8,021,358 B2	9/2011 Doyle et al.	8,262,680 B2	9/2012 Swain et al.		
8,021,362 B2	9/2011 Deem et al.	8,267,854 B2	9/2012 Asada et al.		
8,021,378 B2	9/2011 Sixto, Jr. et al.	8,277,373 B2	10/2012 Maahs et al.		
8,029,504 B2	10/2011 Long	8,282,665 B2	10/2012 Kieturakis et al.		
8,034,046 B2	10/2011 Eidenschink	8,298,161 B2	10/2012 Vargas		
8,037,591 B2	10/2011 Spivey et al.	8,303,581 B2	11/2012 Arts et al.		
8,038,596 B2	10/2011 Miyake et al.	8,308,682 B2	11/2012 Kramer et al.		
8,038,612 B2	10/2011 Paz	8,308,738 B2	11/2012 Nobis et al.		
8,043,289 B2	10/2011 Behl et al.	8,308,743 B2	11/2012 Matsuno et al.		
8,048,060 B2	11/2011 Griffin et al.	8,313,496 B2	11/2012 Sauer et al.		
8,048,067 B2	11/2011 Davalos et al.	8,317,806 B2	11/2012 Coe et al.		
8,048,108 B2	11/2011 Sibbitt, Jr. et al.	8,317,814 B2	11/2012 Karasawa et al.		
8,052,597 B2	11/2011 Boulais	8,328,836 B2	12/2012 Conlon et al.		
8,052,699 B1	11/2011 Sherwinter	8,333,691 B2	12/2012 Schaaf		
8,057,462 B2	11/2011 Weitzner et al.	8,333,777 B2	12/2012 Schaller et al.		
8,057,510 B2	11/2011 Ginn et al.	8,337,394 B2	12/2012 Vakharia		
8,062,306 B2	11/2011 Nobis et al.	8,337,492 B2	12/2012 Kunis et al.		
8,062,311 B2	11/2011 Litscher et al.	8,337,510 B2	12/2012 Rieber et al.		
8,066,632 B2	11/2011 Dario et al.	8,343,041 B2	1/2013 Byers et al.		
8,066,702 B2	11/2011 Rittman, III et al.	8,348,827 B2	1/2013 Zwolinski		
8,070,743 B2	12/2011 Kagan et al.	8,353,487 B2	1/2013 Trusty et al.		
8,070,759 B2	12/2011 Stefanchik et al.	8,357,170 B2	1/2013 Stefanchik		
8,070,804 B2	12/2011 Hyde et al.	8,359,093 B2	1/2013 Wariar		
8,075,478 B2	12/2011 Campos	8,361,066 B2	1/2013 Long et al.		
8,075,567 B2	12/2011 Taylor et al.	8,361,112 B2	1/2013 Carroll, II et al.		
8,075,572 B2	12/2011 Stefanchik et al.	8,366,606 B2	2/2013 Watanabe et al.		
8,075,573 B2	12/2011 Gambale et al.	8,377,044 B2	2/2013 Coe et al.		
8,075,587 B2	12/2011 Ginn	8,377,057 B2	2/2013 Rick et al.		
8,088,062 B2	1/2012 Zwolinski	8,382,790 B2	2/2013 Uenoehara et al.		
8,092,374 B2	1/2012 Smith et al.	8,388,653 B2	3/2013 Nobis et al.		
8,092,549 B2	1/2012 Hillis et al.	8,394,090 B2	3/2013 Ootsubo		
8,096,459 B2	1/2012 Ortiz et al.	8,403,926 B2	3/2013 Nobis et al.		
8,096,941 B2	1/2012 Fowler et al.	8,409,076 B2	4/2013 Pang et al.		
8,096,998 B2	1/2012 Cresina	8,409,197 B2	4/2013 Slater		
8,097,001 B2	1/2012 Nakao	8,409,200 B2	4/2013 Holcomb et al.		
8,100,922 B2	1/2012 Griffith	8,425,505 B2	4/2013 Long		
8,109,872 B2	2/2012 Kennedy, II et al.	8,430,811 B2	4/2013 Hess et al.		
8,109,919 B2	2/2012 Kraft et al.	8,449,452 B2	5/2013 Iddan et al.		
8,109,926 B2	2/2012 Azure	8,449,538 B2	5/2013 Long		
8,114,072 B2	2/2012 Long et al.	8,454,594 B2	6/2013 Demarais et al.		
8,114,113 B2	2/2012 Becker	8,460,275 B2	6/2013 Taylor et al.		
8,114,119 B2	2/2012 Spivey et al.	8,465,419 B2	6/2013 Moriyama		
8,118,738 B2	2/2012 Larkin	8,465,484 B2	6/2013 Davalos et al.		
8,118,821 B2	2/2012 Mouw	8,469,993 B2	6/2013 Rothberg et al.		
8,118,834 B1	2/2012 Goraltchouk et al.	8,475,359 B2	7/2013 Asada et al.		
8,118,835 B2	2/2012 Weisel et al.	8,475,361 B2	7/2013 Barlow et al.		
8,123,677 B2	2/2012 Fujimori	8,475,452 B2	7/2013 Van Wyk et al.		
8,131,371 B2	3/2012 Demarais et al.	8,480,657 B2	7/2013 Bakos		
8,147,424 B2	4/2012 Kassab et al.	8,480,689 B2	7/2013 Spivey et al.		
8,157,813 B2	4/2012 Ko et al.	8,485,968 B2	7/2013 Weimer et al.		
8,157,817 B2	4/2012 Bonadio et al.	8,496,574 B2	7/2013 Trusty et al.		
8,157,834 B2	4/2012 Conlon	8,500,697 B2	8/2013 Kurth et al.		
8,159,549 B2	4/2012 Glukhovsky et al.	8,506,564 B2	8/2013 Long et al.		
8,167,894 B2	5/2012 Miles et al.	8,512,335 B2	8/2013 Cheng et al.		
8,172,772 B2	5/2012 Zwolinski et al.	8,517,921 B2	8/2013 Tremaglio et al.		
8,182,414 B2	5/2012 Handa et al.	8,518,024 B2	8/2013 Williams et al.		
8,187,166 B2	5/2012 Kuth et al.	8,518,052 B2	8/2013 Burgermeister et al.		
8,200,334 B1	6/2012 Min et al.	8,518,062 B2	8/2013 Cole et al.		
8,202,265 B2	6/2012 Boulais	8,523,939 B1	9/2013 Hausen		
8,202,295 B2	6/2012 Kaplan	8,529,563 B2	9/2013 Long et al.		
8,206,295 B2	6/2012 Kaul	8,540,744 B2	9/2013 Spivey et al.		
8,211,119 B2	7/2012 Palmer et al.	8,545,396 B2	10/2013 Cover et al.		
8,211,125 B2	7/2012 Spivey	8,545,450 B2	10/2013 Voegele et al.		
8,216,224 B2	7/2012 Morris et al.	8,551,058 B2	10/2013 Measamer et al.		
8,216,252 B2	7/2012 Vaughan et al.	8,562,513 B2	10/2013 Yamatani		
8,216,255 B2	7/2012 Smith et al.	8,562,602 B2	10/2013 Azure		
8,221,310 B2	7/2012 Saadat et al.	8,568,410 B2	10/2013 Vakharia et al.		
8,221,411 B2	7/2012 Francischelli et al.	8,579,176 B2	11/2013 Smith et al.		
8,241,204 B2	8/2012 Spivey	8,579,897 B2	11/2013 Vakharia et al.		
8,241,309 B2	8/2012 Miles et al.	8,602,970 B2	12/2013 Muyari et al.		
8,246,633 B2	8/2012 Omori	8,603,138 B2	12/2013 Faller et al.		
		8,608,652 B2	12/2013 Voegele et al.		
		8,617,156 B2	12/2013 Werneth et al.		
		8,623,011 B2	1/2014 Spivey		
		8,632,534 B2	1/2014 Pearson et al.		

(56)

References Cited**U.S. PATENT DOCUMENTS**

8,632,563 B2	1/2014	Nagase et al.	9,427,255 B2	8/2016	Griffith et al.
8,636,648 B2	1/2014	Gazdzinski	9,486,241 B2	11/2016	Leiner et al.
8,636,650 B2	1/2014	Lee	9,492,148 B2	11/2016	Ginn et al.
8,636,730 B2	1/2014	Keppel	9,545,290 B2	1/2017	Tellio et al.
8,640,940 B2	2/2014	Ohdaira	9,549,719 B2	1/2017	Shohat et al.
8,641,728 B2	2/2014	Stokes et al.	9,556,126 B2	2/2017	Weitzner et al.
8,652,150 B2	2/2014	Swain et al.	9,572,623 B2	2/2017	Long
8,657,174 B2	2/2014	Yates et al.	9,598,691 B2	3/2017	Davalos
8,663,236 B2	3/2014	Chen et al.	9,627,120 B2	4/2017	Scott et al.
8,668,686 B2	3/2014	Govari et al.	2001/0023333 A1	9/2001	Wise et al.
8,679,003 B2	3/2014	Spivey	2002/0022857 A1	2/2002	Goldsteen et al.
8,684,967 B2	4/2014	Engel et al.	2002/0023353 A1	2/2002	Ting-Kung
8,704,923 B2	4/2014	Ogasawara et al.	2002/0029055 A1	3/2002	Bonutti
8,715,281 B2	5/2014	Barlow et al.	2002/0042562 A1	4/2002	Meron et al.
8,721,658 B2	5/2014	Kahle et al.	2002/0068945 A1	6/2002	Sixto et al.
8,723,936 B2	5/2014	Amling et al.	2002/0082551 A1	6/2002	Yachia et al.
8,727,967 B2	5/2014	Weitzner	2002/0095164 A1	7/2002	Andreas et al.
8,747,401 B2	6/2014	Gonzalez et al.	2002/0133115 A1	9/2002	Gordon et al.
8,753,262 B2	6/2014	Sugiyama et al.	2002/0138086 A1	9/2002	Sixto et al.
8,753,335 B2	6/2014	Moshe et al.	2002/0165592 A1	11/2002	Glukhovsky et al.
8,764,735 B2	7/2014	Coe et al.	2003/0014090 A1	1/2003	Abrahamson
8,771,173 B2	7/2014	Fonger et al.	2003/0018373 A1	1/2003	Eckhardt et al.
8,771,260 B2	7/2014	Conlon et al.	2003/0069602 A1	4/2003	Jacobs et al.
8,774,913 B2	7/2014	Demarais et al.	2003/0078471 A1	4/2003	Foley et al.
8,784,436 B2	7/2014	Ho et al.	2003/0083681 A1	5/2003	Moutafis et al.
8,795,161 B2	8/2014	Carter	2003/0114731 A1	6/2003	Cadeddu et al.
8,821,520 B2	9/2014	Schwemberger et al.	2003/0114732 A1	6/2003	Webler et al.
8,821,532 B2	9/2014	Schaeffer	2003/0120257 A1	6/2003	Houston et al.
8,828,031 B2	9/2014	Fox et al.	2003/0124009 A1	7/2003	Ravi et al.
8,834,461 B2	9/2014	Werneth et al.	2003/0130656 A1	7/2003	Levin
8,858,590 B2	10/2014	Shelton, IV et al.	2003/0139646 A1	7/2003	Sharroo et al.
8,876,701 B2	11/2014	Surti et al.	2003/0158521 A1	8/2003	Ameri
8,876,772 B2	11/2014	Weber et al.	2003/0167062 A1	9/2003	Gambale et al.
8,880,185 B2	11/2014	Hastings et al.	2003/0187351 A1	10/2003	Franck et al.
8,888,792 B2	11/2014	Harris et al.	2003/0225312 A1	12/2003	Suzuki et al.
8,906,035 B2	12/2014	Zwolinski et al.	2003/0225332 A1	12/2003	Okada et al.
8,911,452 B2	12/2014	Skakoon et al.	2003/0229269 A1	12/2003	Humphrey
8,920,442 B2	12/2014	Sibbitt, Jr. et al.	2003/0229371 A1	12/2003	Whitworth
8,926,606 B2	1/2015	Davalos et al.	2004/0002683 A1	1/2004	Nicholson et al.
8,932,208 B2	1/2015	Kendale et al.	2004/0024414 A1	2/2004	Downing
8,939,897 B2	1/2015	Nobis	2004/0098007 A1	5/2004	Heiss
8,986,199 B2	3/2015	Weisenburgh, II et al.	2004/0101456 A1	5/2004	Kuroshima et al.
8,992,517 B2	3/2015	Davalos et al.	2004/0104999 A1	6/2004	Okada
9,005,198 B2	4/2015	Long et al.	2004/0133089 A1	7/2004	Kilcoyne et al.
9,011,431 B2	4/2015	Long et al.	2004/0136779 A1	7/2004	Bhaskar
9,028,483 B2	5/2015	Long et al.	2004/0138529 A1	7/2004	Wiltshire et al.
9,049,987 B2	6/2015	Conlon et al.	2004/0138587 A1	7/2004	Lyons
9,060,782 B2	6/2015	Daniel et al.	2004/0161451 A1	8/2004	Pierce et al.
9,066,655 B2	6/2015	Stefanchik et al.	2004/0167545 A1	8/2004	Sadler et al.
9,078,662 B2	7/2015	Bakos et al.	2004/0176699 A1	9/2004	Walker et al.
9,084,621 B2	7/2015	Weitzner et al.	2004/0186350 A1	9/2004	Brenneman et al.
9,089,323 B2	7/2015	Bonutti et al.	2004/0193009 A1	9/2004	Jaffe et al.
9,125,557 B2	9/2015	Lien et al.	2004/0193186 A1	9/2004	Kortenbach et al.
9,125,631 B2	9/2015	Smith et al.	2004/0193188 A1	9/2004	Francesce
9,125,639 B2	9/2015	Mathis et al.	2004/0193189 A1	9/2004	Kortenbach et al.
9,149,172 B2	10/2015	Iddan et al.	2004/0193200 A1	9/2004	Dworschak et al.
9,155,587 B2	10/2015	Willis et al.	2004/0199052 A1	10/2004	Banik et al.
9,186,203 B2	11/2015	Spivey et al.	2004/0199159 A1	10/2004	Lee et al.
9,198,733 B2	12/2015	Neal, II et al.	2004/0206859 A1	10/2004	Chong et al.
9,220,526 B2	12/2015	Conlon	2004/0210245 A1	10/2004	Erickson et al.
9,226,772 B2	1/2016	Fox	2004/0225186 A1	11/2004	Horne et al.
9,233,241 B2	1/2016	Long	2004/0243108 A1	12/2004	Suzuki
9,248,278 B2	2/2016	Crosby et al.	2004/0249367 A1	12/2004	Saadat et al.
9,254,169 B2	2/2016	Long et al.	2004/0249394 A1	12/2004	Morris et al.
9,265,407 B2	2/2016	Goldfarb et al.	2004/0249443 A1	12/2004	Shanley et al.
9,271,796 B2	3/2016	Buyssse et al.	2004/0254572 A1	12/2004	McIntyre et al.
9,277,957 B2	3/2016	Long et al.	2004/0260315 A1	12/2004	Dell et al.
9,295,485 B2	3/2016	Conlon et al.	2004/0260337 A1	12/2004	Freed
9,308,049 B2	4/2016	Dejima	2005/0004515 A1	1/2005	Hart et al.
9,314,620 B2	4/2016	Long et al.	2005/0043690 A1	2/2005	Todd
9,339,328 B2	5/2016	Ortiz et al.	2005/0059963 A1	3/2005	Phan et al.
9,345,462 B2	5/2016	Weitzner et al.	2005/0059964 A1	3/2005	Fitz
9,352,152 B2	5/2016	Lindenthaler et al.	2005/0065509 A1	3/2005	Coldwell et al.
9,370,341 B2	6/2016	Ceniccola et al.	2005/0070947 A1	3/2005	Franer et al.
9,375,268 B2	6/2016	Long	2005/0080435 A1	4/2005	Smith et al.
			2005/0085693 A1	4/2005	Belson et al.
			2005/0085832 A1	4/2005	Sancoff et al.
			2005/0090837 A1	4/2005	Sixto et al.
			2005/0096502 A1	5/2005	Khalili

(56)	References Cited					
U.S. PATENT DOCUMENTS						
2005/0101837 A1	5/2005	Kalloo et al.	2006/0200121 A1	9/2006	Mowery	
2005/0101838 A1	5/2005	Camilloci et al.	2006/0200169 A1	9/2006	Sniffin	
2005/0107663 A1	5/2005	Saadat et al.	2006/0200170 A1	9/2006	Aranyi	
2005/0107664 A1	5/2005	Kalloo et al.	2006/0217665 A1	9/2006	Prosek	
2005/0119613 A1	6/2005	Moenning et al.	2006/0217742 A1	9/2006	Messerly et al.	
2005/0124855 A1	6/2005	Jaffe et al.	2006/0237023 A1	10/2006	Cox et al.	
2005/0125010 A1	6/2005	Smith et al.	2006/0241570 A1	10/2006	Wilk	
2005/0131457 A1	6/2005	Douglas et al.	2006/0247500 A1	11/2006	Voegele et al.	
2005/0137454 A1	6/2005	Saadat et al.	2006/0247576 A1	11/2006	Poncet	
2005/0143690 A1	6/2005	High	2006/0247663 A1	11/2006	Schwartz et al.	
2005/0143774 A1	6/2005	Polo	2006/0253004 A1	11/2006	Frisch et al.	
2005/0143803 A1	6/2005	Watson et al.	2006/0259010 A1	11/2006	Stefanchik et al.	
2005/0149087 A1	7/2005	Ahlberg et al.	2006/0259073 A1	11/2006	Miyamoto et al.	
2005/0149096 A1	7/2005	Hilal et al.	2006/0264752 A1	11/2006	Rubinsky et al.	
2005/0165272 A1	7/2005	Okada et al.	2006/0264904 A1	11/2006	Kerby et al.	
2005/0165378 A1	7/2005	Heinrich et al.	2006/0270902 A1	11/2006	Igarashi et al.	
2005/0165411 A1	7/2005	Orban	2006/0271042 A1	11/2006	Latterell et al.	
2005/0165429 A1	7/2005	Douglas et al.	2006/0271102 A1	11/2006	Bosshard et al.	
2005/0182429 A1	8/2005	Yamanouchi	2006/0276835 A1	12/2006	Uchida	
2005/0192478 A1	9/2005	Williams et al.	2006/0287644 A1	12/2006	Inganas et al.	
2005/0192602 A1	9/2005	Manzo	2006/0287666 A1	12/2006	Saadat et al.	
2005/0209624 A1	9/2005	Vijay	2007/0000550 A1	1/2007	Osinski	
2005/0215858 A1	9/2005	Vail	2007/0005019 A1	1/2007	Okishige	
2005/0216036 A1	9/2005	Nakao	2007/00115965 A1	1/2007	Cox et al.	
2005/0228224 A1	10/2005	Okada et al.	2007/0032701 A1	2/2007	Fowler et al.	
2005/0228406 A1	10/2005	Bose	2007/0051375 A1	3/2007	Milliman	
2005/0240249 A1	10/2005	Tu et al.	2007/0066869 A1	3/2007	Hoffman	
2005/0250987 A1	11/2005	Ewers et al.	2007/0067017 A1	3/2007	Trapp	
2005/0251176 A1	11/2005	Swanstrom et al.	2007/0073102 A1	3/2007	Matsuno et al.	
2005/0267492 A1	12/2005	Poncet et al.	2007/0078439 A1	4/2007	Grandt et al.	
2005/0272977 A1	12/2005	Saadat et al.	2007/0083192 A1	4/2007	Welch et al.	
2005/0274935 A1	12/2005	Nelson	2007/0100375 A1	5/2007	Mikkaichi et al.	
2005/0277956 A1	12/2005	Francese et al.	2007/0100376 A1	5/2007	Mikkaichi et al.	
2005/0288555 A1	12/2005	Binmoeller	2007/0106113 A1	5/2007	Ravo	
2005/0288730 A1*	12/2005	Deem	2007/0106317 A1	5/2007	Shelton et al.	
		A61B 18/1492	2007/0112251 A1	5/2007	Nakhuda	
		607/42	2007/0112342 A1	5/2007	Pearson et al.	
2006/0004406 A1	1/2006	Wehrstein et al.	2007/0112385 A1	5/2007	Conlon	
2006/0004409 A1	1/2006	Nobis et al.	2007/0112417 A1	5/2007	Shanley et al.	
2006/0004410 A1	1/2006	Nobis et al.	2007/0118115 A1	5/2007	Artale et al.	
2006/0015009 A1	1/2006	Jaffe et al.	2007/0123840 A1	5/2007	Cox	
2006/0015131 A1	1/2006	Kierce et al.	2007/0135803 A1	6/2007	Belson	
2006/0020167 A1	1/2006	Sitzmann	2007/0142706 A1	6/2007	Matsui et al.	
2006/0025654 A1	2/2006	Suzuki et al.	2007/0142710 A1	6/2007	Yokoi et al.	
2006/0025781 A1	2/2006	Young et al.	2007/0142779 A1	6/2007	Duan et al.	
2006/0025812 A1	2/2006	Shelton	2007/0156028 A1	7/2007	Van Lue et al.	
2006/0036267 A1	2/2006	Saadat et al.	2007/0156116 A1	7/2007	Gonzalez	
2006/0041188 A1	2/2006	Dirusso et al.	2007/0161855 A1	7/2007	Mikkaichi et al.	
2006/0058582 A1	3/2006	Maahs et al.	2007/0167901 A1	7/2007	Herrig et al.	
2006/0064083 A1	3/2006	Khalaj et al.	2007/0173686 A1	7/2007	Lin et al.	
2006/0069424 A1	3/2006	Acosta et al.	2007/0173691 A1	7/2007	Yokoi et al.	
2006/0069429 A1	3/2006	Spence et al.	2007/0173869 A1	7/2007	Gannoe et al.	
2006/0074413 A1	4/2006	Behzadian	2007/0173870 A2	7/2007	Zacharias	
2006/0089528 A1	4/2006	Tartaglia et al.	2007/0173872 A1	7/2007	Neuenfeldt	
2006/0095031 A1	5/2006	Ormsby	2007/0179525 A1	8/2007	Frecker et al.	
2006/0100687 A1	5/2006	Fahey et al.	2007/0191904 A1	8/2007	Libbus et al.	
2006/0111209 A1	5/2006	Hinman et al.	2007/0198057 A1	8/2007	Gelbart et al.	
2006/0111210 A1	5/2006	Hinman	2007/0203398 A1	8/2007	Bonadio et al.	
2006/0111703 A1	5/2006	Kunis et al.	2007/0208336 A1	9/2007	Kim et al.	
2006/0111704 A1	5/2006	Brenneman et al.	2007/0208407 A1	9/2007	Gerdts et al.	
2006/0129166 A1	6/2006	Lavelle	2007/0213754 A1	9/2007	Mikkaichi et al.	
2006/0135962 A1	6/2006	Kick et al.	2007/0225552 A1	9/2007	Segawa et al.	
2006/0135971 A1	6/2006	Swanstrom et al.	2007/0233040 A1	10/2007	Macnamara et al.	
2006/0142652 A1	6/2006	Keenan	2007/0244356 A1	10/2007	Carrillo et al.	
2006/0142790 A1	6/2006	Gertner	2007/0244358 A1	10/2007	Lee	
2006/0142798 A1	6/2006	Holman et al.	2007/0255303 A1	11/2007	Bakos et al.	
2006/0149129 A1	7/2006	Watts et al.	2007/0260121 A1	11/2007	Bakos et al.	
2006/0149131 A1	7/2006	Or	2007/0260242 A1	11/2007	Dycus et al.	
2006/0149132 A1	7/2006	Iddan	2007/0260273 A1	11/2007	Cropper et al.	
2006/0161190 A1	7/2006	Gadberry et al.	2007/0260302 A1	11/2007	Igaki	
2006/0167482 A1	7/2006	Swain et al.	2007/0265494 A1	11/2007	Leanna et al.	
2006/0178560 A1	8/2006	Saadat et al.	2007/0270629 A1	11/2007	Charles	
2006/0183975 A1	8/2006	Saadat et al.	2007/0270907 A1	11/2007	Stokes et al.	
2006/0184161 A1	8/2006	Maahs et al.	2007/0282165 A1	12/2007	Hopkins et al.	
2006/0189844 A1	8/2006	Tien	2008/0004650 A1	1/2008	George	
2006/0200005 A1	9/2006	Bjork et al.	2008/0015413 A1	1/2008	Barlow et al.	
			2008/0021416 A1	1/2008	Arai et al.	
			2008/0022927 A1	1/2008	Zhang et al.	
			2008/0027387 A1	1/2008	Grabinsky	

(56)	References Cited					
U.S. PATENT DOCUMENTS						
2008/0033244 A1	2/2008 Matsui et al.	2010/0081875 A1	4/2010 Fowler et al.			
2008/0058586 A1	3/2008 Karpel	2010/0113872 A1	5/2010 Asada et al.			
2008/0065169 A1	3/2008 Colliou et al.	2010/0121362 A1	5/2010 Clague et al.			
2008/0091068 A1	4/2008 Terliuc	2010/0130817 A1	5/2010 Conlon			
2008/0097159 A1	4/2008 Ishiguro	2010/0152539 A1	6/2010 Ghabrial et al.			
2008/0097472 A1	4/2008 Agmon et al.	2010/0152725 A1	6/2010 Pearson et al.			
2008/0103527 A1	5/2008 Martin et al.	2010/0191050 A1	7/2010 Zwolinski			
2008/0114384 A1	5/2008 Chang et al.	2010/0191267 A1	7/2010 Fox			
2008/0125765 A1	5/2008 Berenshteyn et al.	2010/0198248 A1	8/2010 Vakharia			
2008/0125774 A1	5/2008 Palanker et al.	2010/0210906 A1	8/2010 Wendlandt			
2008/0125796 A1	5/2008 Graham	2010/0217367 A1	8/2010 Belson			
2008/0140069 A1	6/2008 Filloux et al.	2010/0249700 A1	9/2010 Spivey			
2008/0140071 A1	6/2008 Vegesna	2010/0268025 A1	10/2010 Belson			
2008/0147056 A1	6/2008 van der Weide et al.	2010/0286791 A1	11/2010 Goldsmith			
2008/0150754 A1	6/2008 Quendt	2010/0298642 A1	11/2010 Trusty et al.			
2008/0171907 A1	7/2008 Long et al.	2010/0312056 A1	12/2010 Galperin et al.			
2008/0188710 A1	8/2008 Segawa et al.	2010/0331622 A2	12/2010 Conlon			
2008/0200755 A1	8/2008 Bakos	2011/0077476 A1	3/2011 Rofougaran et al.			
2008/0200762 A1	8/2008 Stokes et al.	2011/0087224 A1	4/2011 Cadeddu et al.			
2008/0200911 A1	8/2008 Long	2011/0093009 A1	4/2011 Fox			
2008/0200933 A1	8/2008 Bakos et al.	2011/0098694 A1	4/2011 Long			
2008/0200934 A1	8/2008 Fox	2011/0098704 A1	4/2011 Long et al.			
2008/0208213 A1	8/2008 Benjamin et al.	2011/0112434 A1	5/2011 Ghabrial et al.			
2008/0214890 A1	9/2008 Motai et al.	2011/0112527 A1	5/2011 Hamilton, Jr. et al.			
2008/0221587 A1	9/2008 Schwartz	2011/0115891 A1	5/2011 Trusty			
2008/0228213 A1	9/2008 Blakeney et al.	2011/0152610 A1	6/2011 Trusty et al.			
2008/0230972 A1	9/2008 Ganley	2011/0152878 A1	6/2011 Trusty et al.			
2008/0243148 A1	10/2008 Mikkaichi et al.	2011/0282149 A1	11/2011 Vargas et al.			
2008/0262513 A1	10/2008 Stahler et al.	2011/0284014 A1	11/2011 Cadeddu et al.			
2008/0262524 A1	10/2008 Bangera et al.	2012/0029335 A1	2/2012 Sudam et al.			
2008/0262540 A1	10/2008 Bangera et al.	2012/0078266 A1	3/2012 Tyson, Jr.			
2008/0287801 A1	11/2008 Magnin et al.	2012/0088965 A1	4/2012 Stokes et al.			
2008/0300461 A1	12/2008 Shaw et al.	2012/0089089 A1	4/2012 Swain et al.			
2008/0300571 A1	12/2008 LePivert	2012/0089093 A1	4/2012 Trusty			
2008/0306493 A1	12/2008 Shibata et al.	2012/0101331 A1	4/2012 Gilad et al.			
2008/0309758 A1	12/2008 Karasawa et al.	2012/0101413 A1	4/2012 Beetel et al.			
2009/0030278 A1	1/2009 Minakuchi	2012/0109122 A1	5/2012 Arena et al.			
2009/0054728 A1	2/2009 Trusty	2012/0116155 A1	5/2012 Trusty			
2009/0062788 A1	3/2009 Long et al.	2012/0116266 A1	5/2012 Houser et al.			
2009/0062795 A1	3/2009 Vakharia et al.	2012/0149981 A1	6/2012 Khait et al.			
2009/0078736 A1	3/2009 Van Lue	2012/0191075 A1	7/2012 Trusty			
2009/0082627 A1	3/2009 Karasawa et al.	2012/0191076 A1	7/2012 Voegele et al.			
2009/0093690 A1	4/2009 Yoshizawa	2012/0289857 A1	11/2012 Toth et al.			
2009/0112059 A1	4/2009 Nobis	2013/0030430 A1	1/2013 Stewart et al.			
2009/0112063 A1	4/2009 Bakos et al.	2013/0090666 A1	4/2013 Hess et al.			
2009/0131751 A1	5/2009 Spivey et al.	2013/0158348 A1	6/2013 Nobis et al.			
2009/0143639 A1	6/2009 Stark	2013/0245356 A1	9/2013 Fernandez et al.			
2009/0143649 A1	6/2009 Rossi	2013/0331646 A1	12/2013 Pell et al.			
2009/0143794 A1	6/2009 Conlon et al.	2013/0331649 A1	12/2013 Khait et al.			
2009/0163770 A1	6/2009 Torrie et al.	2014/0039491 A1	2/2014 Bakos et al.			
2009/0177219 A1	7/2009 Conlon	2014/0052216 A1	2/2014 Long et al.			
2009/0182332 A1	7/2009 Long et al.	2014/0121678 A1	5/2014 Trusty et al.			
2009/0192344 A1	7/2009 Bakos et al.	2014/0243597 A1	8/2014 Weisenburgh, II et al.			
2009/0192534 A1	7/2009 Ortiz et al.	2015/0032132 A1	1/2015 Harris et al.			
2009/0198212 A1	8/2009 Timberlake et al.	2015/0230858 A1	8/2015 Long et al.			
2009/0198231 A1	8/2009 Esser et al.	2015/0265335 A1	9/2015 Bakos et al.			
2009/0210000 A1	8/2009 Sullivan et al.	2015/0374444 A1	12/2015 Conlon et al.			
2009/0221873 A1	9/2009 McGrath	2016/0074056 A1	3/2016 Conlon			
2009/0228001 A1	9/2009 Pacey	2016/0100879 A1	4/2016 Long			
2009/0259105 A1	10/2009 Miyano et al.	2016/0128759 A1	5/2016 Long et al.			
2009/0281559 A1	11/2009 Swain et al.	2016/0166311 A1	6/2016 Long et al.			
2009/0287206 A1	11/2009 Jun	2016/0296280 A1	10/2016 Long			
2009/0287236 A1	11/2009 Bakos et al.					
2009/0292167 A1	11/2009 Kimoto					
2009/0306470 A1	12/2009 Karasawa et al.					
2009/0322864 A1	12/2009 Karasawa et al.					
2010/0010294 A1	1/2010 Conlon et al.	DE 4323585 A1	1/1995			
2010/0010298 A1	1/2010 Bakos et al.	DE 19713797 A1	10/1997			
2010/0010303 A1	1/2010 Bakos	DE 19757056 B4	8/2008			
2010/0023032 A1	1/2010 Granja Filho	DE 102006027873 B4	10/2009			
2010/0036198 A1	2/2010 Tacchino et al.	EP 0086338 A1	8/1983			
2010/0048990 A1	2/2010 Bakos	EP 0286415 A2	10/1988			
2010/0049223 A1	2/2010 Granja Filho	EP 0499491 A2	8/1992			
2010/0056862 A1	3/2010 Bakos	EP 0589454 A2	3/1994			
2010/0076451 A1	3/2010 Zwolinski et al.	EP 0464479 B1	3/1995			
		EP 0529675 B1	2/1996			

FOREIGN PATENT DOCUMENTS

US 10,004,558 B2

Page 14

(56)	References Cited				
FOREIGN PATENT DOCUMENTS					
EP	0773003 A1	5/1997	JP	2007020806 A	2/2007
EP	0621009 B1	7/1997	JP	2007125264 A	5/2007
EP	0724863 B1	7/1999	JP	2007516792 A	6/2007
EP	0760629 B1	11/1999	JP	2010503496 A	2/2010
EP	0818974 B1	7/2001	JP	5646674 B2	12/2014
EP	1281356 A2	2/2003	NL	1021295 C2	2/2004
EP	0947166 B1	5/2003	SU	194230	5/1967
EP	0836832 B1	12/2003	SU	980703 A1	12/1982
EP	1402837 A1	3/2004	WO	8401707 A1	5/1984
EP	0744918 B1	4/2004	WO	8607543 A1	12/1986
EP	0931515 B1	8/2004	WO	9213494 A1	8/1992
EP	0941128 B1	10/2004	WO	9310850 A1	6/1993
EP	1411843 B1	10/2004	WO	9320760 A1	10/1993
EP	1150614 B1	11/2004	WO	9320765 A1	10/1993
EP	1481642 A1	12/2004	WO	9422383 A1	10/1994
EP	1493391 A1	1/2005	WO	9509666 A1	4/1995
EP	0848598 B1	2/2005	WO	9622056 A1	7/1996
EP	1281360 B1	3/2005	WO	9627331 A1	9/1996
EP	1568330 A1	8/2005	WO	9639946 A1	12/1996
EP	1452143 B1	9/2005	WO	9712557 A1	4/1997
EP	1616527 A2	1/2006	WO	9930622 A2	6/1999
EP	1006888 B1	3/2006	WO	0022996 A1	4/2000
EP	1629764 A1	3/2006	WO	0035358 A1	6/2000
EP	1013229 B1	6/2006	WO	0068665 A1	11/2000
EP	1721561 A1	11/2006	WO	0110319 A1	2/2001
EP	1153578 B1	3/2007	WO	0126708 A1	4/2001
EP	1334696 B1	3/2007	WO	0141627 A2	6/2001
EP	1836971 A2	9/2007	WO	0158360 A2	8/2001
EP	1836980 A1	9/2007	WO	0211621 A2	2/2002
EP	1854421 A2	11/2007	WO	0234122 A2	5/2002
EP	1857061 A1	11/2007	WO	02094082 A2	11/2002
EP	1875876 A1	1/2008	WO	03045260 A1	6/2003
EP	1891881 A1	2/2008	WO	03047684 A2	6/2003
EP	1902663 A1	3/2008	WO	03059412 A2	7/2003
EP	1477106 B1	6/2008	WO	03078721 A2	9/2003
EP	1949844 A1	7/2008	WO	03081761 A2	10/2003
EP	1518499 B1	8/2008	WO	03082129 A2	10/2003
EP	1582138 B1	9/2008	WO	2004006789 A1	1/2004
EP	1709918 B1	10/2008	WO	2004028613 A2	4/2004
EP	1985226 A2	10/2008	WO	2004037123 A1	5/2004
EP	1994904 A1	11/2008	WO	2004037149 A1	5/2004
EP	1707130 B1	12/2008	WO	2004052221 A1	6/2004
EP	1477104 B1	1/2009	WO	2004086984 A1	10/2004
EP	0723462 B1	3/2009	WO	2005009211 A2	2/2005
EP	1769749 B1	11/2009	WO	2005018467 A2	3/2005
EP	2135545 A2	12/2009	WO	2005037088 A2	4/2005
EP	1769766 B1	2/2010	WO	2005048827 A1	6/2005
EP	1493397 B1	9/2011	WO	2005065284 A2	7/2005
EP	2659847 A1	11/2013	WO	2005097019 A2	10/2005
FR	2731610 A1	9/1996	WO	2005097234 A2	10/2005
GB	330629 A	6/1930	WO	2005112810 A2	12/2005
GB	2335860 A	10/1999	WO	2005120363 A1	12/2005
GB	2403909 A	1/2005	WO	2005122866 A1	12/2005
GB	2421190 A	6/2006	WO	2006007399 A1	1/2006
GB	2443261 A	4/2008	WO	2006012630 A2	2/2006
JP	S63309252 A	12/1988	WO	2006040109 A1	4/2006
JP	H0438960 A	2/1992	WO	2006041881 A2	4/2006
JP	H06269460 A	9/1994	WO	2006060405 A2	6/2006
JP	H0829699 A	2/1996	WO	2006110733 A2	10/2006
JP	H0975365 A	3/1997	WO	2006113216 A2	10/2006
JP	H1024049 A	1/1998	WO	2007013059 A2	2/2007
JP	3007713 B2	2/2000	WO	2007014063 A2	2/2007
JP	2000107197 A	4/2000	WO	2007035537 A2	3/2007
JP	2000245683 A	9/2000	WO	2007048085 A2	4/2007
JP	20011526072 A	12/2001	WO	2007063550 A2	6/2007
JP	2002369791 A	12/2002	WO	2007100067 A1	9/2007
JP	2003088494 A	3/2003	WO	2007109171 A2	9/2007
JP	2003235852 A	8/2003	WO	2007135577 A2	11/2007
JP	2004033525 A	2/2004	WO	2007143200 A2	12/2007
JP	2004065745 A	3/2004	WO	2007144004 A1	12/2007
JP	2005121947 A	5/2005	WO	2008005433 A1	1/2008
JP	2005261514 A	9/2005	WO	2008033356 A2	3/2008
JP	2005296063 A	10/2005	WO	2008034103 A2	3/2008
JP	2006297005 A	11/2006	WO	2008041225 A2	4/2008
JP	2006343510 A	12/2006	WO	2008076337 A1	6/2008

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO	2008076800	A2	6/2008
WO	2008079440	A2	7/2008
WO	2008080062	A2	7/2008
WO	2008101075	A2	8/2008
WO	2008101086	A2	8/2008
WO	2008102154	A2	8/2008
WO	2008108863	A2	9/2008
WO	2008151237	A1	12/2008
WO	2009021030	A1	2/2009
WO	2009027065	A1	3/2009
WO	2009029065	A1	3/2009
WO	2009032623	A2	3/2009
WO	2009036457	A1	3/2009
WO	2009121017	A1	10/2009
WO	2009132190	A2	10/2009
WO	2010027688	A1	3/2010
WO	2010056716	A2	5/2010
WO	2010080974	A1	7/2010
WO	2010088481	A1	8/2010
WO	2012031204	A2	3/2012
WO	2012071526	A2	5/2012
WO	2013044378	A1	4/2013

OTHER PUBLICATIONS

- "Ethicon Endo-Surgery Studies Presented At DDW Demonstrate Potential Of Pure NOTES Surgery With Company's Toolbox," Jun. 3, 2009 Press Release; URL http://www.jnj.com/connect/news/product/20090603_120000; accessed Aug. 28, 2009 (3 pages).
- Castellvi et al., "Hybrid Transvaginal NOTES Sleeve Gastrectomy in a Porcine Model Using A Magnetically Anchored Camera and Novel Instrumentation," Abstract submitted along with Poster at SAGES Annual Meeting in Phoenix, AZ, Apr. 22, 2009 (1 page).
- Castellvi et al., "Hybrid Transvaginal NOTES Sleeve Gastrectomy in a Porcine Model Using A Magnetically Anchored Camera and Novel Instrumentation," Poster submitted along with Abstract at Sages Annual Meeting in Phoenix, AZ, Apr. 22, 2009 (1 page).
- OCTO Port Modular Laparoscopy System for Single Incision Access, Jan. 4, 2010; URL http://www.medgadget.com/archives/2010/01/octo_port_modular_laparo.html; accessed Jan. 5, 2010 (4 pages).
- Hakko Retractors, obtained Aug. 25, 2009 (5 pages).
- Zadno et al., "Linear Superelasticity in Cold-Worked Ni—Ti," Engineering Aspects of Shape Memory Alloys, pp. 414-419 (1990).
- How Stuff Works "How Smart Structures Will Work," <http://science.howstuffworks.com/engineering/structural/smart-structure1.htm>; accessed online Nov. 1, 2011 (3 pages).
- Instant Armor: Science Videos—Science News—Sciencentral; http://www.scientcentral.com/articles/view.php3?article_id=218392121; accessed online Nov. 1, 2011 (2 pages).
- Stanway, Smart Fluids: Current and Future Developments. Material Science and Technology, 20, pp. 931-939, 2004; accessed online Nov. 1, 2011 at <http://www.dynamics.group.shef.ac.uk/smart/smart.html> (7 pages).
- Jolly et al., Properties and Applications of Commercial Magnetorheological Fluids. SPIE 5th Annual Int. Symposium on Smart Structures and Materials, 1998 (18 pages).
- Rutala et al. "Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008" (available at http://www.cdc.gov/hicpac/Disinfection_Sterilization/13_11sterilizingPractices.html).
- Bewlay et al., "Spinning" in ASM Handbook, vol. 14B, Metalworking: Sheet Forming (2006).
- Schoenbach et al. "Bacterial Decontamination of Liquids with Pulsed Electric Fields" IEEE Transactions on Dielectrics and Electrical Insulation, vol. 7 No. 5. Oct. 2000, pp. 637-645.
- Widera et al., "Increased DNA Vaccine Delivery and Immunogenicity by Electroporation In Vivo," The Journal of Immunology, 164, pp. 4635-4640 (2000).
- Davalos, et al., "Tissue Ablation with Irreversible Electroporation," Annals of Biomedical Engineering, 33.2 (2005): 223-231.
- Maxim Integrated Application Note 3977: Class D Amplifiers: Fundamentals of Operation and Recent Developments, Jan. 31, 2007.
- International Search Report for PCT/US2010/020465, dated Jun. 30, 2010 (6 pages).
- Written Opinion for PCT/US2010/020465, dated Jun. 30, 2010 (9 pages).
- Ethicon, Inc., "Wound Closure Manual: Chapter 3 (The Surgical Needle)," 15 pages, (1994).
- Guido M. Scelabas, M.D., et al., "Endoluminal Methods for Gastroscopy Closure in Natural Orifice TransEnteric Surgery (NOTES)," Surgical Innovation, vol. 13, No. 1, pp. 23-30, Mar. 2006.
- Fritscher-Ravens, et al., "Transgastric Gastropexy and Hiatal Hernia Repair for GERD Under EUS Control: a Porcine Model," Gastrointestinal Endoscopy, vol. 59, No. 1, pp. 89-95, 2004.
- Ogando, "Prototype Tools That Go With the Flow," Design News, 2 pages, Jul. 17, 2006.
- Edd, et al., "In Vivo Results of a New Focal Tissue Ablation Technique: Irreversible Electroporation," IEEE Trans Biomed Eng, vol. 53, pp. 1409-1415, 2006.
- Kennedy, et al., "High-Burst-Strength, Feedback-Controlled Bipolar Vessel Sealing," Surgical Endoscopy, vol. 12, pp. 376-378 (1998).
- Collins et al., "Local Gene Therapy of Solid Tumors with GM-CSF and B7-1 Eradicates Both Treated and Distal Tumors," Cancer Gene Therapy, vol. 13, pp. 1061-1071 (2006).
- K. Sumiyama et al., "Transesophageal Mediastinoscopy by Submucosal Endoscopy With Mucosal Flap Safety Valve Technique," Gastrointest Endosc., Apr. 2007, vol. 65(4), pp. 679-683 (Abstract).
- K. Sumiyama et al., "Submucosal Endoscopy with Mucosal Flap Safety Valve," Gastrointest Endosc. Apr. 2007, vol. 65(4) pp. 694-695 (Abstract).
- K. Sumiyama et al., "Transgastric Cholecystectomy: Transgastric Accessibility to the Gallbladder Improved with the SEMF Method and a Novel Multibending Therapeutic Endoscope," Gastrointest Endosc., Jun. 2007, vol. 65(7), pp. 1028-1034 (Abstract).
- K. Sumiyama et al., "Endoscopic Caps," Tech. Gastrointest. Endosc., vol. 8, pp. 28-32, 2006.
- "Z-Offset Technique Used in the Introduction of Trocar During Laparoscopic Surgery." M.S. Hershey NOTES Presentation to EES NOTES Development Team, Sep. 27, 2007.
- F.N. Denans, Nouveau Procede Pour La Guerison Des Plaies Des Intestines. Extrait Des Seances De La Societe Royale De Medecine De Marseille, Pendant Le Mois De Decembre 1825, et le Premier Tremestre De 1826, Seance Du 24 Fevrier 1826. Recueil De La Societe Royale De Medecin De Marseille. Marseille: Impr. D'Achard, 1826; 1:127-31. (with English translation).
- I. Fraser, "An Historical Perspective on Mechanical Aids in Intestinal Anastomosis," Surg. Gynecol. Obstet. (Oct. 1982), vol. 155, pp. 566-574.
- M.E. Ryan et al., "Endoscopic Intervention for Biliary Leaks After Laparoscopic Cholecystectomy: A Multicenter Review," Gastrointest. Endosc., vol. 47(3), 1998, pp. 261-266.
- C. Cope, "Creation of Compression Gastroenterostomy by Means of the Oral, Percutaneous, or Surgical Introduction of Magnets: Feasibility Study in Swine," J. Vasc Inter Radiol., (1995), vol. 6(4), pp. 539-545.
- J.W. Hazey et al., "Natural Orifice Transgastric Endoscopic Peritoneoscopy in Humans: Initial Clinical Trial," Surg Endosc, (Jan. 2008), vol. 22(1), pp. 16-20.
- N. Chopita et al., "Endoscopic Gastroenteric Anastomosis Using Magnets," Endoscopy, (2005), vol. 37(4), pp. 313-317.
- C. Cope et al., "Long Term Patency of Experimental Magnetic Compression Gastroenteric Anastomoses Achieved with Covered Stents," Gastrointest Endosc., (2001), vol. 53, pp. 780-784.
- H. Okajima et al., "Magnet Compression Anastomosis for Bile Duct Stenosis After Duct to Duct Biliary Reconstruction in Living Donor Liver Transplantation," Liver Transplantation (2005), pp. 473-475.
- A. Fritscher-Ravens et al., "Transluminal Endosurgery: Single Lumen Access Anastomotic Device for Flexible Endoscopy," Gastrointestinal Endosc., (2003), vol. 58(4), pp. 585-591.

(56)

References Cited

OTHER PUBLICATIONS

- G.A. Hallenbeck, M.D. et al., "An Instrument for Colorectal Anastomosis Without Sutures," *Dis Col Rectum*, (1963), vol. 5, pp. 98-101.
- T. Hardy, Jr., M.D. et al., "A Biofragmentable Ring for Sutureless Bowel Anastomosis. An Experimental Study," *Dis Col Rectum*, (1985), vol. 28, pp. 484-490.
- P. O'Neill, M.D. et al., "Nonsuture Intestinal Anastomosis," *Am J. Surg.*, (1962), vol. 104, pp. 761-767.
- C.P. Swain, M.D. et al., "Anastomosis at Flexible Endoscopy: An Experimental Study of Compression Button Gastrojejunostomy," *Gastrointest Endosc.*, (1991), vol. 37, pp. 628-632.
- J.B. Murphy, M.D., "Cholecysto-Intestinal, Gastro-Intestinal, Entero-Intestinal Anastomosis, and Approximation Without Sutures (original research)," *Med Rec*, (Dec. 10, 1892), vol. 42(24), pp. 665-676.
- USGI® EndoSurgical Operating System—g-Prox® Tissue Grasper/Approximation Device; [online] URL: <http://www.usgimedical.com/eos/components-gprox.htm>—accessed May 30, 2008 (2 pages).
- Printout of web page—[http://www.webmd.com/digestive-disorders/endoscopic-retrograde-cholangiopancreatogram-ercp.htm](http://www.vacumed.com/zcom/product/Product.do?compid=27&prodid=852,#51XX Low-Cost Permanent Tubes 2MM ID, Smooth Interior Walls, VacuMed, Ventura, California, Accessed Jul. 24, 2007.</p><p>Endoscopic Retrograde Cholangiopancreatogram (ERCP); [online] URL: <a href=); last updated: Apr. 30, 2007; accessed: Feb. 21, 2008 (6 pages).
- ERCP; Jackson Siegelbaum Gastroenterology; [online] URL: <http://www.gicare.com/pated/epdgs20.htm>; accessed Feb. 21, 2008 (3 pages).
- D.G. Fong et al., "Transcolonic Ventral Wall Hernia Mesh Fixation in a Porcine Model," *Endoscopy* 2007; 39: 865-869.
- B. Rubinsky, Ph.D., "Irreversible Electroporation in Medicine," *Technology in Cancer Research and Treatment*, vol. 6, No. 4, Aug. (2007), pp. 255-259.
- D.B. Nelson, MD et al., "Endoscopic Hemostatic Devices," *Gastrointestinal Endoscopy*, vol. 54, No. 6, 2001, pp. 533-540.
- CRE™ A Pulmonary Balloon Dilator; [online] URL: http://www.bostonscientific.com/Device.bsci?page=HCP_Overview&navReId=1000.1003&method=D . . . , accessed Jul. 18, 2008 (4 pages).
- J.D. Paulson, M.D., et al., "Development of Flexible Culdoscopy," *The Journal of the American Association of Gynecologic Laparoscopists*, Nov. 1999, vol. 6, No. 4, pp. 487-490.
- H. Seifert, et al., "Retroperitoneal Endoscopic Debridement for Infected Peripancreatic Necrosis," *The Lancet, Research Letters*, vol. 356, Aug. 19, 2000, pp. 653-655.
- K.E. Mönkemüller, M.D., et al., "Transmural Drainage of Pancreatic Fluid Collections Without Electrocautery Using the Seldinger Technique," *Gastrointestinal Endoscopy*, vol. 48, No. 2, 1998, pp. 195-200, (Received Oct. 3, 1997; Accepted Mar. 31, 1998).
- D. Wilhelm et al., "An Innovative, Safe and Sterile Sigmoid Access (ISSA) for NOTES," *Endoscopy* 2007, vol. 39, pp. 401-406.
- Nakazawa et al., "Radiofrequency Ablation of Hepatocellular Carcinoma: Correlation Between Local Tumor Progression After Ablation and Ablative Margin," *AJR*, 188, pp. 480-488 (Feb. 2007).
- Miklavčič et al., "A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy," *Biochimica et Biophysica Acta*, 1523, pp. 73-83 (2000).
- Evans, "Ablative and cathether-delivered therapies for colorectal liver metastases (CRLM)," *EJSO*, 33, pp. S64-S75 (2007).
- Wong et al., "Combined Percutaneous Radiofrequency Ablation and Ethanol Injection for Hepatocellular Carcinoma in High-Risk Locations," *AJR*, 190, pp. W187-W195 (2008).
- Heller et al., "Electrically mediated plasmid DNA delivery to hepatocellular carcinomas in vivo," *Gene Therapy*, 7, pp. 826-829 (2000).
- Weaver et al., "Theory of electroporation: A review," *Bioelectrochemistry and Bioenergetics*, 41, pp. 135-160 (1996).
- Mulier et al., "Radiofrequency Ablation Versus Resection for Resectable Colorectal Liver Metastases: Time for a Randomized Trial?" *Annals of Surgical Oncology*, 15(1), pp. 144-157 (2008).
- Link et al., "Regional Chemotherapy of Nonresectable Colorectal Liver Metastases with Mitoxanthrone, 5-Fluorouracil, Folinic Acid, and Mitomycin C May Prolong Survival," *Cancer*, 92, pp. 2746-2753 (2001).
- Guyton et al., "Membrane Potentials and Action Potentials," W.B. Sanders, ed. *Textbook of Medical Physiology*, p. 56 (2000).
- Guyton et al., "Contraction of Skeletal Muscle," *Textbook of Medical Physiology*, pp. 82-84 (2000).

* cited by examiner




FIG. 1




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 2E




FIG. 3




FIG. 4




FIG. 5




FIG. 6

FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11






FIG. 12






FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23

ELECTRICAL ABLATION DEVICES**CROSS REFERENCE TO RELATED APPLICATIONS**

This non-provisional patent application is a continuation patent application claiming priority under 35 U.S.C. § 120 of U.S. patent application Ser. No. 13/602,742, filed Sep. 4, 2012, entitled ELECTRICAL ABLATION DEVICES, now U.S. Patent Application Publication No. 2012/0330306, which is a divisional patent application claiming priority under 35 U.S.C. § 121 of U.S. patent application Ser. No. 12/352,375, filed Jan. 12, 2009, entitled ELECTRICAL ABLATION DEVICES, now U.S. Pat. No. 8,361,066, the entire disclosures of which are hereby incorporated by reference herein.

BACKGROUND

Electrical ablation therapy has been employed in medicine for the treatment of undesirable tissue such as diseased tissue, cancer, malignant and benign tumors, masses, lesions, and other abnormal tissue growths. While conventional apparatuses, systems, and methods for the electrical ablation of undesirable tissue are effective, one drawback with conventional electrical ablation treatment is the resulting permanent damage that may occur to the healthy tissue surrounding the abnormal tissue due primarily to the detrimental thermal effects resulting from exposing the tissue to thermal energy generated by the electrical ablation device. This may be particularly true when exposing the tissue to electric potentials sufficient to cause cell necrosis using high temperature thermal therapies including focused ultrasound ablation, radiofrequency (RF) ablation, or interstitial laser coagulation. Other techniques for tissue ablation include chemical ablation, in which chemical agents are injected into the undesirable tissue to cause ablation as well as surgical excision, cryotherapy, radiation, photodynamic therapy, Moh's micrographic surgery, topical treatments with 5-fluorouracil, laser ablation. Other drawbacks of conventional thermal, chemical, and other ablation therapy are cost, length of recovery, and the extraordinary pain inflicted on the patient.

Conventional thermal, chemical, and other ablation techniques have been employed for the treatment of a variety of undesirable tissue. Thermal and chemical ablation techniques have been used for the treatment of varicose veins resulting from reflux disease of the greater saphenous vein (GSV), in which the varicose vein is stripped and then is exposed to either chemical or thermal ablation. Other techniques for the treatment of undesirable tissue are more radical. Prostate cancer, for example, may be removed using a prostatectomy, in which the entire or part of prostate gland and surrounding lymph nodes are surgically removed. Like most other forms of cancer, radiation therapy may be used in conjunction with or as an alternate method for the treatment of prostate cancer. Another thermal ablation technique for the treatment of prostate cancer is RF interstitial tumor ablation (RITA) via trans-rectal ultrasound guidance. While these conventional methods for the treatment of prostate cancer are effective, they are not preferred by many surgeons and may result in detrimental thermal effects to healthy tissue surrounding the prostate. Similar thermal ablation techniques may be used for the treatment of basal cell carcinoma (BCC) tissue, a slowly growing cutaneous malignancy derived from the rapidly proliferating basal layer of the epidermis. BCC tissue in tumors ranging in size

from about 5 mm to about 40 mm may be thermally ablated with a pulsed carbon dioxide laser. Nevertheless, carbon dioxide laser ablation is a thermal treatment method and may cause permanent damage to healthy tissue surrounding the BCC tissue. Furthermore, this technique requires costly capital investment in carbon dioxide laser equipment. Undesirable tissue growing inside a body lumen such as the esophagus, large bowel, or in cavities formed in solid tissue such as the breast, for example, can be difficult to destroy using conventional ablation techniques. Surgical removal of undesirable tissue, such as a malignant or benign tumor, from the breast is likely to leave a cavity. Surgical resection of residual intraluminal tissue may remove only a portion of the undesirable tissue cells within a certain margin of healthy tissue. Accordingly, some undesirable tissue is likely to remain within the wall of the cavity due to the limitation of conventional ablation instrument configurations, which may be effective for treating line-of-sight regions of tissue, but may be less effective for treating the residual undesirable tissue.

Accordingly, there remains a need for improved electrical ablation apparatuses, systems, and methods for the treatment of undesirable tissue found in diseased tissue, cancer, malignant and benign tumors, masses, lesions, and other abnormal tissue growths. There remains a need for minimally invasive treatment of undesirable tissue through the use of irreversible electroporation (IRE) ablation techniques without causing the detrimental thermal effects of conventional thermal ablation techniques.

FIGURES

The novel features of the various described embodiments are set forth with particularity in the appended claims. The various embodiments, however, both as to organization and methods of operation, together with advantages thereof, may be understood in accordance with the following description taken in conjunction with the accompanying drawings as follows.

FIG. 1 illustrates one embodiment of an electrical ablation system.

FIGS. 2A-D illustrate one embodiment of the electrical ablation device in various phases of deployment.

FIG. 2E illustrates one embodiment of the electrical ablation device comprising multiple needle electrodes.

FIG. 3 illustrates one embodiment of the electrical ablation system shown in FIGS. 1 and 2A-D in use to treat undesirable tissue located on the surface of the liver.

FIG. 4 illustrates a detailed view of one embodiment of the electrical ablation system shown in FIG. 3 in use to treat undesirable tissue located on the surface of the liver.

FIG. 5 is a graphical representation of a series of electrical pulses that may be applied to undesirable tissue to create a first necrotic zone by inducing irreversible electroporation in the tissue and to create a second necrotic zone by inducing thermal effects near the electrode-tissue-interface using the electrical ablation system shown in FIG. 4.

FIGS. 6, 7, and 8 illustrate one embodiment of an electrical ablation device to treat undesirable tissue within body lumen using electrical energy, where FIG. 6 illustrates a sectioned view of one embodiment of an electrical ablation device, FIG. 7 illustrates an end view of one embodiment of the electrical ablation device shown in FIG. 6, and FIG. 8 illustrates a cross-sectional view of one embodiment of the electrical ablation device shown in FIG. 6.

FIG. 9 illustrates one embodiment of an electrical ablation system in use to treat non-metastatic prostate cancer in a patient.

FIG. 10 is a graphical representation of a series of electrical pulses that may be applied to undesirable tissue to induce irreversible electroporation suitable to ablate non-metastatic cancer of the prostate as described in FIG. 9.

FIG. 11 illustrates one embodiment of the electrical ablation system described FIG. 1 in use to treat basal cell carcinoma (BCC) tissue.

FIG. 12 is a graphical representation of a series of electrical pulses for treating basal cell carcinoma (BCC) tissue as shown in FIG. 11 with irreversible electroporation energy.

FIG. 13A illustrates one embodiment of an electrical ablation device, in a collapsed state, the device having a configuration suitable for the treatment of abnormal tissue located in a lumen, abscess, void, or cavity.

FIG. 13B illustrates one embodiment of the electrical ablation device shown in FIG. 13A, in an inflated state, the device having a configuration suitable for the treatment of abnormal tissue located in a lumen, abscess, void, or cavity.

FIG. 14 is a cross-sectional view of the electrical ablation device showing a cross-sectional view of the conductive elastomer electrode and the non-conductive catheter shown in FIGS. 13A and 13B.

FIG. 15 illustrates one embodiment of the electrical ablation device shown in FIG. 13A inserted through the mouth and esophagus to ablate cancerous tissue in the esophagus using electrical pulses.

FIG. 16 illustrates a distal portion of an endoscope used in conjunction with the electrical ablation device shown in FIG. 13A.

FIG. 17 illustrates a cross-sectional view of a breast showing a cavity that may be left after a lumpectomy to remove a tumor from the breast.

FIG. 18 illustrates one embodiment of a catheter inserted into the cavity left in the breast following a lumpectomy procedure as shown in FIG. 17.

FIG. 19 illustrates an expanded sponge filling the cavity left in the breast following a lumpectomy as shown in FIG. 17.

FIG. 20 illustrates the expanded sponge intact to fill the cavity left in the breast as shown in FIG. 17 following irreversible electroporation ablation therapy.

FIG. 21 illustrates a mesh of a finite element model of a sponge inserted in the cavity left in the breast as shown in FIG. 17.

FIG. 22 is a graphical representation of electric potential and electrical field strength sufficient to induce irreversible electroporation when applied to the sponge located within the breast cavity as shown in FIG. 17.

FIG. 23 is a graphical representation of electric field strength contours in volts per meter (V/m) developed when electrodes are energized by an energy source.

DESCRIPTION

Various embodiments are directed to apparatuses, systems, and methods for the electrical ablation treatment of undesirable tissue such as diseased tissue, cancer, malignant and benign tumors, masses, lesions, and other abnormal tissue growths without causing any detrimental thermal effects to surrounding healthy tissue. Numerous specific details are set forth to provide a thorough understanding of the overall structure, function, manufacture, and use of the embodiments as described in the specification and illustrated

in the accompanying drawings. It will be understood by those skilled in the art, however, that the embodiments may be practiced without the specific details. In other instances, well-known operations, components, and elements have not been described in detail so as not to obscure the embodiments described in the specification. Those of ordinary skill in the art will understand that the embodiments described and illustrated herein are non-limiting examples, and thus it can be appreciated that the specific structural and functional details disclosed herein may be representative and do not necessarily limit the scope of the embodiments, the scope of which is defined solely by the appended claims.

Reference throughout the specification to “various embodiments,” “some embodiments,” “one embodiment,” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, appearances of the phrases “in various embodiments,” “in some embodiments,” “in one embodiment,” or “in an embodiment” in places throughout the specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. Thus, the particular features, structures, or characteristics illustrated or described in connection with one embodiment may be combined, in whole or in part, with the features structures, or characteristics of one or more other embodiments without limitation.

It will be appreciated that the terms “proximal” and “distal” may be used throughout the specification with reference to a clinician manipulating one end of an instrument used to treat a patient. The term “proximal” refers to the portion of the instrument closest to the clinician and the term “distal” refers to the portion located furthest from the clinician. It will be further appreciated that for conciseness and clarity, spatial terms such as “vertical,” “horizontal,” “up,” and “down” may be used herein with respect to the illustrated embodiments. However, surgical instruments may be used in many orientations and positions, and these terms are not intended to be limiting and absolute.

Various embodiments of apparatuses, systems, and methods for the electrical ablation treatment of undesirable tissue such as diseased tissue, cancer, malignant and benign tumors, masses, lesions, and other abnormal tissue growths, are described throughout the specification and illustrated in the accompanying drawings. The electrical ablation devices in accordance with the described embodiments may comprise one or more electrodes configured to be positioned into or proximal to undesirable tissue in a tissue treatment region (e.g., target site, worksite) where there is evidence of abnormal tissue growth, for example. In general, the electrodes comprise an electrically conductive portion (e.g., medical grade stainless steel) and are configured to electrically couple to an energy source. Once the electrodes are positioned into or proximal to the undesirable tissue, an energizing potential is applied to the electrodes to create an electric field to which the undesirable tissue is exposed. The energizing potential (and the resulting electric field) may be characterized by multiple parameters such as frequency, amplitude, pulse width (duration of a pulse or pulse length), and/or polarity. Depending on the diagnostic or therapeutic treatment to be rendered, a particular electrode may be configured either as an anode (+) or a cathode (-) or may comprise a plurality of electrodes with at least one configured as an anode and at least one other configured as a cathode. Regardless of the initial polar configuration, the

polarity of the electrodes may be reversed by reversing the polarity of the output of the energy source.

In various embodiments, a suitable energy source may comprise an electrical waveform generator, which may be configured to create an electric field that is suitable to create irreversible electroporation in undesirable tissue at various electric field amplitudes and durations. The energy source may be configured to deliver irreversible electroporation pulses in the form of direct-current (DC) and/or alternating-current (AC) voltage potentials (e.g., time-varying voltage potentials) to the electrodes. The irreversible electroporation pulses may be characterized by various parameters such as frequency, amplitude, pulse length, and/or polarity. The undesirable tissue may be ablated by exposure to the electric potential difference across the electrodes.

In one embodiment, the energy source may comprise a wireless transmitter to deliver energy to the electrodes using wireless energy transfer techniques via one or more remotely positioned antennas. Those skilled in the art will appreciate that wireless energy transfer or wireless power transmission is the process of transmitting electrical energy from an energy source to an electrical load without interconnecting wires. An electrical transformer is the simplest instance of wireless energy transfer. The primary and secondary circuits of a transformer are not directly connected and the transfer of energy takes place by electromagnetic coupling through a process known as mutual induction. Power also may be transferred wirelessly using RF energy. Wireless power transfer technology using RF energy is produced by Powercast, Inc. and can achieve an output of 6 volts for a little over one meter. Other low-power wireless power technology has been proposed such as described in U.S. Pat. No. 6,967,462.

The apparatuses, systems, and methods in accordance with the described embodiments may be configured for minimally invasive ablation treatment of undesirable tissue through the use of irreversible electroporation to be able to ablate undesirable tissue in a controlled and focused manner without inducing thermally damaging effects to the surrounding healthy tissue. The apparatuses, systems, and methods in accordance with the described embodiments may be configured to ablate undesirable tissue through the use of electroporation or electropermeabilization. More specifically, the apparatuses, systems, and methods in accordance with the described embodiments may be configured to ablate undesirable tissue through the use of irreversible electroporation. Electroporation increases the permeabilization of a cell membrane by exposing the cell to electric pulses. The external electric field (electric potential per unit length) to which the cell membrane is exposed to significantly increases the electrical conductivity and permeability of the plasma in the cell membrane. The primary parameter affecting the transmembrane potential is the potential difference across the cell membrane. Irreversible electroporation is the application of an electric field of a specific magnitude and duration to a cell membrane such that the permeabilization of the cell membrane cannot be reversed, leading to cell death without inducing a significant amount of heat in the cell membrane. The destabilizing potential forms pores in the cell membrane when the potential across the cell membrane exceeds its dielectric strength causing the cell to die under a process known as apoptosis and/or necrosis. The application of irreversible electroporation pulses to cells is an effective way for ablating large volumes of undesirable tissue without deleterious thermal effects to the surrounding healthy tissue associated with thermal-inducing ablation treatments. This is because irreversible electroporation

destroys cells without heat and thus does not destroy the cellular support structure or regional vasculature. A destabilizing irreversible electroporation pulse, suitable to cause cell death without inducing a significant amount of thermal damage to the surrounding healthy tissue, may have amplitude in the range of about several hundred to about several thousand volts and is generally applied across biological membranes over a distance of about several millimeters, for example, for a relatively long duration. Thus, the undesirable tissue may be ablated in-vivo through the delivery of destabilizing electric fields by quickly creating cell necrosis.

The apparatuses, systems, and methods for electrical ablation therapy in accordance with the described embodiments may be adapted for use in minimally invasive surgical procedures to access the tissue treatment region in various anatomic locations such as the brain, lungs, breast, liver, gall bladder, pancreas, prostate gland, and various internal body lumen defined by the esophagus, stomach, intestine, colon, arteries, veins, anus, vagina, cervix, fallopian tubes, and the peritoneal cavity, for example, without limitation. Minimally invasive electrical ablation devices may be introduced to the tissue treatment region using a trocar inserted through a small opening formed in the patient's body or through a natural body orifice such as the mouth, anus, or vagina using transluminal access techniques known as Natural Orifice Transluminal Endoscopic Surgery (NOTES)TM. Once the electrical ablation devices (e.g., electrodes) are located into or proximal to the undesirable tissue in the treatment region, electric field potentials can be applied to the undesirable tissue by the energy source. The electrical ablation devices comprise portions that may be inserted into the tissue treatment region percutaneously (e.g., where access to inner organs or other tissue is done via needle-puncture of the skin). Other portions of the electrical ablation devices may be introduced into the tissue treatment region endoscopically (e.g., laparoscopically and/or thoracoscopically) through trocars or working channels of the endoscope, through small incisions, or transcutaneously (e.g., where electric pulses are delivered to the tissue treatment region through the skin).

FIG. 1 illustrates one embodiment of an electrical ablation system 10. The electrical ablation system 10 may be employed to ablate undesirable tissue such as diseased tissues, cancers, tumors, masses, lesions, abnormal tissue growths inside a patient using electrical energy. The electrical ablation system 10 may be used in conjunction with endoscopic, laparoscopic, thoracoscopic, open surgical procedures via small incisions or keyholes, percutaneous techniques, transcutaneous techniques, and/or external non-invasive techniques, or any combinations thereof without limitation. The electrical ablation system 10 may be configured to be positioned within a natural body orifice of the patient such as the mouth, anus, or vagina and advanced through internal body lumen or cavities such as the esophagus, colon, cervix, urethra, for example, to reach the tissue treatment region. The electrical ablation system 10 also may be configured to be positioned and passed through a small incision or keyhole formed through the skin or abdominal wall of the patient to reach the tissue treatment region using a trocar. The tissue treatment region may be located in the brain, lungs, breast, liver, gall bladder, pancreas, prostate gland, various internal body lumen defined by the esophagus, stomach, intestine, colon, arteries, veins, anus, vagina, cervix, fallopian tubes, and the peritoneal cavity, for example, without limitation. The electrical ablation system 10 can be configured to treat a number of lesions and osteopathologies comprising metastatic lesions, tumors, fractures, infected sites, inflamed sites. Once positioned into or

proximate the tissue treatment region, the electrical ablation system 10 can be actuated (e.g., energized) to ablate the undesirable tissue. In one embodiment, the electrical ablation system 10 may be configured to treat diseased tissue in the gastrointestinal (GI) tract, esophagus, lung, or stomach that may be accessed orally. In another embodiment, the electrical ablation system 10 may be adapted to treat undesirable tissue in the liver or other organs that may be accessible using transluminal access techniques such as, without limitation, NOTESTM techniques, where the electrical ablation devices may be initially introduced through a natural orifice such as the mouth, anus, or vagina and then advanced to the tissue treatment site by puncturing the walls of internal body lumen such as the stomach, intestines, colon, cervix. In various embodiments, the electrical ablation system 10 may be adapted to treat undesirable tissue in the brain, liver, breast, gall bladder, pancreas, or prostate gland, using one or more electrodes positioned percutaneously, transcutaneously, transluminally, minimally invasively, and/or through open surgical techniques, or any combination thereof.

In one embodiment, the electrical ablation system 10 may be employed in conjunction with a flexible endoscope 12, as well as a rigid endoscope, laparoscope, or thoracoscope, such as the GIF-100 model available from Olympus Corporation. In one embodiment, the endoscope 12 may be introduced to the tissue treatment region trans-anally through the colon, trans-orally through the esophagus and stomach, trans-vaginally through the cervix, transcutaneously, or via an external incision or keyhole formed in the abdomen in conjunction with a trocar. The electrical ablation system 10 may be inserted and guided into or proximate the tissue treatment region using the endoscope 12.

In the embodiment illustrated in FIG. 1, the endoscope 12 comprises an endoscope handle 34 and an elongate relatively flexible shaft 32. The distal end of the flexible shaft 32 may comprise a light source and a viewing port. Optionally, the flexible shaft 32 may define one or more working channels for receiving various instruments, such as electrical ablation devices, for example, therethrough. Images within the field of view of the viewing port are received by an optical device, such as a camera comprising a charge coupled device (CCD) usually located within the endoscope 12, and are transmitted to a display monitor (not shown) outside the patient.

In one embodiment, the electrical ablation system 10 may comprise an electrical ablation device 20, a plurality of electrical conductors 18, a handpiece 16 comprising an activation switch 62, and an energy source 14, such as an electrical waveform generator, electrically coupled to the activation switch 62 and the electrical ablation device 20. The electrical ablation device 20 comprises a relatively flexible member or shaft 22 that may be introduced to the tissue treatment region using a variety of known techniques such as an open incision and a trocar, through one of more of the working channels of the endoscope 12, percutaneously, or transcutaneously.

In one embodiment, one or more electrodes (e.g., needle electrodes, balloon electrodes), such as first and second electrodes 24a,b, extend out from the distal end of the electrical ablation device 20. In one embodiment, the first electrode 24a may be configured as the positive electrode and the second electrode 24b may be configured as the negative electrode. The first electrode 24a is electrically connected to a first electrical conductor 18a, or similar electrically conductive lead or wire, which is coupled to the positive terminal of the energy source 14 through the acti-

vation switch 62. The second electrode 24b is electrically connected to a second electrical conductor 18b, or similar electrically conductive lead or wire, which is coupled to the negative terminal of the energy source 14 through the activation switch 62. The electrical conductors 18a,b are electrically insulated from each other and surrounding structures, except for the electrical connections to the respective electrodes 24a,b. In various embodiments, the electrical ablation device 20 may be configured to be introduced into or proximate the tissue treatment region using the endoscope 12 (laparoscope or thoracoscope), open surgical procedures, or external and non-invasive medical procedures. The electrodes 24a,b may be referred to herein as endoscopic or laparoscopic electrodes, although variations thereof may be inserted transcutaneously or percutaneously. As previously discussed, either one or both electrodes 24a,b may be adapted and configured to slideably move in and out of a cannula, lumen, or channel defined within the flexible shaft 22.

Once the electrodes 24a,b are positioned at the desired location into or proximate the tissue treatment region, the electrodes 24a,b may be connected to or disconnected from the energy source 14 by actuating or de-actuating the switch 62 on the handpiece 16. The switch 62 may be operated manually or may be mounted on a foot switch (not shown), for example. The electrodes 24a,b deliver electric field pulses to the undesirable tissue. The electric field pulses may be characterized based on various parameters such as pulse shape, amplitude, frequency, and duration. The electric field pulses may be sufficient to induce irreversible electroporation in the undesirable tissue. The induced potential depends on a variety of conditions such as tissue type, cell size, and electrical pulse parameters. The primary electrical pulse parameter affecting the transmembrane potential for a specific tissue type is the amplitude of the electric field and pulse length that the tissue is exposed to.

In one embodiment, a protective sleeve or sheath 26 may be slidably disposed over the flexible shaft 22 and within a handle 28. In another embodiment, the sheath 26 may be slidably disposed within the flexible shaft 22 and the handle 28, without limitation. The sheath 26 is slideable and may be located over the electrodes 24a,b to protect the trocar and prevent accidental piercing when the electrical ablation device 20 is advanced therethrough. Either one or both of the electrodes 24a,b of the electrical ablation device 20 may be adapted and configured to slideably move in and out of a cannula, lumen, or channel formed within the flexible shaft 22. The second electrode 24b may be fixed in place. The second electrode 24b may provide a pivot about which the first electrode 24a can be moved in an arc to other points in the tissue treatment region to treat larger portions of the diseased tissue that cannot be treated by fixing the electrodes 24a,b in one location. In one embodiment, either one or both of the electrodes 24a,b may be adapted and configured to slideably move in and out of a working channel formed within a flexible shaft 32 of the flexible endoscope 12 or may be located independently of the flexible endoscope 12. Various features of the first and second electrodes 24a,b are described in more detail in FIGS. 2A-D.

In one embodiment, the first and second electrical conductors 18a,b may be provided through the handle 28. In the illustrated embodiment, the first electrode 24a can be slideably moved in and out of the distal end of the flexible shaft 22 using a slide member 30 to retract and/or advance the first electrode 24a. In various embodiments either or both electrodes 24a,b may be coupled to the slide member 30, or additional slide members, to advance and retract the elec-

trodes 24a,b, e.g., position the electrodes 24a,b. In the illustrated embodiment, the first electrical conductor 18a coupled to the first electrode 24a is coupled to the slide member 30. In this manner, the first electrode 24a, which is slidably movable within the cannula, lumen, or channel defined by the flexible shaft 22, can advanced and retracted with the slide member 30.

In various other embodiments, transducers or sensors 29 may be located in the handle 28 of the electrical ablation device 20 to sense the force with which the electrodes 24a,b penetrate the tissue in the tissue treatment zone. This feedback information may be useful to determine whether either one or both of the electrodes 24a,b have been properly inserted in the tissue treatment region. As is particularly well known, cancerous tumor tissue tends to be denser than healthy tissue and thus greater force is required to insert the electrodes 24a,b therein. The transducers or sensors 29 can provide feedback to the operator, surgeon, or clinician to physically sense when the electrodes 24a,b are placed within the cancerous tumor. The feedback information provided by the transducers or sensors 29 may be processed and displayed by circuits located either internally or externally to the energy source 14. The sensor 29 readings may be employed to determine whether the electrodes 24a,b have been properly located within the cancerous tumor thereby assuring that a suitable margin of error has been achieved in locating the electrodes 24a,b.

In one embodiment, the input to the energy source 14 may be connected to a commercial power supply by way of a plug (not shown). The output of the energy source 14 is coupled to the electrodes 24a,b, which may be energized using the activation switch 62 on the handpiece 16, or in one embodiment, an activation switch mounted on a foot activated pedal (not shown). The energy source 14 may be configured to produce electrical energy suitable for electrical ablation, as described in more detail below.

In one embodiment, the electrodes 24a,b are adapted and configured to electrically couple to the energy source 14 (e.g., generator, waveform generator). Once electrical energy is coupled to the electrodes 24a,b, an electric field is formed at a distal end of the electrodes 24a,b. The energy source 14 may be configured to generate electric pulses at a predetermined frequency, amplitude, pulse length, and/or polarity that are suitable to induce irreversible electroporation to ablate substantial volumes of undesirable tissue in the treatment region. For example, the energy source 14 may be configured to deliver DC electric pulses having a predetermined frequency, amplitude, pulse length, and/or polarity suitable to induce irreversible electroporation to ablate substantial volumes of undesirable tissue in the treatment region. The DC pulses may be positive or negative relative to a particular reference polarity. The polarity of the DC pulses may be reversed or inverted from positive-to-negative or negative-to-positive a predetermined number of times to induce irreversible electroporation to ablate substantial volumes of undesirable tissue in the treatment region.

In one embodiment, a timing circuit may be coupled to the output of the energy source 14 to generate electric pulses. The timing circuit may comprise one or more suitable switching elements to produce the electric pulses. For example, the energy source 14 may produce a series of n electric pulses (where n is any positive integer) of sufficient amplitude and duration to induce irreversible electroporation suitable for tissue ablation when the n electric pulses are applied to the electrodes 24a,b. In one embodiment, the electric pulses may have a fixed or variable pulse length, amplitude, and/or frequency.

The electrical ablation device 20 may be operated either in bipolar or monopolar mode. In bipolar mode, the first electrode 24a is electrically connected to a first polarity and the second electrode 24b is electrically connected to the opposite polarity. For example, in monopolar mode, the first electrode 24a is coupled to a prescribed voltage and the second electrode 24b is set to ground. In the illustrated embodiment, the energy source 14 may be configured to operate in either the bipolar or monopolar modes with the electrical ablation system 10. In bipolar mode, the first electrode 24a is electrically connected to a prescribed voltage of one polarity and the second electrode 24b is electrically connected to a prescribed voltage of the opposite polarity. When more than two electrodes are used, the polarity of the electrodes may be alternated so that any two adjacent electrodes may have either the same or opposite polarities, for example.

In monopolar mode, it is not necessary that the patient be grounded with a grounding pad. Since a monopolar energy source 14 is typically constructed to operate upon sensing a ground pad connection to the patient, the negative electrode of the energy source 14 may be coupled to an impedance simulation circuit. In this manner, the impedance circuit simulates a connection to the ground pad and thus is able to activate the energy source 14. It will be appreciated that in monopolar mode, the impedance circuit can be electrically connected in series with either one of the electrodes 24a,b that would otherwise be attached to a grounding pad.

In one embodiment, the energy source 14 may be configured to produce RF waveforms at predetermined frequencies, amplitudes, pulse widths or durations, and/or polarities suitable for electrical ablation of cells in the tissue treatment region. One example of a suitable RF energy source is a commercially available conventional, bipolar/monopolar electrosurgical RF generator such as Model Number ICC 350, available from Erbe, GmbH.

In one embodiment, the energy source 14 may be configured to produce destabilizing electrical potentials (e.g., fields) suitable to induce irreversible electroporation. The destabilizing electrical potentials may be in the form of bipolar/monopolar DC electric pulses suitable for inducing irreversible electroporation to ablate tissue undesirable tissue with the electrical ablation device 20. A commercially available energy source suitable for generating irreversible electroporation electric field pulses in bipolar or monopolar mode is a pulsed DC generator such as Model Number ECM 830, available from BTX Molecular Delivery Systems Boston, Mass. In bipolar mode, the first electrode 24a may be electrically coupled to a first polarity and the second electrode 24b may be electrically coupled to a second (e.g., opposite) polarity of the energy source 14. Bipolar/monopolar DC electric pulses may be produced at a variety of frequencies, amplitudes, pulse lengths, and/or polarities. Unlike RF ablation systems, however, which require high power and energy levels delivered into the tissue to heat and thermally destroy the tissue, irreversible electroporation requires very little energy input into the tissue to kill the undesirable tissue without the detrimental thermal effects because with irreversible electroporation the cells are destroyed by electric field potentials rather than heat.

In one embodiment, the energy source 14 may be coupled to the first and second electrodes 24a,b by either a wired or a wireless connection. In a wired connection, the energy source 14 is coupled to the electrodes 24a,b by way of the electrical conductors 18a,b, as shown. In a wireless connection, the electrical conductors 18a,b may be replaced with a first antenna (not shown) coupled the energy source 14 and

a second antenna (not shown) coupled to the electrodes 24a,b, wherein the second antenna is remotely located from the first antenna. In one embodiment, the energy source may comprise a wireless transmitter to deliver energy to the electrodes using wireless energy transfer techniques via one or more remotely positioned antennas. As previously discussed, wireless energy transfer or wireless power transmission is the process of transmitting electrical energy from the energy source 14 to an electrical load, e.g., the abnormal cells in the tissue treatment region, without using the interconnecting electrical conductors 18a,b. An electrical transformer is the simplest instance of wireless energy transfer. The primary and secondary circuits of a transformer are not directly connected. The transfer of energy takes place by electromagnetic coupling through a process known as mutual induction. Wireless power transfer technology using RF energy is produced by Powercast, Inc. The Powercast system can achieve a maximum output of 6 volts for a little over one meter. Other low-power wireless power technology has been proposed such as described in U.S. Pat. No. 6,967,462.

In one embodiment, the energy source 14 may be configured to produce DC electric pulses at frequencies in the range of about 1 Hz to about 10000 Hz, amplitudes in the range of about ± 100 to about ± 3000 VDC, and pulse lengths (e.g., pulse width, pulse duration) in the range of about 1 μ s to about 100 ms. The polarity of the electric potentials coupled to the electrodes 24a,b may be reversed during the electrical ablation therapy. For example, initially, the DC electric pulses may have a positive polarity and an amplitude in the range of about +100 to about +3000 VDC. Subsequently, the polarity of the DC electric pulses may be reversed such that the amplitude is in the range of about -100 to about -3000 VDC. In one embodiment, the undesirable cells in the tissue treatment region may be electrically ablated with DC pulses suitable to induce irreversible electroporation at frequencies of about 10 Hz to about 100 Hz, amplitudes in the range of about +700 to about +1500 VDC, and pulse lengths of about 10 μ s to about 50 μ s. In another embodiment, the abnormal cells in the tissue treatment region may be electrically ablated with an electrical waveform having an amplitude of about +500 VDC and pulse duration of about 20 ms delivered at a pulse period T or repetition rate, frequency $f=1/T$, of about 10 Hz. It has been determined that an electric field strength of 1,000V/cm is suitable for destroying living tissue by inducing irreversible electroporation.

FIGS. 2A-D illustrate one embodiment of the electrical ablation device 20 in various phases of deployment. In the embodiment illustrated in FIGS. 2A-D, the sheath 26 is disposed over the flexible shaft 22, however, those skilled in the art will appreciate that the sheath 26 may be disposed within the flexible shaft 22. The electrical ablation device 20 may be used in conjunction with the electrical ablation system 10 shown in FIG. 1. It will be appreciated that other devices and electrode configurations may be employed without limitation. FIG. 2A illustrates an initial phase of deployment wherein the sheath 26 is extended in the direction indicated by arrow 40 to cover the electrodes 24a,b. The electrodes 24a,b may have dimensions of about 0.5 mm, about 1 mm, or about 1.5 mm in diameter. It will be appreciated that the dimensions of the electrodes 24a,b may be anywhere from about 0.5 mm to about 1.5 mm in diameter. The electrical ablation device 20 may be introduced into the tissue treatment region through a trocar, as illustrated in FIG. 3, for example. FIG. 2B illustrates another phase of deployment wherein the sheath 26 is retracted

within the handle 28 in the direction indicated by arrow 42. In this phase of deployment, the first and second electrodes 24a,b extend through the distal end of the flexible shaft 22 and are ready to be inserted into or proximate the tissue treatment region. The first electrode 24a may be retracted in direction 42 through a lumen 44 formed in the flexible shaft 22 by holding the handle 28 and pulling on the slide member 30. FIG. 2C illustrates a transition phase wherein the first electrode 24a is the process of being retracted in direction 42 by pulling on the slide member 30 handle, for example, in the same direction. FIG. 2D illustrates another phase of deployment wherein the first electrode 24a is in a fully retracted position. In this phase of deployment the electrical ablation device 20 can be pivotally rotated about an axis 46 defined by the second electrode 24b. The electrodes 24a,b are spaced apart by a distance "r." The distance "r" between the electrodes 24a,b may be 5.0 mm, about 7.5 mm, or about 10 mm. It will be appreciated that the distance "r" between the electrodes 24a,b may be anywhere from about 5.0 mm to about 10.0 mm. Thus, the electrical ablation device 20 may be rotated in an arc about the pivot formed by the second electrode 24b, the first electrode 24a may be placed in a new location in the tissue treatment region within the radius "r." Retracting the first electrode 24a and pivoting about the second electrode 24b enables the surgeon or clinician to target and treat a larger tissue treatment region essentially comprising a circular region having a radius "r," which is the distance between the electrodes 24a,b. Thus, the electrodes 24a,b may be located in a plurality of positions in and around the tissue treatment region in order to treat much larger regions of tissue. Increasing the electrode 24a,b diameter and spacing the electrodes 24a,b further apart enables the generation of an electric field over a much larger tissue regions and thus the ablation of larger volumes of undesirable tissue. In this manner, the operator can treat a larger tissue treatment region comprising cancerous lesions, polyps, or tumors, for example.

Although the electrical ablation electrodes according to the described embodiments have been described in terms of the particular needle type electrodes 24a,b as shown and described in FIGS. 1 and 2A-D, those skilled in the art will appreciate that other configurations of electrical ablation electrodes may be employed for the ablation of undesirable tissue, without limitation. In one embodiment, the electrical ablation device 20 may comprise two or more fixed electrodes that are non-retractable. In another embodiment, the electrical ablation device 20 may comprise two or more retractable electrodes, one embodiment of which is described below with reference to FIG. 2E. In another embodiment, the electrical ablation device 20 may comprise at least one slidable electrode disposed within at least one working channel of the flexible shaft 32 of the endoscope 12. In another embodiment, the electrical ablation device 20 may comprise at least one electrode may be configured to be inserted into the tissue treatment region transcutaneously or percutaneously. Still in various other embodiments, the electrical ablation device 20 may comprise at least one electrode configured to be introduced to the tissue treatment region transcutaneously or percutaneously and at least one other electrode may be configured to be introduced to the tissue treatment region through at least one working channel of the flexible shaft 32 of the endoscope 12. The embodiments, however, are not limited in this context.

FIG. 2E illustrates one embodiment of an electrical ablation device 800 comprising multiple needle electrodes 824m, where m is any positive integer. In the illustrated embodiment, the electrical ablation device 800 comprises

four electrodes **824a**, **824b**, **824c**, **824d**. It will be appreciated that in one embodiment, the electrical ablation device **800** also may comprise three needle electrodes **824a**, **824b**, **824c**, without limitation. The electrical ablation device **800** may be used in conjunction with the electrical ablation system **10** shown in FIG. 1. It will be appreciated that other devices and electrode configurations may be employed without limitation. The electrodes **824a-m** each may have dimensions of about 0.5 mm, about 1 mm, or about 1.5 mm in diameter. It will be appreciated that the dimensions of each of the electrodes **824a-m** may be anywhere from about 0.5 mm to about 1.5 mm in diameter. The electrical ablation device **800** may be introduced into the tissue treatment region through a trocar, as subsequently described and illustrated with reference to FIG. 3, for example.

The electrical ablation device **800** comprises essentially the same components as the electrical ablation device **20** described with reference to FIGS. 2A-D. The electrical ablation device **800** comprises the relatively flexible member or shaft **22**, the protective sheath **26**, and one or more handles **28** to operate either the sheath **26**, the electrodes **824a,b,c,d**, or both. The electrodes **824a,b,c,d** may be individually or simultaneously deployable and/or retractable in the direction indicated by arrow **842**. The electrodes **824a,b,c,d** extend out from the distal end of the electrical ablation device **800**. In one embodiment, the first and second electrodes **824a**, **824b** may be configured as the positive electrode coupled to the anode of the energy source **14** via corresponding first and second electrical conductors **818a**, **818b**, and the third and fourth **824c**, **824d** may be configured as the negative electrode coupled to the cathode of the energy source **14** via corresponding third and fourth electrical conductors **818c**, **818d**, or similar electrically conductive leads or wires, through the activation switch **62**. Once the electrodes **824a,b,c,d** are positioned at the desired location into or proximate the tissue treatment region, the electrodes **824a,b,c,d** may be connected/disconnected from the energy source **14** by actuating/de-actuating the switch **62**.

As previously discussed with reference to FIGS. 2A-D, as shown in FIG. 2E in one embodiment, the protective sleeve or sheath **26** may be slidably disposed over the flexible shaft **22** and within the handle **28**. In an initial phase of deployment, the sheath **26** is extended in direction **40** to cover the electrodes **824a,b,c,d** to protect the trocar and prevent accidental piercing when the electrical ablation device **800** is advanced therethrough. Once the electrodes **824a,b,c,d** are located into or proximate the tissue treatment region, the sheath **26** is refracted in direction **42** to expose the electrodes **824a,b,c,d**. One or more of the electrodes **824a,b,c,d** of the electrical ablation device **800** may be adapted and configured to slideably move in and out of a cannula, lumen, or channel formed within the flexible shaft **22**. In one embodiment all of the electrodes **824a,b,c,d** are configured to slideably move in and out channels formed within lumens formed within the flexible shaft **22**, referred to for example as the lumen **44** in FIGS. 2A-D, to advance and retract the electrodes **824a,b,c,d** as may be desired by the operator. Nevertheless, in other embodiments, it may be desired to fix all or certain ones of the one or more electrodes **824a,b,c,d** in place.

The various embodiments of electrodes described in the present specification, e.g., the electrodes **24a,b**, or **824a-m**, may be configured for use with an electrical ablation device (not shown) comprising an elongated flexible shaft to house the needle electrodes **24a,b**, or **824a-m**, for example. The needle electrodes **24a,b**, or **824a-m**, are free to extend past

a distal end of the electrical ablation device. The flexible shaft comprises multiple lumen formed therein to slidably receive the needle electrodes **24a,b**, or **824a-m**. A flexible sheath extends longitudinally from a handle portion to the distal end. The handle portion comprises multiple slide members received in respective slots defining respective walls. The slide members are coupled to the respective needle electrodes **24a,b**, or **824a-m**. The slide members are movable to advance and retract the electrode **24a,b**, or **824a-m**. The needle electrodes **24a,b**, or **824a-m**, may be independently movable by way of the respective slide members. The needle electrodes **24a,b**, or **824a-m**, may be deployed independently or simultaneously. An electrical ablation device (not shown) comprising an elongated flexible shaft to house multiple needle electrodes and a suitable handle is described with reference to FIGS. 4-10 in commonly owned U.S. patent application Ser. No. 11/897,676 titled ELECTRICAL ABLATION SURGICAL INSTRUMENTS, filed Aug. 31, 2007, now U.S. Patent Application Publication No. 2009/0062788, the entire disclosure of which is incorporated herein by reference in its entirety.

It will be appreciated that the electrical ablation devices **20**, **800** described with referenced to FIGS. 2A-E, may be introduced inside a patient endoscopically (as shown in FIG. 15), transcutaneously, percutaneously, through an open incision, through a trocar (as shown in FIG. 3), through a natural orifice (as shown in FIG. 15), or any combination thereof. In one embodiment, the outside diameter of the electrical ablation devices **20**, **800** may be sized to fit within a working channel of an endoscope and in other embodiments the outside diameter of the electrical ablation devices **20**, **800** may be sized to fit within a hollow outer sleeve **620**, or trocar, as shown in FIG. 15, for example. The hollow outer sleeve **620** or trocar is inserted into the upper gastrointestinal tract of a patient and may be sized to also receive a flexible endoscopic portion of an endoscope **622** (e.g., gastroscope), similar to the endoscope **12** described in FIG. 1.

FIG. 3 illustrates one embodiment of the electrical ablation system **10** shown in FIGS. 1 and 2A-D in use to treat undesirable tissue **48** located on the surface of the liver **50**. The undesirable tissue **48** may be representative of a variety of diseased tissues, cancers, tumors, masses, lesions, abnormal tissue growths, for example. In use, the electrical ablation device **20** may be introduced into or proximate the tissue treatment region through a port **52** of a trocar **54**. The trocar **54** is introduced into the patient via a small incision **59** formed in the skin **56**. The endoscope **12** may be introduced into the patient trans-anally through the colon, trans-orally down the esophagus and through the stomach using transluminal techniques, or through a small incision or keyhole formed through the patient's abdominal wall (e.g., the peritoneal wall). The endoscope **12** may be employed to guide and locate the distal end of the electrical ablation device **20** into or proximate the undesirable tissue **48**. Prior to introducing the flexible shaft **22** through the trocar **54**, the sheath **26** is slid over the flexible shaft **22** in a direction toward the distal end thereof to cover the electrodes **24a,b** (as shown in FIG. 2A) until the distal end of the electrical ablation device **20** reaches the undesirable tissue **48**.

Once the electrical ablation device **20** has been suitably introduced into or proximate the undesirable tissue **48**, the sheath **26** is retracted to expose the electrodes **24a,b** (as shown in FIG. 2B) to treat the undesirable tissue **48**. To ablate the undesirable tissue **48**, the operator initially may locate the first electrode **24a** at a first position **58a** and the second electrode **24b** at a second position **60** using endo-

scopic visualization and maintaining the undesirable tissue **48** within the field of view of the flexible endoscope **12**. The first position **58a** may be near a perimeter edge of the undesirable tissue **48**. Once the electrodes **24a,b** are located into or proximate the undesirable tissue **48**, the electrodes **24a,b** are energized with irreversible electroporation pulses to create a first necrotic zone **65a**. For example, once the first and second electrodes **24a,b** are located in the desired positions **60** and **58a**, the undesirable tissue **48** may be exposed to an electric field generated by energizing the first and second electrodes **24a,b** with the energy source **14**. The electric field may have a magnitude, frequency, and pulse length suitable to induce irreversible electroporation in the undesirable tissue **48** within the first necrotic zone **65a**. The size of the necrotic zone is substantially dependent on the size and separation of the electrodes **24a,b**, as previously discussed. The treatment time is defined as the time that the electrodes **24a,b** are activated or energized to generate the electric pulses suitable for inducing irreversible electroporation in the undesirable tissue **48**.

This procedure may be repeated to destroy relatively larger portions of the undesirable tissue **48**. The position **60** may be taken as a pivot point about which the first electrode **24a** may be rotated in an arc of radius “r,” the distance between the first and second electrodes **24a,b**. Prior to rotating about the second electrode **24b**, the first electrode **24a** is refracted by pulling on the slide member **30** (FIGS. 1 and 2A-D) in a direction toward the proximal end and rotating the electrical ablation device **20** about the pivot point formed at position **60** by the second electrode **24b**. Once the first electrode **24a** is rotated to a second position **58b**, it is advanced to engage the undesirable tissue **48** at point **58b** by pushing on the slide member **30** in a direction towards the distal end. A second necrotic zone **65b** is formed upon energizing the first and second electrodes **24a,b**. A third necrotic zone **65c** is formed by retracting the first electrode **24a**, pivoting about pivot point **60** and rotating the first electrode **24a** to a new location, advancing the first electrode **24a** into the undesirable tissue **48** and energizing the first and second electrodes **24a,b**. This process may be repeated as often as necessary to create any number of necrotic zones **65p**, where *p* is any positive integer, within multiple circular areas of radius “r,” for example, that is suitable to ablate the entire undesirable tissue **48** region. At anytime, the surgeon or clinician can reposition the first and second electrodes **24a,b** and begin the process anew. In other embodiments, the electrical ablation device **800** comprising multiple needle electrodes **824a-m** described with reference to FIG. 2E may be employed to treat the undesirable tissue **48**. Those skilled in the art will appreciate that similar techniques may be employed to ablate any other undesirable tissues that may be accessible trans-anally through the colon, and/or orally through the esophagus and the stomach using transluminal access techniques. Therefore, the embodiments are not limited in this context.

FIG. 4 illustrates a detailed view of one embodiment of the electrical ablation system **10** shown in FIG. 3 in use to treat undesirable tissue **48** located on the surface of the liver **50**. The first and second electrodes **24a,b** are embedded into or proximate the undesirable tissue **48** on the liver **50**. The first and second electrodes **24a,b** are energized to deliver one or more electrical pulses of amplitude and length sufficient to induce irreversible electroporation in the undesirable tissue **48** and create the first necrotic zone **65a**. Additional electric pulses may be applied to the tissue immediately surrounding the respective electrodes **24a,b** to form second, thermal, necrotic zones **63a,b** near the electrode-tissue-

interface. The duration of an irreversible electroporation energy pulse determines whether the temperature of the tissue **63a,b** immediately surrounding the respective electrodes **24a,b** raises to a level sufficient to create thermal necrosis. As previously discussed, varying the electrode **24a,b** size and spacing can control the size and shape of irreversible electroporation induced necrotic zone **65a**. Electric pulse amplitude and length can be varied to control the size and shape of the thermally induced necrotic zones near the tissue-electrode-interface. In other embodiments, the electrical ablation device **800** comprising multiple needle electrodes **824a-m** may be used to treat the undesirable tissue **48** located on the surface of the liver **50**, for example.

FIG. 5 is a graphical representation of a series of electrical pulses that may be applied to undesirable tissue to create a first necrotic zone by inducing irreversible electroporation in the tissue and to create a second necrotic zone by inducing thermal effects near the electrode-tissue-interface using the electrical ablation system **10** shown in FIG. 4. Time (*t*) is shown along the horizontal axis and voltage (VDC) is shown along the vertical axis. Initially the undesirable tissue **48** is exposed to a first series of electrical pulses **70** of a first predetermined amplitude, length, and frequency sufficient to induce the irreversible electroporation necrotic zone **65a**. Subsequently, the undesirable tissue near the electrode-tissue-interface is exposed to a second series of electrical pulses **72** of a second predetermined amplitude, length, and frequency sufficient to induce thermal necrotic effects on the tissue and create thermal necrotic zones **63a,b**. As shown in FIG. 5, the first series of pulses **70** comprises about 20 to 40 electric pulses having an amplitude of about 1000 VDC, pulse length *t₁* of about 10 μ s to about 15 μ s, and a period *T₁* (e.g., pulse repetition rate *f₁=1/T₁*) of about 100 μ s (*f₁=10000 Hz*). The first series of pulses is sufficient to induce irreversible electroporation in the necrotic zone **65a**. The period *T₁* is defined as the pulse length *t₁* plus the pulse spacing **74**, e.g., the time between a falling edge of a pulse and a rising edge of a subsequent pulse. The second series of pulses **72** may comprise a single pulse or multiple pulses having an amplitude of about 500 VDC, pulse length *t₂* of about 10 ms to about 15 ms, and a period *T₂* of about 100 ms (*f₂=10 Hz*). The second series of pulses is sufficient to create thermal necrotic zones **63a,b** in the tissue near the electrode-tissue-interface immediately surrounding the respective electrodes **24a,b**. In one embodiment, *f₁=f₂=10 Hz* (i.e., *T₁=T₂=100 MS*).

In one embodiment, the thermal necrotic zones **63a,b** formed in the tissue immediately surrounding the electrodes **24a,b** at the tissue-electrode-interface are beneficial to stop bleeding in the undesirable tissue **48** as a result of the mechanical trauma resulting from inserting or embedding the electrodes **24a,b** into the undesirable tissue **48** of the liver **50**. Although in general irreversible electroporation induced by electric pulses do not cause thermal necrosis or other detrimental thermal effects, the longer electrical pulses **72** may be applied to the undesirable tissue **48** in succession to thermally seal the tissue immediately surrounding the electrodes **24a,b** at the tissue-electrode-interface. Thus, the technique of applying a combination of a first series of substantially shorter electrical pulses **70** (in the microseconds range) and a second series of substantially longer energy pulses **72** (in the milliseconds range) may be employed for sealing vessels prior to transecting a vessel. Accordingly, the first series of pulses **70** may be applied to a vessel to induce cell necrosis by irreversible electropora-

tion. Then, the second series of pulses 72 may be applied to vessel to create thermal necrotic zones to seal the vessel prior to dissecting the vessel.

In various embodiments, a series of electrical pulses may be characterized according to the following parameters as may be provided by the energy source 14, for example. In one embodiment, the energy source 14 may be configured to produce DC electric pulses at frequencies in the range of about 1 Hz to about 10000 Hz, amplitudes in the range of about ± 100 to about ± 3000 VDC, and pulse lengths (e.g., pulse width, pulse duration) in the range of about 1 μ s to about 100 ms. The polarity of the electric potentials coupled to the electrodes 24a,b may be reversed during the electrical ablation therapy. For example, initially, the DC electric pulses may have a positive polarity and an amplitude in the range of about +100 to about +3000 VDC. Subsequently, the polarity of the DC electric pulses may be reversed such that the amplitude is in the range of about -100 to about -3000 VDC. In one embodiment, the undesirable cells in the tissue treatment region may be electrically ablated with DC pulses suitable to induce irreversible electroporation at frequencies of about 10 Hz to about 100 Hz, amplitudes in the range of about +700 to about +1500 VDC, and pulse lengths of about 10 μ s to about 50 μ s. In another embodiment, the abnormal cells in the tissue treatment region may be electrically ablated with an electrical waveform having an amplitude of about +500 VDC and pulse duration of about 20 ms delivered at a pulse period T or repetition rate, frequency $f=1/T$, of about 10 Hz.

FIGS. 6, 7, and 8 illustrate one embodiment of an electrical ablation device 290 to treat undesirable tissue located within body lumen using electrical energy. FIG. 6 illustrates a sectioned view of one embodiment of the electrical ablation device 290. FIG. 7 illustrates an end view of the embodiment of the electrical ablation device 290 shown in FIG. 6. FIG. 8 illustrates a cross-sectional view of the embodiment of the electrical ablation device 290 shown in FIG. 6. As previously discussed, reflux disease of the greater saphenous vein (GSV) can result in a varicose vessel 292, which is illustrated in FIG. 8. Conventionally, varicose veins have been treated by stripping and then applying either chemical or thermal ablation to internal portions of a lumen defined by the varicose vessel 292. In the embodiment illustrated in FIGS. 6-8, the electrical ablation device 290 is configured to couple to the energy source 14 and to be inserted within a lumen defined by the varicose vessel 292. Once inserted into the varicose vessel 292, the electrical ablation device 290 may be energized by the energy source 14 to apply high-voltage DC electrical pulses to an inner wall 294 portion of the varicose vessel 292. High-voltage DC pulses may be used to ablate the undesirable tissue and to subsequently seal the varicose vessel 292. The embodiment illustrated in FIGS. 6-8, however, is not limited in this context, and the electrical ablation device 290 may be employed to treat and seal tissue within any inner body lumen using energy in the form of electrical pulses supplied by the energy source 14.

Referring to FIGS. 6-8, the electrical ablation device 290 comprises a probe 296 comprising a cannula, channel, or lumen 300 extending longitudinally therethrough. The distal end 298 of the probe 296 comprises first and second ring electrodes 302a,b to which a potential difference may be applied by the energy source 14. The first and second ring electrodes 302a,b may be coupled to respective positive and negative terminals of the energy source 14 through corresponding first and second electrical conductors 304a,b. The first and second electrical conductors 304a,b extend through

respective conduits 306a,b formed within the probe 296 and extend longitudinally therethrough. The first and second electrical conductors 304a,b may be electrically coupled to the first and second ring electrodes 302a,b in any suitable manner. The first and second ring electrodes 302a,b are adapted to receive energy in the form of electrical pulses from the energy source 14. The electrical pulses generate an electric field suitable for treating, e.g., ablating, the undesirable tissue within a lumen such as the lumen defined by the varicose vessel 292 as shown in FIG. 8. In one embodiment, once energized by the energy source 14, the first and second ring electrodes 302a,b generate an electric field suitable to induce irreversible electroporation in the undesirable tissue. It will be appreciated that a potential difference may be created across the first and second ring electrodes 302a,b to generate an electric field strength suitable to induce irreversible electroporation in the undesirable tissue. In other embodiments, the probe 296 may comprise one or more electrodes in addition to the first and second ring electrodes 302a,b.

The electrical ablation probe 296 has a form factor that is suitable to be inserted within a lumen defined by the varicose vessel 292 and to ablate tissue in the tapered lumen 298 portion of the varicose vessel 292. The probe 296 engages the inner wall 294 of the varicose vessel 292 in the tapered lumen 298 portion of the varicose vessel 292. Suction 306 applied at a proximal end of the probe 296 draws a vacuum within the lumen 300 of the probe 296 to collapse the varicose vessel 292 at the distal end 298 of the probe 296. Once the vessel 292 is collapsed or pulled down by the suction 306, a first pulse train 302 of high-voltage DC electrical pulses at a first amplitude A_1 (e.g., ~1000V amplitude) and a first pulse length T_1 (e.g., ~50 microseconds) is applied to the first and second ring electrodes 302a,b by the energy source 14. The high-voltage DC pulse train 302 eventually kills the cells within the tapered lumen 298 portion of the varicose vessel 292 by irreversible electroporation. A second pulse train 304 having a lower voltage amplitude A_2 (e.g., ~500 VDC) and a second longer pulse length T_2 (e.g., ~15 milliseconds) is applied to the first and second ring electrodes 302a,b of the probe 296 to thermally seal the varicose vessel 292. As previously discussed, in one embodiment, the polarity of the electrical pulses may be inverted or reversed by the energy source 14 during the ablation or sealing treatment process. In various embodiments, the electrical pulses may be characterized by the parameters in accordance with the output of the energy source 14 as discussed with respect to FIGS. 1 and 5, for example.

FIG. 9 illustrates one embodiment of an electrical ablation system 400 in use to treat non-metastatic prostate cancer in a patient. As previously discussed, a radical prostatectomy in which the entire prostate 404 and surrounding lymph nodes are removed is one of the conventional treatments for prostate cancer. Like most other forms of cancer, radiation therapy may be used in conjunction with or as an alternate method for the treatment of prostate cancer. Another thermal ablation technique for the treatment of prostate cancer is RF interstitial tumor ablation (RITA) via trans-rectal ultrasound guidance. While these conventional methods for the treatment of prostate cancer are effective, they are not preferred by many surgeons and may result in detrimental thermal effects to healthy tissue surrounding the prostate. The electrical ablation system 400 in accordance with the described embodiments provides improved electrical ablation of prostate cancer using irreversible electroporation pulses through

supplied by an energy source to electrodes positioned into and/or proximate the prostate cancer tissue.

With reference to FIG. 9, the electrical ablation system 400 comprises an electrical ablation device 402 comprising at least two electrodes 402a,b, and the energy source 14. The electrical ablation system 400 may be adapted for use in conjunction with the electrical ablation system 10 described in FIG. 1. The electrodes 402a,b are configured to be positioned within internal body lumens or cavities and, in one embodiment, may be configured for use in conjunction with the flexible endoscope 12 also described in FIG. 1. The electrodes 402a,b are configured to couple to the corresponding electrical conductors 18a,b, the handpiece 16, the activation switch 62, and the energy source 14, as previously discussed in FIG. 1. The first electrode 402a comprises a wire or flexible conductive tube that may be introduced through the urethra 406 into the prostate 404 proximally to the bladder 410. The first electrode 402a may be located into the prostate 404 using well known fluoroscopy or ultrasonic guidance, for example. The second electrode 402b comprises a pad and may be introduced into the anus 408 and advanced to a location proximate to the prostate 404. The first electrode 402a has a much smaller surface area relative to the trans-anally placed second electrode 402b pad. The first electrode 402a may be connected to the positive (+) terminal of the energy source 14 and the second electrode 402b may be connected to the negative (-) terminal of the energy source 14. In one embodiment, the energy source 14 may be configured as a high-voltage DC electric pulse generator. The activation switch 62 portion of the handpiece 16, as shown in FIG. 1, can be used to energize the electrical ablation system 400 to ablate the non-metastatic cancer in the prostate 404 by irreversible electroporation pulses supplied by the energy source 14 and delivered through the electrodes 402a,b as described in FIG. 10 below. In other embodiments, the probe 296 may comprise one or more electrodes in addition to the first and second electrodes 402a,b.

FIG. 10 is a graphical representation of a series of electrical pulses 412 that may be applied to undesirable tissue to induce irreversible electroporation suitable to ablate non-metastatic cancer of the prostate 404 as described in FIG. 9. Time (t) is shown along the horizontal axis and voltage (V) is shown along the vertical axis. A series of electrical pulses 412 having a predetermined amplitude V_o and pulse length t_o sufficient to induce irreversible electroporation may be applied to the prostate 404 through the electrodes 402a,b to ablate the undesirable cancerous tissue. Multiple electrical pulses 412, for example, 20 to 40 pulses, of amplitude of about 1500 to about 3000 volts DC (V_o) each having a pulse length t_o of about 10 μ s to about 50 μ s, and a period (T) of about 10 ms. The electrical pulses 412 having such parameters are sufficient to induce irreversible electroporation to ablate the cancerous tissue in the prostate 404. The period T (e.g., pulse repetition rate $f=1/T$) may be defined as the pulse length t_o plus 10 μ s the length of time between pulses, or the pulse spacing 414. A conductive fluid may be introduced into the urethra 406 to extend the range of the positive electrode 402a. In various embodiments, the electrical pulses may be characterized by the parameters in accordance with the output of the energy source 14 as discussed with respect to FIGS. 1 and 5, for example.

FIG. 11 illustrates one embodiment of the electrical ablation system 10 described FIG. 1 in use to treat basal cell carcinoma (BCC) tissue. In FIG. 11, the electrical ablation system 10, described in FIG. 1, is shown in use to treat BCC tissue 502. BCC tissue 502 is a slowly growing cutaneous

malignancy derived from a rapidly proliferating basal layer of the epidermis 504. As previously discussed, conventional treatments for BCC include surgical excision, cryotherapy, radiation, photodynamic therapy, Moh's micrographic surgery, and topical treatments with 5-fluorouracil. Minimally-invasive methods of treating BCC include laser ablation with a pulsed carbon dioxide laser. Although, the treatment of BCC with a carbon dioxide laser has been shown to be effective on tumors ranging in size from about 5 mm to about 40 mm, carbon dioxide treatment is a thermal method of treating tissue that may cause permanent thermal damage to healthy tissue surrounding the BCC tissue and requires costly capital investment in carbon dioxide laser equipment.

The electrical ablation device 20 of the electrical ablation system 10 may be used to induce irreversible electroporation suitable to treat undesirable BCC tissue using electrical pulses supplied by the energy source 14. The first and second electrodes 24a,b are transcutaneously inserted through the epidermis 504 and embedded into the BCC tissue 502. The first and second electrodes 24a,b are separated by a distance "D." The first electrode 24a is electrically connected to the positive (+) output of the energy source 14 and the second electrode 24b is electrically connected to the negative (-) output of the energy source 14. In one embodiment, the energy source 14 may be a high-voltage DC generator. The energized electrodes 24a,b generate an electric field inducing irreversible electroporation suitable for ablating the undesirable BCC tissue 502 located between the electrodes 24a,b. A larger portion of the BCC tissue 502 may be ablated by relocating and re-energizing the first and second electrodes 24a,b using the technique previously described with reference to FIG. 3, for example. As previously discussed, varying the electrode 24a,b size and spacing can control the size and shape of irreversible electroporation induced necrotic zone. Accordingly, as previously discussed, increasing the electrode 24a,b diameter and spacing between the electrodes 24a,b enables the generation of an electric field over a much larger tissue regions and thus the ablation of larger volumes of undesirable tissue. In other embodiments, the electrical ablation device 800 comprising multiple needle electrodes 824a-m may be used to treat the BCC tissue 502, for example.

FIG. 12 is a graphical representation of a series of electrical pulses 512 that may be applied to undesirable tissue to induce irreversible electroporation suitable to ablate BCC tissue as described in FIG. 11. Time (t) is shown along the horizontal axis and voltage (V) is shown along the vertical axis. As shown in FIG. 12, a series of electrical pulses 512 having a predetermined amplitude V_o and pulse length t_o sufficient to induce irreversible electroporation may be applied to the BCC tissue 502 to ablate the undesirable cancerous tissue. About 20 to about 40 pulses 512 of with an amplitude of about 1500 to about 3000 VDC (V_o), a pulse length t_o of about 10 μ s to about 50 μ s, a period T (the pulse length t_o plus the pulse spacing 54) of about 10 ms may be suitable for inducing irreversible electroporation to ablate the undesirable BCC tissue 502 in the region D between the electrodes 24a,b. Multiple placements of the electrode 24a,b in rapid succession and the application of additional pulses 512 can be used to ablate larger portions of the BCC tissue 502, as previously discussed in FIG. 3. As previously discussed, varying the electrode 24a,b size and spacing can control the size and shape of irreversible electroporation induced necrotic zone. Accordingly, increasing the electrode 24a,b diameter and spacing the electrodes 24a,b further apart (e.g., greater than "D") enables the generation of an electric field over a much larger tissue regions and thus the

ablation of larger volumes of undesirable tissue. Injecting a conductive fluid into the BCC tissue 502 is another technique to increase the size and shape of the irreversible electroporation induced necrotic zone and extend the range of the positive electrode 24a, for example. In various embodiments, the electrical pulses may be characterized by the parameters in accordance with the output of the energy source 14 as discussed with respect to FIGS. 1 and 5, for example.

FIG. 13A illustrates one embodiment of an electrical ablation device 600 in a collapsed state. The electrical ablation device 600 has a configuration suitable for the treatment of undesirable tissue located in a lumen, abscess, void, or cavity. Although other electrode configurations may be effective for treating line-of-sight regions of tissue, such electrodes may not be as effective at treating tissue within a cavity. To overcome these limitations, the electrical ablation device 600 comprises an electrode configured to inflate and expand into the cavity to make contact with tissue along the inner wall of the cavity. The electrical ablation device 600 comprises an elongate tubular body extending from a proximal end to a distal end. In one embodiment, the electrical ablation device 600 may comprise a conductive elastomer electrode 602 portion (e.g., balloon, tip) and a non-conductive catheter 604 portion, which may be formed of a non-electrically conductive (e.g., electrically insulative) elastomeric material. The electrical ablation device 600 may be referred to as a balloon catheter, balloon probe, or balloon-tipped catheter, for example, without limitation. In one embodiment, the inflatable portion of the conductive elastomer electrode 602 may be formed of an electrically conductive elastomer suitable for coupling to the energy source 14 via an electrically conductive terminal 610 and a first electrically conductive wire 608a. Once inflated, the elastomeric properties of the conductive elastomer electrode 602 conform to the internal walls of the cavity. Upon energizing, the conductive elastomer electrode 602 delivers electrical pulses to the tissue within the internal walls of the cavity to induce irreversible electroporation.

In one embodiment, the electrical ablation device 600 may be fabricated using a concurrent injection process such that the conductive elastomer electrode 602 portion and the non-conductive catheter 604 portion are formally integrally. In another embodiment, the electrical ablation device 600 may be fabricated by manufacturing the conductive elastomer electrode 602 and the non-conductive catheter 604 separately and then joining the two components using any suitable joining method such as, for example, bolting, screwing, welding, crimping, gluing, bonding, brazing, soldering, press fitting, riveting, heat shrinking, heat welding, ultrasonic welding, or any other suitable method.

FIG. 13B illustrates one embodiment of the electrical ablation device 600 shown in FIG. 13A in an inflated state. As previously discussed, in an inflated state the conductive elastomer electrode 602 may be employed for ablating cancerous tumors growing within internal body lumens such as the esophagus or the large bowel, or in cavities remaining when cancerous tumors are removed from solid tissue, such as the breast. Although surgical resection of tumors in solid tissue can include a margin of healthy tissue, cancer cells may remain in the tissue within the cavity. The conductive elastomer electrode 602 may be inserted in the cavity, inflated, and energized by the energy source 14 to expose the tissue within the cavity to electrical pulses suitable to induce irreversible electroporation to ablate any cancer cells remaining within the cavity.

FIG. 14 is a cross-sectional view of the electrical ablation device 600 showing a cross-sectional view of the conductive elastomer electrode 602 and the non-conductive catheter 604 shown in FIGS. 13A and 13B. The conductive elastomer electrode 602 may be coupled to a first end 606 of the electrically conductive wire 608a. The wire 608a may be located through the non-conductive catheter 604 and the first end 606 electrically connected (e.g., bonded, soldered, brazed) to the conductive elastomer electrode 602 through the electrically conductive terminal 610. In one embodiment, the non-conductive catheter 604 may be extruded with an embedded strip of conductive material serving as the electrically conductive terminal 610. The wire 608a may be electrically connected to one end of the electrically conductive terminal 610. In one embodiment, the electrical ablation device 600 may be configured to couple to one terminal of the energy source 14 via a second end of the electrically conductive wire 608a. A return electrode 612 (e.g., in the form of a pad or needle electrode) is coupled to a second electrically conductive wire 608b, which is coupled to another terminal of the energy source 14. The return electrode 612 may be orientated proximal to the conductive elastomer electrode 602 of the electrical ablation device 600 (e.g., the balloon catheter). When irreversible electroporation energy pulses are applied to the conductive elastomer electrode 602 of the electrical ablation device 600, the tissue between the conductive elastomer portion 602 and the return electrode 608b is ablated, e.g., destroyed by the pulsed irreversible electroporation energy. In other embodiments, the return electrode 612 may comprise multiple electrodes, for example.

In one embodiment, the conductive elastomer electrode 602 may be fabricated from or may comprise an electrically conductive material suitable for conducting electrical energy from the energy source 14 to the internal cavity sufficient to induce irreversible electroporation to the tissue within the cavity. The electrically conductive elastomer material is similar to conductive elastomers used as gasket material for electronic enclosures used for shielding electronic devices from electromagnetic interference (EMI). Conductive elastomers may be formed by infiltrating an elastomeric matrix with electrically conductive filler materials such as silver, gold, copper, or aluminum, to produce a hybrid material having the elastic properties of the elastomeric matrix and the electrically conductive properties of the metallic filler materials (some materials may have volume resistivity values as low as 0.004 Ω-cm, for example). The conductive elastomer may be formed as thin sheets, catheters, and balloons suitable for medical applications. In one embodiment, the conductive elastomer electrode 602 may be fabricated from medical grade polyurethane material comprising at least one electrically conductive coating on an outer surface thereof. In another embodiment, the conductive elastomer electrode 602 may be made from an electrically conductive material. In yet another embodiment, the conductive elastomer electrode 602 may be made from an electrically insulative material, such as the medical grade polyurethane, and inflated with a conductive fluid (e.g., saline) to form the electrically conductive portion of the conductive elastomer electrode 602.

In one embodiment the conductive elastomer electrode 602 may be coupled to the anode (+) electrode of the energy source 14 and in another embodiment the conductive elastomer electrode 602 may be coupled to the cathode (-) electrode of the energy source 14. It will be appreciated that the polarity of the conductive elastomer electrode 602 may be reversed by reversing the output polarity of the energy

source 14. In one embodiment, the conductive elastomer electrode 602 may be coupled to either the anode (+) or the cathode (-) of the energy source 14. For example, the conductive elastomer electrode 602 may be coupled to the cathode (+) of the energy source 14 relative to a ground plane cathode (-) in contact with the patient and coupled to the negative terminal of the energy source 14.

FIG. 15 illustrates one embodiment of the electrical ablation device shown in FIG. 13A inserted through the mouth and esophagus to ablate cancerous tissue in the esophagus using electrical pulses. As shown in FIG. 15, a hollow outer sleeve 620 or trocar is inserted into the upper gastrointestinal tract of a patient and receives a flexible endoscopic portion of an endoscope 622 (e.g., gastroscope), similar to the endoscope 12 described in FIG. 1. A variety of different types of endoscopes are known and, therefore, their specific construction and operation will not be discussed in great detail herein. In various embodiments, the flexible endoscopic portion 620 may be fabricated from nylon or high-density polyethylene plastic, for example. FIG. 15 illustrates, in general form, one embodiment of the electrical ablation device 600 that can be inserted through a natural orifice such as the mouth 626 and advanced through a cavity or lumen such as the esophagus 628, e.g., esophageal cavity, to apply electrical pulses sufficient to induce irreversible electroporation to ablate the undesirable cancerous tissue 630 located in the esophagus 628.

FIG. 16 illustrates the distal portion 624 of the endoscope 622 shown in FIG. 15. As shown in FIG. 16, the electrical ablation device 600 is advanced through the distal end 624 of the endoscope 622. In various embodiments, the endoscope 622 can serve to define various tool-receiving passages 628, or "working channels," that extend from the natural orifice 626 to the surgical site. In addition, the endoscope 622 comprises a viewing port 630. The endoscope 622 may be used for viewing the surgical site within the patient's body. Various cameras and/or lighting apparatuses may be inserted into the viewing port 630 of the endoscope 622 to provide the surgeon with a view of the surgical site.

With reference now to FIGS. 15 and 16, the electrical ablation device 600 is one of the tools or surgical instruments that can be accommodated in the tool-receiving passage 628 of the endoscope 622. The conductive elastomer electrode 602 (e.g., balloon, tip) and the non-conductive catheter 604 are configured to communicate with at least one pressurized air source 634 and a vacuum source 632 to respectively inflate and deflate the conductive elastomer electrode 602. In one embodiment, a vacuum/air tube 636 can be sized to receive other surgical instruments therein. In various embodiments, the endoscope 622 may comprise a video camera that communicates with a video display unit 638 that can be viewed by the surgeon during the operation. In addition, the endoscope 622 may further comprise a fluid-supply lumen therethrough that is coupled to an inflation fluid such as a water source 640, saline solution, and/or any other suitable inflation fluid and/or an air supply lumen that is coupled to the air source 642. In various embodiments, the fluid-supply lumen, e.g., the inflation fluid line, may be coupled to conventional inline valves (not shown) to control the flow of inflation fluid. For example, a proximal end of the inline valve may be removably coupled to a conventional inflation syringe. The fluid-supply lumen defines an inflation lumen that fluidically communicates with the interior of the conductive elastomer electrode 602 (e.g., the balloon electrode) via an aperture (not shown). The fluid-supply lumen provides a fluid communication path for

inflating the conductive elastomer electrode 602 with a conductive fluid. The fluid may be either saline or air or other suitable electrically conductive inflation fluid. As previously discussed, the conductive elastomer electrode 602 is coupled to the energy source 14 to deliver electrical pulses to the esophageal cavity. The transcutaneous electrode 612 is also coupled to the energy source 14 through electrically conductive wire 608.

In use, the electrical ablation device 600 may be introduced into a natural orifice such as the mouth 626 and advanced into a lumen, abscess, void, or cavity such as the esophagus 628, as shown in FIG. 15. In the illustrated embodiment, the conductive elastomer electrode 602 is inserted through the working channel 628 of the endoscope 622 and into the lumen or cavity defined by the esophagus 628 and the return electrode 612 is inserted transcutaneously and is located proximate to the cancerous tissue 630. Once located within the esophagus 628, the conductive elastomer electrode 602 may be inflated using either the water source 640 or the air source 642. The water source 640 may supply a conductive solution (e.g., saline solution) to enhance the conductivity of the conductive elastomer electrode 602 and to enhance the contact area between the conductive elastomer electrode 602 and the inner wall of the esophageal cavity 628 including the cancerous tissue 630. Once inflated, the conductive elastomer electrode 602 is energized by the energy source 14 with a number of high-voltage DC electrical pulses to cause necrosis of the undesirable cancerous tissue 630 between the conductive elastomer electrode 602 and the return electrode 612. In this example, the high-voltage DC electrical pulses generate an electric field in a concentric zone around the esophageal cavity 628. The electric field has a sufficient magnitude and pulse length to induce irreversible electroporation in the undesirable cancerous tissue 630. The depth of the necrotic zone depends on the amplitude of the applied electric field, the pulse length, the number of pulses, and the repetition rate or frequency of the pulses. In various embodiments, the electrical pulses may be characterized by the parameters in accordance with the output of the energy source 14 as discussed with respect to FIGS. 1 and 5, for example.

FIGS. 17-20 illustrate a method of treating residual undesirable tissue within cavities formed in the solid tissue after removal of a mass of undesirable tissue. FIG. 17 illustrates a cross-sectional view of a breast 702 showing a cavity 700 that may be left after a lumpectomy to remove a tumor from the breast 702. In tumors that grow in solid tissue, the rate of recurrence of undesirable tissue depends on the margin of healthy tissue relative to the undesirable tissue that is removed. Accordingly, to minimize the recurrence of the tumor once the undesirable tissue is removed from the breast 702, the residual tissue in the cavity 700 should be ablated. The residual tissue may be ablated using the techniques previously described in FIGS. 13-16 above or the techniques described in FIGS. 18-20 below.

FIG. 18 illustrates one embodiment of a catheter 704 inserted into the cavity 700 left in the breast 702 after a lumpectomy procedure. A distal end 706 of the catheter 704 comprises a compressed sponge 708 or any suitable type of expandable foam material. A sleeve 710 slidably disposed over the catheter 704 and the sponge 708 contains the sponge 708 until it is ready to expand into the cavity 700. When the sleeve 710 is retracted in the direction indicated by arrow 712, the sponge 708 may be expanded into the cavity 700 by pumping saline into the sponge 708 through the catheter 704. An electrode 714 is inserted through the catheter 704 and into the sponge 708 such that the electrode

714 is in electrical communication with the sponge **708**. The electrode **714** may be coupled to the positive terminal of the energy source **14**, for example.

FIG. 19 illustrates an expanded sponge filling the cavity **700** left in the breast **702** following a lumpectomy as shown in FIG. 17. As shown in FIG. 19, the sponge **708** has been soaked with saline solution and has expanded to fill the cavity **700** upon removal of the sleeve **710**. Multiple wire electrodes **714** may be embedded in the saline soaked sponge **708**. Each of these wire electrodes **714** may be coupled to the positive terminal of the energy source **14**. The body or outer portion of the breast **702** may be electrically grounded through one or more large surface area electrodes **716a,b**. It will be appreciated that in other embodiments that either a single surface area electrode or more than two surface area electrodes may be employed, without limitation. The negative electrodes **716a,b** are connected to the negative terminal of the energy source **14**. The sponge **708** and the residual tissue within the cavity **700** are exposed to a series of electric pulses (e.g., high-voltage DC electric pulses) suitable for inducing irreversible electroporation. The high-voltage DC electric pulses in the form graphically illustrated in FIG. 5, 10, or 12 generate an electric field sufficient to cause apoptosis/necrosis in a zone extending beyond the edge of the cavity **700**, for example. In various embodiments, the electrical pulses may be characterized by the parameters in accordance with the output of the energy source **14** as discussed with respect to FIGS. 1 and 5, for example.

FIG. 20 illustrates the expanded sponge **708** intact to fill the cavity **700** left in the breast **702** as shown in FIG. 17 following irreversible electroporation ablation therapy. After the irreversible electroporation ablation treatment is completed, the positive electrode **714** is removed from the cavity **700** and the negative electrodes **716a,b** are removed from the breast **702**. The sponge **708**, however, may be left inside to fill the cavity **700**.

FIG. 21 illustrates a mesh of a finite element model **709** of a sponge inserted in the cavity **700** left in the breast **702** as shown in FIG. 17. The horizontal and the vertical axes represent distance in meters (m) with the center defined at (0,0). As shown in FIG. 21, the mesh of the finite element model **709** is a two-dimensional representation of the sponge similar to the sponge **708** inserted in the cavity **700** of the breast **702** previously described in FIGS. 17-20, for example.

FIG. 22 is a graphical representation of electric potential and electrical field strength sufficient to induce irreversible electroporation when applied to the sponge **708** located within the breast cavity **700** as shown in FIG. 17. The horizontal and the vertical axes represent distance in meters (m) with the center defined at (0,0). As shown in FIG. 22, electric field strength in Volts/meter (V/m) is represented by electric field lines **718** shown as concentric contours or circles extending from an outer perimeter of the sponge **708** to a point in space **726** where the electric field strength is at a minimum. A scale **722** to the right of the graph represents electric field strength in V/m. Electric potential **720** in Volts (V) applied to the sponge **708** within the cavity **700** is represented by the shaded zones **720**. A vertical scale **724** shown to the right of the electric field strength scale **722** represents electric potential in V with the minimum potential at the bottom and the maximum potential at the top. The electrical field lines **718a,b** just outside the outer perimeter of the sponge **708** are representative of an electric field potential **720a** of about 1400 to about 2000 V sufficient to cause cell necrosis by irreversible electroporation.

FIG. 23 is a graphical representation of electric field strength contours in volts per meter (V/m) developed when electrodes are energized by an energy source. The horizontal and the vertical axes represent distance in meters (m) with the center defined at (0,0). FIG. 23 illustrates a graph **730** of electric field strength contours developed when the electrodes **24a,b** are inserted into the sponge **708** and energized by the energy source **14**, as described in FIGS. 17-22. A vertical scale **732** shown to the right of the graph **730** represents the electric field strength in a range from a minimum of about 50,000V/m (bottom) to a maximum of about 100,000V/m (top). Irreversible electroporation energy in this range of electric field strength (e.g., about 50,000V/m to about 100,000V/m) are suitable for efficient and effective treatment of medical conditions that require the ablation of undesirable tissue from a localized region (i.e., in the case of the treatment of cancer). With reference to the embodiment described in FIGS. 17-22, needle-probes or electrodes **24a,b** are inserted into the sponge **708**. As shown in the graph **730**, electric field strength contours **734, 736** represent the maximum electric field strength (e.g., about 80,000 to about 100,000V/m) in a region proximate to the location where the needle electrodes **24a,b** are inserted into the sponge **708**. Electric field strength contour **738** represents electric field strength of about 50,000V/m. In regions outside the sponge **708**, the electric field strength peaks at contour **742** to about 100,000V/m and then tapers off with distance to about 80,000V/m at contour **744** to about 50,000V/m at contour **746**. It will be appreciated that other electric field strength contours may be developed to render effective irreversible electroporation ablation therapy. Accordingly, the embodiments described herein should not be limited in this context.

The embodiments of the electrical ablation devices described herein may be introduced inside a patient using minimally invasive or open surgical techniques. In some instances it may be advantageous to introduce the electrical ablation devices inside the patient using a combination of minimally invasive and open surgical techniques. Minimally invasive techniques provide more accurate and effective access to the treatment region for diagnostic and treatment procedures. To reach internal treatment regions within the patient, the electrical ablation devices described herein may be inserted through natural openings of the body such as the mouth, anus, and/or vagina, for example. Minimally invasive procedures performed by the introduction of various medical devices into the patient through a natural opening of the patient are known in the art as NOTESTM procedures. Surgical devices, such as an electrical ablation devices, may be introduced to the treatment region through the working channels of the endoscope to perform key surgical activities (KSA), including, for example, electrical ablation of tissues using irreversible electroporation energy. Some portions of the electrical ablation devices may be introduced to the tissue treatment region percutaneously or through small-keyhole-incisions.

Endoscopic minimally invasive surgical and diagnostic medical procedures are used to evaluate and treat internal organs by inserting a small tube into the body. The endoscope may have a rigid or a flexible tube. A flexible endoscope may be introduced either through a natural body opening (e.g., mouth, anus, and/or vagina). A rigid endoscope may be introduced via trocar through a relatively small-keyhole-incision (usually 0.5-1.5 cm). The endoscope can be used to observe surface conditions of internal organs, including abnormal or diseased tissue such as lesions and other surface conditions and capture images for visual inspection and photography. The endoscope may be adapted

and configured with working channels for introducing medical instruments to the treatment region for taking biopsies, retrieving foreign objects, and/or performing surgical procedures.

Once an electrical ablation device is inserted in the human body internal organs may be reached using trans-organ or transluminal surgical procedures. The electrical ablation device may be advanced to the treatment site using endoscopic transluminal access techniques to perforate a lumen, and then, advance the electrical ablation device and the endoscope into the peritoneal cavity. Transluminal access procedures for perforating a lumen wall, inserting, and advancing an endoscope therethrough, and pneumoperitoneum devices for insufflating the peritoneal cavity and closing or suturing the perforated lumen wall are well known. During a transluminal access procedure, a puncture must be formed in the stomach wall or in the gastrointestinal tract to access the peritoneal cavity. One device often used to form such a puncture is a needle knife which is inserted through the working channel of the endoscope, and which utilizes energy to penetrate through the tissue. A guidewire is then fed through the endoscope and is passed through the puncture in the stomach wall and into the peritoneal cavity. The needle knife is removed, leaving the guidewire as a placeholder. A balloon catheter is then passed over the guidewire and through the working channel of the endoscope to position the balloon within the opening in the stomach wall. The balloon can then be inflated to increase the size of the opening, thereby enabling the endoscope to push against the rear of the balloon and to be feed through the opening and into the peritoneal cavity. Once the endoscope is positioned within the peritoneal cavity, numerous procedures can be performed through the working channel of the endoscope.

The endoscope may be connected to a video camera (single chip or multiple chips) and may be attached to a fiber-optic cable system connected to a "cold" light source (halogen or xenon), to illuminate the operative field. The video camera provides a direct line-of-sight view of the treatment region. The abdomen is usually insufflated with carbon dioxide (CO_2) gas to create a working and viewing space. The abdomen is essentially blown up like a balloon (insuffed), elevating the abdominal wall above the internal organs like a dome. CO_2 gas is used because it is common to the human body and can be removed by the respiratory system if it is absorbed through tissue.

Once the electrical ablation devices are located at the target site, the diseased tissue may be electrically ablated or destroyed using the various embodiments of electrodes discussed herein. The placement and location of the electrodes can be important for effective and efficient electrical ablation therapy. For example, the electrodes may be positioned proximal to a treatment region (e.g., target site or worksite) either endoscopically or transcutaneously (percutaneously). In some implementations, it may be necessary to introduce the electrodes inside the patient using a combination of endoscopic, transcutaneous, and/or open techniques. The electrodes may be introduced to the tissue treatment region through a working channel of the endoscope, an overtube, or a trocar and, in some implementations, may be introduced through percutaneously or through small-key-hole-incisions.

Preferably, the various embodiments of the devices described herein will be processed before surgery. First, a new or used instrument is obtained and if necessary cleaned. The instrument can then be sterilized. In one sterilization technique, the instrument is placed in a closed and sealed

container, such as a plastic or TYVEK® bag. The container and instrument are then placed in a field of radiation that can penetrate the container, such as gamma radiation, x-rays, or high-energy electrons. The radiation kills bacteria on the instrument and in the container. The sterilized instrument can then be stored in the sterile container. The sealed container keeps the instrument sterile until it is opened in the medical facility.

It is preferred that the device is sterilized. This can be done by any number of ways known to those skilled in the art including beta or gamma radiation, ethylene oxide, steam.

Although the various embodiments of the devices have been described herein in connection with certain disclosed embodiments, many modifications and variations to those embodiments may be implemented. For example, different types of end effectors may be employed. Also, where materials are disclosed for certain components, other materials may be used. The foregoing description and following claims are intended to cover all such modification and variations.

Any patent, publication, or other disclosure material, in whole or in part, that is said to be incorporated by reference herein is incorporated herein only to the extent that the incorporated materials does not conflict with existing definitions, statements, or other disclosure material set forth in this disclosure. As such, and to the extent necessary, the disclosure as explicitly set forth herein supersedes any conflicting material incorporated herein by reference. Any material, or portion thereof, that is said to be incorporated by reference herein, but which conflicts with existing definitions, statements, or other disclosure material set forth herein will only be incorporated to the extent that no conflict arises between that incorporated material and the existing disclosure material.

The invention claimed is:

1. A method for using an electrical ablation apparatus, comprising:

inserting an elongated tubular body made of an electrically conductive material comprising an arcuate closed distal end and a first electrode received in an open proximal end of the elongated tubular body into a first natural orifice of a body, wherein the first electrode is electrically coupled to the elongated tubular body; inserting a second electrode, located external to the elongated tubular body, into the body; electrically contacting a first conductive terminal of an energy source with the first electrode, and electrically contacting a second conductive terminal of the energy source with the second electrode; and delivering, by the energy source, a first series of electrical pulses sufficient to induce cell necrosis by irreversible electroporation across the first electrode and the second electrode,

wherein the first series of electrical pulses are characterized by a first amplitude, a first pulse length, and a first frequency.

2. The method of claim 1, wherein inserting an elongated tubular body into a first natural orifice of a body comprises inserting the elongated tubular body through the first natural orifice of the body into a lung of the body.

3. The method of claim 1, wherein inserting the second electrode into the body comprises inserting the second electrode into a second natural orifice of the body.

4. The method of claim 1, wherein inserting the second electrode into the body comprises inserting the second electrode transcutaneously into the body.

29

5. The method of claim 1, further comprising placing a distal end of the second electrode proximate to a distal end of the first electrode independent of a placement of the distal end of the first electrode.
6. An electrical ablation system, comprising:
 an elongated tubular body made of an electrically conductive material, the elongated tubular body comprising:
 an arcuate closed distal end configured for entry into a first natural orifice of a body;
 an open proximal end; and
 a first electrode received in the open proximal end of the elongated tubular body, the first electrode electrically coupled to the elongated tubular body;
 a visualization device configured to visualize an internal compartment of the body and configured to receive the elongated tubular body;
 a second electrode, located external to the elongated tubular body, the second electrode configured for entry into the body; and
 an energy source having a first conductive terminal in electrical communication with the first electrode and a second conductive terminal in electrical communication with the second electrode, the energy source con-

30

- figured to deliver a first series of electrical pulses sufficient to induce cell necrosis by irreversible electroporation across the first electrode and the second electrode;
- 5 wherein the first series of electrical pulses are characterized by a first amplitude, a first pulse length, and a first frequency.
7. The system of claim 6, wherein visualization device comprises an endoscope, a thoracoscope, or a laparoscope.
- 10 8. The system of claim 6, wherein visualization device comprises a plurality of working channels.
9. The system of claim 6, wherein the visualization device further comprises a viewing port.
10. The system of claim 6, wherein the second electrode further comprises a conductive portion in electrical communication with a distal end of the second electrode.
11. The system of claim 10, wherein the conductive portion is a sharpened portion.
12. The system of claim 10, wherein the conductive portion is a pad.
13. The system of claim 10, further comprising a hand-piece comprising an activation switch in electrical communication with the energy source.

* * * * *

专利名称(译)	电消融装置		
公开(公告)号	US10004558	公开(公告)日	2018-06-26
申请号	US14/673111	申请日	2015-03-30
[标]申请(专利权)人(译)	伊西康内外科公司		
申请(专利权)人(译)	爱惜康内镜手术 , INC.		
当前申请(专利权)人(译)	爱惜康内镜手术 , INC.		
[标]发明人	LONG GARY L GHABRIAL RAGAE M PLESCIA DAVID N VAKHARIA OMAR J		
发明人	LONG, GARY L. GHABRIAL, RAGAE M. PLESCIA, DAVID N. VAKHARIA, OMAR J.		
IPC分类号	A61B18/14 A61B18/12 A61B18/00		
CPC分类号	A61B18/1492 A61B18/1206 A61B18/1477 A61B2018/00214 A61B2018/00482 A61B2018/1425 A61B2018/00577 A61B2018/00613 A61B2018/00898 A61B2018/124 A61B2018/00547		
其他公开文献	US20150265342A1		
外部链接	Espacenet		

摘要(译)

电消融装置包括第一和第二电极。每个电极包括被配置成耦合能量源的第一端和被配置到组织治疗区域的第二端。能量源连接到第一和第二电极。能量源被配置为通过第一和第二电极中的至少一个传递足以通过不可逆电穿孔诱发细胞坏死的第一系列电脉冲和足以通过热加热诱发细胞坏死的第二系列电脉冲。第一系列电脉冲的特征在于第一振幅，第一脉冲长度和第一频率。第二系列电脉冲的特征在于第二振幅，第二脉冲长度和第二频率。

